{"enrichmentVersion":"1.1.0","generatedAt":"2026-08-21T13:07:36.268Z","basedOnSnapshotHash":"d989db23183e5333a9dd9724f11818bb4c5e5c338346b2e4edacbecfa1882ef8","basedOnMethodologyVersion":"2.1.0","sourceDataTimestamp":"2026-08-20T09:00:05","note":"Patient-result mapping rules are the published methodology 2.1.0 mapper applied to every included study with posted results. comparatorClass, adverse-event counts, result publications, time-to-effect, recruiting lists and pair matrices are enrichment additions; nothing is pooled across studies.","counts":{"studiesFetchedLight":3745,"studiesWithResults":1184,"termsWithComparativeResult":53,"termsWithAnyMappedResult":61,"studiesReferenced":103},"studies":{"NCT00421993":{"title":"A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Adapalene/Benzoyl Peroxide Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"3","seriousAtRisk":"419","otherAffected":"90","otherAtRisk":"419"},{"id":"EG001","title":"Adapalene Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"418","otherAffected":"60","otherAtRisk":"418"},{"id":"EG002","title":"Benzoyl Peroxide Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"415","otherAffected":"35","otherAtRisk":"415"},{"id":"EG003","title":"Gel Vehicle","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"418","otherAffected":"22","otherAtRisk":"418"}]},"refs":[]},"NCT00807014":{"title":"Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Duac Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"83","otherAffected":"13","otherAtRisk":"83"},{"id":"EG001","title":"Differin Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"85","otherAffected":"22","otherAtRisk":"85"}]},"refs":[]},"NCT00829049":{"title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Tazarotene Cream 0.1%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"72","otherAffected":"10","otherAtRisk":"72"},{"id":"EG001","title":"Adapalene Gel 0.3%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"85","otherAffected":"9","otherAtRisk":"85"}]},"refs":[]},"NCT00776919":{"title":"Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Duac Low-dose (LD) Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"327","otherAffected":"72","otherAtRisk":"327"},{"id":"EG001","title":"Clindamycin Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"328","otherAffected":"83","otherAtRisk":"328"},{"id":"EG002","title":"BPO Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"328","otherAffected":"102","otherAtRisk":"328"},{"id":"EG003","title":"Vehicle Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"332","otherAffected":"87","otherAtRisk":"332"}]},"refs":[]},"NCT03522441":{"title":"Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris","ae":{"timeFrame":"6 months","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Clindamycin 1% Gel (Akorn Pharmaceuticals)","deathsAffected":"0","deathsAtRisk":"450","seriousAffected":"0","seriousAtRisk":"450","otherAffected":"0","otherAtRisk":"450"},{"id":"EG001","title":"Clindamycin 1% Gel (Greenstone LLC)","deathsAffected":"0","deathsAtRisk":"450","seriousAffected":"0","seriousAtRisk":"450","otherAffected":"0","otherAtRisk":"450"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"225","seriousAffected":"0","seriousAtRisk":"225","otherAffected":"0","otherAtRisk":"225"}]},"refs":[]},"NCT00422240":{"title":"Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","ae":{"timeFrame":"From start of the study drug administration up to Week 12.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Adapalene/Benzoyl Peroxide Gel","deathsAffected":"0","deathsAtRisk":"415","seriousAffected":"2","seriousAtRisk":"415","otherAffected":"44","otherAtRisk":"415"},{"id":"EG001","title":"Adapalene Gel, 0.1%","deathsAffected":"0","deathsAtRisk":"420","seriousAffected":"3","seriousAtRisk":"420","otherAffected":"51","otherAtRisk":"420"},{"id":"EG002","title":"Benzoyl Peroxide Gel 2.5%","deathsAffected":"0","deathsAtRisk":"415","seriousAffected":"0","seriousAtRisk":"415","otherAffected":"29","otherAtRisk":"415"},{"id":"EG003","title":"Gel Vehicle","deathsAffected":"0","deathsAtRisk":"418","seriousAffected":"1","seriousAtRisk":"418","otherAffected":"34","otherAtRisk":"418"}]},"refs":[]},"NCT01138735":{"title":"Epiduo Pediatric Acne Study","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Adapalene/Benzoyl Peroxide","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"142","otherAffected":"37","otherAtRisk":"142"},{"id":"EG001","title":"Topical Gel Vehicle","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"143","otherAffected":"18","otherAtRisk":"143"}]},"refs":[]},"NCT01188538":{"title":"Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel","ae":{"timeFrame":"During the study (from baseline to Week 12)","frequencyThreshold":"2.5","groups":[{"id":"EG000","title":"Epiduo Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"1","otherAtRisk":"20"},{"id":"EG001","title":"Benzoyl Peroxide (BPO) Gel","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"0","otherAtRisk":"20"}]},"refs":[]},"NCT00907335":{"title":"A Study of Acne Treatment in Children Ages 9 to 11","ae":{"timeFrame":"12 Weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Retin-A Micro","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"55","otherAffected":"25","otherAtRisk":"55"},{"id":"EG001","title":"Vehicle Control","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"55","otherAffected":"7","otherAtRisk":"55"}]},"refs":[]},"NCT01243450":{"title":"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo","ae":{"timeFrame":"","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Active Generic","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"401","otherAffected":"0","otherAtRisk":"401"},{"id":"EG001","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"135","otherAffected":"0","otherAtRisk":"135"},{"id":"EG002","title":"Brand","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"404","otherAffected":"0","otherAtRisk":"404"}]},"refs":[]},"NCT02249767":{"title":"Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel","ae":{"timeFrame":"12 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Generic Tretinoin","deathsAffected":"0","deathsAtRisk":"230","seriousAffected":"0","seriousAtRisk":"230","otherAffected":"49","otherAtRisk":"230"},{"id":"EG001","title":"Brand Tretinoin","deathsAffected":"0","deathsAtRisk":"229","seriousAffected":"0","seriousAtRisk":"229","otherAffected":"46","otherAtRisk":"229"},{"id":"EG002","title":"Placebo Vehicle","deathsAffected":"0","deathsAtRisk":"115","seriousAffected":"0","seriousAtRisk":"115","otherAffected":"26","otherAtRisk":"115"}]},"refs":[]},"NCT06415305":{"title":"A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne","ae":{"timeFrame":"56 Weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Winlevi (Clascoterone) 1% Cream","deathsAffected":"0","deathsAtRisk":"9","seriousAffected":"0","seriousAtRisk":"9","otherAffected":"0","otherAtRisk":"9"}]},"refs":[]},"NCT02944461":{"title":"Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris","ae":{"timeFrame":"16 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Dapsone Gel 7.5%","deathsAffected":"0","deathsAtRisk":"20","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"3","otherAtRisk":"20"}]},"refs":[]},"NCT02557399":{"title":"DUAC® Early Onset Efficacy Study in Japanese Subjects","ae":{"timeFrame":"AE and SAE were collected up to Week 12.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Duac","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"172","otherAffected":"34","otherAtRisk":"172"},{"id":"EG001","title":"ADA 0.1% +CLDM 1%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"177","otherAffected":"78","otherAtRisk":"177"}]},"refs":[]},"NCT02267746":{"title":"A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris","ae":{"timeFrame":"Adverse event data were collected over approximately 13 weeks.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Test","deathsAffected":"0","deathsAtRisk":"292","seriousAffected":"0","seriousAtRisk":"292","otherAffected":"41","otherAtRisk":"292"},{"id":"EG001","title":"Reference","deathsAffected":"0","deathsAtRisk":"288","seriousAffected":"0","seriousAtRisk":"288","otherAffected":"55","otherAtRisk":"288"},{"id":"EG002","title":"Vehicle","deathsAffected":"0","deathsAtRisk":"294","seriousAffected":"0","seriousAtRisk":"294","otherAffected":"43","otherAtRisk":"294"}]},"refs":[]},"NCT02886715":{"title":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","ae":{"timeFrame":"From baseline to week 12 (end of study)","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Test","deathsAffected":"0","deathsAtRisk":"442","seriousAffected":"1","seriousAtRisk":"442","otherAffected":"45","otherAtRisk":"442"},{"id":"EG001","title":"Reference","deathsAffected":"0","deathsAtRisk":"445","seriousAffected":"0","seriousAtRisk":"445","otherAffected":"57","otherAtRisk":"445"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"223","seriousAffected":"0","seriousAtRisk":"223","otherAffected":"12","otherAtRisk":"223"}]},"refs":[]},"NCT00392223":{"title":"Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Azithromycin","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"58","otherAffected":"29","otherAtRisk":""},{"id":"EG001","title":"Minocycline","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"60","otherAffected":"21","otherAtRisk":""}]},"refs":[]},"NCT02815267":{"title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","ae":{"timeFrame":"Double blind: Screening Day until Week 12; Open-label: Week 16 until Week 52","frequencyThreshold":"2","groups":[{"id":"EG000","title":"Double-blind-FMX-101, 4% Minocycline Foam","deathsAffected":"0","deathsAtRisk":"307","seriousAffected":"1","seriousAtRisk":"307","otherAffected":"13","otherAtRisk":"307"},{"id":"EG001","title":"Double-blind-Vehicle Foam","deathsAffected":"0","deathsAtRisk":"159","seriousAffected":"0","seriousAtRisk":"159","otherAffected":"11","otherAtRisk":"159"},{"id":"EG002","title":"Open-label-FMX-101, 4% Minocycline Foam","deathsAffected":"0","deathsAtRisk":"284","seriousAffected":"1","seriousAtRisk":"284","otherAffected":"19","otherAtRisk":"284"}]},"refs":[]},"NCT02815280":{"title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","ae":{"timeFrame":"Double blind: From Baseline until Week 12; Open-label: Week 16 until Week 52","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Double-blind-FMX-101, 4% Minocycline Foam","deathsAffected":"0","deathsAtRisk":"333","seriousAffected":"4","seriousAtRisk":"333","otherAffected":"40","otherAtRisk":"333"},{"id":"EG001","title":"Double-blind-Vehicle Foam","deathsAffected":"0","deathsAtRisk":"162","seriousAffected":"2","seriousAtRisk":"162","otherAffected":"15","otherAtRisk":"162"},{"id":"EG002","title":"Open-label-FMX-101, 4% Minocycline Foam","deathsAffected":"0","deathsAtRisk":"373","seriousAffected":"1","seriousAtRisk":"373","otherAffected":"38","otherAtRisk":"373"}]},"refs":[]},"NCT05550337":{"title":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","ae":{"timeFrame":"7.5 months","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Test: Trifarotene Cream, 0.005%","deathsAffected":"23","deathsAtRisk":"269","seriousAffected":"0","seriousAtRisk":"269","otherAffected":"23","otherAtRisk":"269"},{"id":"EG001","title":"AKLIEF®","deathsAffected":"37","deathsAtRisk":"269","seriousAffected":"1","seriousAtRisk":"269","otherAffected":"37","otherAtRisk":"269"},{"id":"EG002","title":"Vehicle Product","deathsAffected":"18","deathsAtRisk":"269","seriousAffected":"0","seriousAtRisk":"269","otherAffected":"18","otherAtRisk":"269"}]},"refs":[]},"NCT01796665":{"title":"A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris","ae":{"timeFrame":"84 days","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Test Product","deathsAffected":"0","deathsAtRisk":"474","seriousAffected":"2","seriousAtRisk":"474","otherAffected":"0","otherAtRisk":"474"},{"id":"EG001","title":"Reference Product","deathsAffected":"0","deathsAtRisk":"469","seriousAffected":"0","seriousAtRisk":"469","otherAffected":"0","otherAtRisk":"469"},{"id":"EG002","title":"Placebo Product","deathsAffected":"0","deathsAtRisk":"237","seriousAffected":"1","seriousAtRisk":"237","otherAffected":"0","otherAtRisk":"237"}]},"refs":[]},"NCT01548404":{"title":"Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis","ae":{"timeFrame":"All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 197) regardless of seriousness or relationship to investigational product.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"7","seriousAtRisk":"54","otherAffected":"31","otherAtRisk":"54"},{"id":"EG001","title":"Dupilumab 300 mg","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"55","otherAffected":"38","otherAtRisk":"55"}]},"refs":[{"pmid":"25006719","short":"Beck LA et al."}]},"NCT02210780":{"title":"Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)","ae":{"timeFrame":"Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo qw","deathsAffected":"0","deathsAtRisk":"97","seriousAffected":"0","seriousAtRisk":"97","otherAffected":"29","otherAtRisk":"97"},{"id":"EG001","title":"Dupilumab 300 mg qw","deathsAffected":"0","deathsAtRisk":"97","seriousAffected":"3","seriousAtRisk":"97","otherAffected":"30","otherAtRisk":"97"}]},"refs":[]},"NCT04417894":{"title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","ae":{"timeFrame":"From first dose to Week 28","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Matching Placebo","deathsAffected":"0","deathsAtRisk":"66","seriousAffected":"1","seriousAtRisk":"66","otherAffected":"34","otherAtRisk":"66"},{"id":"EG001","title":"Dupilumab Q2W","deathsAffected":"0","deathsAtRisk":"67","seriousAffected":"3","seriousAtRisk":"67","otherAffected":"33","otherAtRisk":"67"}]},"refs":[]},"NCT03443024":{"title":"A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis","ae":{"timeFrame":"Baseline up to 271 days","frequencyThreshold":"0","groups":[{"id":"EG000","title":"125 mg Lebrikizumab (Q4W)","deathsAffected":"0","deathsAtRisk":"73","seriousAffected":"2","seriousAtRisk":"73","otherAffected":"41","otherAtRisk":"73"},{"id":"EG001","title":"250 mg Lebrikizumab (Q4W)","deathsAffected":"0","deathsAtRisk":"80","seriousAffected":"0","seriousAtRisk":"80","otherAffected":"39","otherAtRisk":"80"},{"id":"EG002","title":"250 mg Lebrikizumab (Q2W)","deathsAffected":"0","deathsAtRisk":"75","seriousAffected":"2","seriousAtRisk":"75","otherAffected":"45","otherAtRisk":"75"},{"id":"EG003","title":"Placebo","deathsAffected":"0","deathsAtRisk":"52","seriousAffected":"2","seriousAtRisk":"52","otherAffected":"24","otherAtRisk":"52"}]},"refs":[]},"NCT03131648":{"title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","ae":{"timeFrame":"Initial Treatment Period: Week 0 to Week 16, Maintenance Treatment Period: Week 16 to Week 52, Open-label Treatment: Week 16 to Week 52; Safety Follow-up Period: Week 52 to Week 66 and Week 68 to Week 82 (for selected Japanese subjects).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Initial Period - Tralokinumab Q2W","deathsAffected":"0","deathsAtRisk":"602","seriousAffected":"23","seriousAtRisk":"602","otherAffected":"351","otherAtRisk":"602"},{"id":"EG001","title":"Initial Period - Placebo","deathsAffected":"0","deathsAtRisk":"196","seriousAffected":"8","seriousAtRisk":"196","otherAffected":"114","otherAtRisk":"196"},{"id":"EG002","title":"Maintenance Period - Tralokinumab Q2W","deathsAffected":"0","deathsAtRisk":"68","seriousAffected":"1","seriousAtRisk":"68","otherAffected":"37","otherAtRisk":"68"},{"id":"EG003","title":"Maintenance Period - Tralokinumab Q4W","deathsAffected":"0","deathsAtRisk":"76","seriousAffected":"3","seriousAtRisk":"76","otherAffected":"39","otherAtRisk":"76"},{"id":"EG004","title":"Maintenance Period - Placebo","deathsAffected":"0","deathsAtRisk":"35","seriousAffected":"0","seriousAtRisk":"35","otherAffected":"20","otherAtRisk":"35"},{"id":"EG005","title":"Maintenance Period - Placebo - Tralokinumab Naive","deathsAffected":"0","deathsAtRisk":"29","seriousAffected":"1","seriousAtRisk":"29","otherAffected":"9","otherAtRisk":"29"},{"id":"EG006","title":"Open-label Period - Tralokinumab Q2W + Optional TCS","deathsAffected":"0","deathsAtRisk":"563","seriousAffected":"27","seriousAtRisk":"563","otherAffected":"304","otherAtRisk":"563"},{"id":"EG007","title":"Safety Follow-up","deathsAffected":"0","deathsAtRisk":"595","seriousAffected":"16","seriousAtRisk":"595","otherAffected":"29","otherAtRisk":"595"}]},"refs":[]},"NCT03160885":{"title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","ae":{"timeFrame":"Initial Treatment Period: Week 0 to Week 16; Maintenance Treatment Period: Week 16 to Week 52; Open-label Treatment: Week 16 to Week 52; Safety follow-up Period (All treatment arms): Week 52 to Week 66","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Initial Period - Tralokinumab Q2W","deathsAffected":"0","deathsAtRisk":"592","seriousAffected":"10","seriousAtRisk":"592","otherAffected":"202","otherAtRisk":"592"},{"id":"EG001","title":"Initial Period - Placebo","deathsAffected":"0","deathsAtRisk":"200","seriousAffected":"5","seriousAtRisk":"200","otherAffected":"89","otherAtRisk":"200"},{"id":"EG002","title":"Maintenance Period - Tralokinumab Q2W","deathsAffected":"0","deathsAtRisk":"91","seriousAffected":"0","seriousAtRisk":"91","otherAffected":"37","otherAtRisk":"91"},{"id":"EG003","title":"Maintenance Period - Tralokinumab Q4W","deathsAffected":"0","deathsAtRisk":"89","seriousAffected":"3","seriousAtRisk":"89","otherAffected":"28","otherAtRisk":"89"},{"id":"EG004","title":"Maintenance Period - Placebo","deathsAffected":"0","deathsAtRisk":"46","seriousAffected":"0","seriousAtRisk":"46","otherAffected":"21","otherAtRisk":"46"},{"id":"EG005","title":"Maintenance Period - Placebo - Tralokinumab Naive","deathsAffected":"0","deathsAtRisk":"31","seriousAffected":"0","seriousAtRisk":"31","otherAffected":"9","otherAtRisk":"31"},{"id":"EG006","title":"Open-label Period - Tralokinumab Q2W + Optional TCS","deathsAffected":"0","deathsAtRisk":"558","seriousAffected":"16","seriousAtRisk":"558","otherAffected":"226","otherAtRisk":"558"},{"id":"EG007","title":"Safety Follow-up","deathsAffected":"0","deathsAtRisk":"641","seriousAffected":"4","seriousAtRisk":"641","otherAffected":"28","otherAtRisk":"641"}]},"refs":[]},"NCT05958407":{"title":"A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy","ae":{"timeFrame":"Treatment emergent adverse events were collected during the 32 weeks of treatment + 4 weeks of follow-up.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Tralokinumab DB","deathsAffected":"0","deathsAtRisk":"156","seriousAffected":"3","seriousAtRisk":"156","otherAffected":"50","otherAtRisk":"156"},{"id":"EG001","title":"Placebo DB","deathsAffected":"0","deathsAtRisk":"79","seriousAffected":"1","seriousAtRisk":"79","otherAffected":"19","otherAtRisk":"79"},{"id":"EG002","title":"Tralokinumab OL","deathsAffected":"0","deathsAtRisk":"214","seriousAffected":"4","seriousAtRisk":"214","otherAffected":"31","otherAtRisk":"214"}]},"refs":[]},"NCT03334435":{"title":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis","ae":{"timeFrame":"Baseline through Week 200","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo","deathsAffected":"0","deathsAtRisk":"91","seriousAffected":"5","seriousAtRisk":"91","otherAffected":"21","otherAtRisk":"91"},{"id":"EG001","title":"Bari 1-mg","deathsAffected":"0","deathsAtRisk":"45","seriousAffected":"1","seriousAtRisk":"45","otherAffected":"14","otherAtRisk":"45"},{"id":"EG002","title":"Bari 2-mg","deathsAffected":"0","deathsAtRisk":"766","seriousAffected":"32","seriousAtRisk":"766","otherAffected":"263","otherAtRisk":"766"},{"id":"EG003","title":"Bari 4-mg","deathsAffected":"1","deathsAtRisk":"743","seriousAffected":"40","seriousAtRisk":"743","otherAffected":"268","otherAtRisk":"743"},{"id":"EG004","title":"2 mg Bari to Placebo Substudy","deathsAffected":"1","deathsAtRisk":"92","seriousAffected":"2","seriousAtRisk":"92","otherAffected":"15","otherAtRisk":"92"},{"id":"EG005","title":"2 mg Bari to 1 mg Bari Substudy","deathsAffected":"0","deathsAtRisk":"91","seriousAffected":"1","seriousAtRisk":"91","otherAffected":"27","otherAtRisk":"91"},{"id":"EG006","title":"2 mg Bari to 2 mg Bari Substudy","deathsAffected":"0","deathsAtRisk":"92","seriousAffected":"3","seriousAtRisk":"92","otherAffected":"38","otherAtRisk":"92"},{"id":"EG007","title":"4 mg Bari to Placebo Substudy","deathsAffected":"0","deathsAtRisk":"84","seriousAffected":"3","seriousAtRisk":"84","otherAffected":"16","otherAtRisk":"84"},{"id":"EG008","title":"4 mg Bari to 2 mg Bari Substudy","deathsAffected":"0","deathsAtRisk":"84","seriousAffected":"1","seriousAtRisk":"84","otherAffected":"21","otherAtRisk":"84"},{"id":"EG009","title":"4 mg Bari to 4 mg Bari Substudy","deathsAffected":"0","deathsAtRisk":"84","seriousAffected":"11","seriousAtRisk":"84","otherAffected":"42","otherAtRisk":"84"},{"id":"EG010","title":"Placebo to Placebo Non-substudy","deathsAffected":"0","deathsAtRisk":"70","seriousAffected":"1","seriousAtRisk":"70","otherAffected":"14","otherAtRisk":"70"},{"id":"EG011","title":"1 mg Bari to 1 mg Bari Non-substudy","deathsAffected":"0","deathsAtRisk":"32","seriousAffected":"3","seriousAtRisk":"32","otherAffected":"14","otherAtRisk":"32"},{"id":"EG012","title":"2 mg Bari to 2 mg Bari Non-substudy","deathsAffected":"0","deathsAtRisk":"249","seriousAffected":"16","seriousAtRisk":"249","otherAffected":"96","otherAtRisk":"249"},{"id":"EG013","title":"4 mg Bari to 4 mg Bari Non-substudy","deathsAffected":"1","deathsAtRisk":"264","seriousAffected":"25","seriousAtRisk":"264","otherAffected":"110","otherAtRisk":"264"}]},"refs":[]},"NCT03559270":{"title":"A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis","ae":{"timeFrame":"Baseline to Follow-up (Up to 204 Weeks)","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo/Baricitinib 2-mg","deathsAffected":"0","deathsAtRisk":"117","seriousAffected":"8","seriousAtRisk":"117","otherAffected":"35","otherAtRisk":"117"},{"id":"EG001","title":"Baricitinib 1-mg/Baricitinib 2-mg","deathsAffected":"2","deathsAtRisk":"119","seriousAffected":"8","seriousAtRisk":"119","otherAffected":"22","otherAtRisk":"119"},{"id":"EG002","title":"Baricitinib 2-mg/Baricitinib 2-mg","deathsAffected":"0","deathsAtRisk":"108","seriousAffected":"10","seriousAtRisk":"108","otherAffected":"28","otherAtRisk":"108"},{"id":"EG003","title":"Baricitinib 2-mg Open-Label Addendum","deathsAffected":"0","deathsAtRisk":"29","seriousAffected":"0","seriousAtRisk":"29","otherAffected":"2","otherAtRisk":"29"}]},"refs":[]},"NCT03569293":{"title":"Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)","ae":{"timeFrame":"All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time followed ranged from 128.5 days to 133.0 days for the double-blind period and from 1688.0 days to 1711.5 days for the blinded extension period.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Adults: Double-blind Period - Placebo","deathsAffected":"0","deathsAtRisk":"241","seriousAffected":"9","seriousAtRisk":"241","otherAffected":"111","otherAtRisk":"241"},{"id":"EG001","title":"Adults: Double-blind Period - Upadacitinib 15 mg QD","deathsAffected":"0","deathsAtRisk":"239","seriousAffected":"5","seriousAtRisk":"239","otherAffected":"104","otherAtRisk":"239"},{"id":"EG002","title":"Adults: Double-blind Period - Upadacitinib 30 mg QD","deathsAffected":"0","deathsAtRisk":"243","seriousAffected":"8","seriousAtRisk":"243","otherAffected":"142","otherAtRisk":"243"},{"id":"EG003","title":"Adolescents: Double-blind Period - Placebo","deathsAffected":"0","deathsAtRisk":"61","seriousAffected":"1","seriousAtRisk":"61","otherAffected":"18","otherAtRisk":"61"},{"id":"EG004","title":"Adolescents: Double-blind Period - Upadacitinib 15 mg QD","deathsAffected":"0","deathsAtRisk":"64","seriousAffected":"2","seriousAtRisk":"64","otherAffected":"33","otherAtRisk":"64"},{"id":"EG005","title":"Adolescents: Double-blind Period - Upadacitinib 30 mg QD","deathsAffected":"0","deathsAtRisk":"64","seriousAffected":"0","seriousAtRisk":"64","otherAffected":"32","otherAtRisk":"64"},{"id":"EG006","title":"Adults: Blinded Extension Period - Upadacitinib 15 mg","deathsAffected":"2","deathsAtRisk":"231","seriousAffected":"33","seriousAtRisk":"231","otherAffected":"160","otherAtRisk":"231"},{"id":"EG007","title":"Adults: Blinded Extension Period - Upadacitinib 30 mg","deathsAffected":"2","deathsAtRisk":"228","seriousAffected":"42","seriousAtRisk":"228","otherAffected":"189","otherAtRisk":"228"},{"id":"EG008","title":"Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg","deathsAffected":"0","deathsAtRisk":"102","seriousAffected":"15","seriousAtRisk":"102","otherAffected":"78","otherAtRisk":"102"},{"id":"EG009","title":"Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg","deathsAffected":"1","deathsAtRisk":"105","seriousAffected":"21","seriousAtRisk":"105","otherAffected":"89","otherAtRisk":"105"},{"id":"EG010","title":"Adolescents: Blinded Extension Period - Upadacitinib 15 mg QD","deathsAffected":"0","deathsAtRisk":"64","seriousAffected":"8","seriousAtRisk":"64","otherAffected":"44","otherAtRisk":"64"},{"id":"EG011","title":"Adolescents: Blinded Extension Period - Upadacitinib 30 mg QD","deathsAffected":"0","deathsAtRisk":"64","seriousAffected":"7","seriousAtRisk":"64","otherAffected":"48","otherAtRisk":"64"},{"id":"EG012","title":"Adolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mg","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"1","seriousAtRisk":"30","otherAffected":"20","otherAtRisk":"30"},{"id":"EG013","title":"Adolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg","deathsAffected":"0","deathsAtRisk":"27","seriousAffected":"6","seriousAtRisk":"27","otherAffected":"22","otherAtRisk":"27"}]},"refs":[]},"NCT03607422":{"title":"A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)","ae":{"timeFrame":"All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time followed ranged from 132 days to 137 days for the double-blind period and from 1234 days to 1713 days for the blinded extension period.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Adults: Double-blind Period - Placebo","deathsAffected":"0","deathsAtRisk":"242","seriousAffected":"7","seriousAtRisk":"242","otherAffected":"93","otherAtRisk":"242"},{"id":"EG001","title":"Adults: Double-blind Period - Upadacitinib 15 mg QD","deathsAffected":"0","deathsAtRisk":"243","seriousAffected":"3","seriousAtRisk":"243","otherAffected":"117","otherAtRisk":"243"},{"id":"EG002","title":"Adults: Double-blind Period - Upadacitinib 30 mg QD","deathsAffected":"0","deathsAtRisk":"247","seriousAffected":"7","seriousAtRisk":"247","otherAffected":"126","otherAtRisk":"247"},{"id":"EG003","title":"Adolescents: Double-blind Period - Placebo","deathsAffected":"0","deathsAtRisk":"60","seriousAffected":"3","seriousAtRisk":"60","otherAffected":"19","otherAtRisk":"60"},{"id":"EG004","title":"Adolescents: Double-blind Period - Upadacitinib 15 mg QD","deathsAffected":"0","deathsAtRisk":"58","seriousAffected":"2","seriousAtRisk":"58","otherAffected":"26","otherAtRisk":"58"},{"id":"EG005","title":"Adolescents: Double-blind Period - Upadacitinib 30 mg QD","deathsAffected":"0","deathsAtRisk":"62","seriousAffected":"0","seriousAtRisk":"62","otherAffected":"33","otherAtRisk":"62"},{"id":"EG006","title":"Adults: Blinded Extension Period - Upadacitinib 15 mg","deathsAffected":"1","deathsAtRisk":"229","seriousAffected":"38","seriousAtRisk":"229","otherAffected":"180","otherAtRisk":"229"},{"id":"EG007","title":"Adults: Blinded Extension Period - Upadacitinib 30 mg","deathsAffected":"1","deathsAtRisk":"235","seriousAffected":"41","seriousAtRisk":"235","otherAffected":"186","otherAtRisk":"235"},{"id":"EG008","title":"Adolescents: Blinded Extension Period - Upadacitinib 15 mg","deathsAffected":"0","deathsAtRisk":"55","seriousAffected":"6","seriousAtRisk":"55","otherAffected":"38","otherAtRisk":"55"},{"id":"EG009","title":"Adolescents: Blinded Extension Period - Upadacitinib 30 mg","deathsAffected":"0","deathsAtRisk":"59","seriousAffected":"10","seriousAtRisk":"59","otherAffected":"46","otherAtRisk":"59"},{"id":"EG010","title":"Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg","deathsAffected":"1","deathsAtRisk":"104","seriousAffected":"11","seriousAtRisk":"104","otherAffected":"78","otherAtRisk":"104"},{"id":"EG011","title":"Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg","deathsAffected":"0","deathsAtRisk":"104","seriousAffected":"18","seriousAtRisk":"104","otherAffected":"80","otherAtRisk":"104"},{"id":"EG012","title":"Adolescents: Blinded Extension Period - PBO/Upadacitinib 15 mg","deathsAffected":"0","deathsAtRisk":"26","seriousAffected":"4","seriousAtRisk":"26","otherAffected":"19","otherAtRisk":"26"},{"id":"EG013","title":"Adolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg","deathsAffected":"0","deathsAtRisk":"29","seriousAffected":"4","seriousAtRisk":"29","otherAffected":"23","otherAtRisk":"29"}]},"refs":[]},"NCT03107611":{"title":"Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis","ae":{"timeFrame":"Day 15","frequencyThreshold":"4","groups":[{"id":"EG000","title":"Test","deathsAffected":"0","deathsAtRisk":"215","seriousAffected":"0","seriousAtRisk":"215","otherAffected":"0","otherAtRisk":"215"},{"id":"EG001","title":"Reference Standard","deathsAffected":"0","deathsAtRisk":"214","seriousAffected":"0","seriousAtRisk":"214","otherAffected":"0","otherAtRisk":"214"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"220","seriousAffected":"0","seriousAtRisk":"220","otherAffected":"0","otherAtRisk":"220"}]},"refs":[]},"NCT04306965":{"title":"Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab","ae":{"timeFrame":"From Baseline - week 24","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Apremilast","deathsAffected":"0","deathsAtRisk":"10","seriousAffected":"0","seriousAtRisk":"10","otherAffected":"8","otherAtRisk":"10"}]},"refs":[]},"NCT03011892":{"title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis","ae":{"timeFrame":"Up to Week 24","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Vehicle BID","deathsAffected":"0","deathsAtRisk":"52","seriousAffected":"0","seriousAtRisk":"52","otherAffected":"10","otherAtRisk":"52"},{"id":"EG001","title":"Triamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BID","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"1","seriousAtRisk":"51","otherAffected":"3","otherAtRisk":"51"},{"id":"EG002","title":"INCB018424 0.15% QD","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"0","seriousAtRisk":"51","otherAffected":"6","otherAtRisk":"51"},{"id":"EG003","title":"INCB018424 0.5% QD","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"0","seriousAtRisk":"51","otherAffected":"2","otherAtRisk":"51"},{"id":"EG004","title":"INCB018424 1.5% QD","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"0","seriousAtRisk":"51","otherAffected":"6","otherAtRisk":"51"},{"id":"EG005","title":"INCB018424 1.5% BID","deathsAffected":"0","deathsAtRisk":"259","seriousAffected":"0","seriousAtRisk":"259","otherAffected":"23","otherAtRisk":"259"}]},"refs":[]},"NCT04921969":{"title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)","ae":{"timeFrame":"up to 60 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Vehicle Cream BID","deathsAffected":"0","deathsAtRisk":"65","seriousAffected":"0","seriousAtRisk":"65","otherAffected":"4","otherAtRisk":"65"},{"id":"EG001","title":"Ruxolitinib 0.75% Cream BID","deathsAffected":"0","deathsAtRisk":"159","seriousAffected":"0","seriousAtRisk":"159","otherAffected":"50","otherAtRisk":"159"},{"id":"EG002","title":"Ruxolitinib 1.5% Cream BID","deathsAffected":"0","deathsAtRisk":"154","seriousAffected":"3","seriousAtRisk":"154","otherAffected":"49","otherAtRisk":"154"}]},"refs":[]},"NCT03645057":{"title":"ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis","ae":{"timeFrame":"6 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Crisaborole-children","deathsAffected":"0","deathsAtRisk":"16","seriousAffected":"0","seriousAtRisk":"16","otherAffected":"2","otherAtRisk":"16"},{"id":"EG001","title":"Tacrolimus-children","deathsAffected":"0","deathsAtRisk":"21","seriousAffected":"0","seriousAtRisk":"21","otherAffected":"3","otherAtRisk":"21"}]},"refs":[]},"NCT00557284":{"title":"Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Treatment Arm","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"9","otherAffected":"0","otherAtRisk":"9"},{"id":"EG001","title":"Placebo Arm","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"11","otherAffected":"0","otherAtRisk":"11"}]},"refs":[]},"NCT04605094":{"title":"Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis","ae":{"timeFrame":"Adverse events in the on-study period were reported from the first dose of study treatment (Day 1) up to end of follow-up, approximately a maximum up to Week 60","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Benralizumab","deathsAffected":"0","deathsAtRisk":"96","seriousAffected":"3","seriousAtRisk":"96","otherAffected":"38","otherAtRisk":"96"},{"id":"EG001","title":"Placebo","deathsAffected":"0","deathsAtRisk":"98","seriousAffected":"0","seriousAtRisk":"98","otherAffected":"10","otherAtRisk":"98"},{"id":"EG002","title":"Placebo to Benralizumab","deathsAffected":"0","deathsAtRisk":"87","seriousAffected":"2","seriousAtRisk":"87","otherAffected":"29","otherAtRisk":"87"}]},"refs":[]},"NCT05732454":{"title":"A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection","ae":{"timeFrame":"Part 1, DB Period: Day 1 to Week 16; Part 1, OLE Period: Week 20 to Week 68; Part 1, DB +OLE Period: Day 1 to Week 68","frequencyThreshold":"5","groups":[{"id":"EG000","title":"DB Period: Etrasimod 2 mg","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"0","seriousAtRisk":"30","otherAffected":"6","otherAtRisk":"30"},{"id":"EG001","title":"DB Period: Placebo","deathsAffected":"0","deathsAtRisk":"28","seriousAffected":"0","seriousAtRisk":"28","otherAffected":"4","otherAtRisk":"28"},{"id":"EG002","title":"OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"1","seriousAtRisk":"30","otherAffected":"4","otherAtRisk":"30"},{"id":"EG003","title":"OLE Period: Etrasimod 2 mg (Placebo in DB Period)","deathsAffected":"0","deathsAtRisk":"28","seriousAffected":"0","seriousAtRisk":"28","otherAffected":"1","otherAtRisk":"28"},{"id":"EG004","title":"DB Etrasimod 2 mg Then OLE Etrasimod 2 mg","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"1","seriousAtRisk":"30","otherAffected":"9","otherAtRisk":"30"},{"id":"EG005","title":"DB Placebo Then OLE Etrasimod 2 mg","deathsAffected":"0","deathsAtRisk":"28","seriousAffected":"0","seriousAtRisk":"28","otherAffected":"5","otherAtRisk":"28"}]},"refs":[]},"NCT02975206":{"title":"Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis","ae":{"timeFrame":"Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the first study drug administration through the follow-up visit at Week 10. After the Week 10 visit, SAEs that are believed to be drug related will be reported, without a specific end time.","frequencyThreshold":"3","groups":[{"id":"EG000","title":"Serlopitant 5 mg","deathsAffected":"1","deathsAtRisk":"161","seriousAffected":"2","seriousAtRisk":"161","otherAffected":"27","otherAtRisk":"161"},{"id":"EG001","title":"Serlopitant 1 mg","deathsAffected":"0","deathsAtRisk":"160","seriousAffected":"1","seriousAtRisk":"160","otherAffected":"22","otherAtRisk":"160"},{"id":"EG002","title":"Placebo Oral Tablet","deathsAffected":"0","deathsAtRisk":"158","seriousAffected":"2","seriousAtRisk":"158","otherAffected":"32","otherAtRisk":"158"}]},"refs":[]},"NCT04086121":{"title":"A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032","ae":{"timeFrame":"From first dose until last dose + 16 weeks, up to 765 days.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Spesolimab 600 mg","deathsAffected":"0","deathsAtRisk":"14","seriousAffected":"2","seriousAtRisk":"14","otherAffected":"11","otherAtRisk":"14"}]},"refs":[]},"NCT05014438":{"title":"A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis","ae":{"timeFrame":"Adverse Events and Serious Adverse Events: (From first dose to last dose + 8 weeks follow up): Approximately 29 Weeks All-Cause mortality (From randomization to end of study): Approximately 29 Weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo","deathsAffected":"0","deathsAtRisk":"4","seriousAffected":"0","seriousAtRisk":"4","otherAffected":"2","otherAtRisk":"4"},{"id":"EG001","title":"Treatment 1","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"1","seriousAtRisk":"3","otherAffected":"3","otherAtRisk":"3"},{"id":"EG002","title":"Treatment 2","deathsAffected":"0","deathsAtRisk":"4","seriousAffected":"0","seriousAtRisk":"4","otherAffected":"2","otherAtRisk":"4"},{"id":"EG003","title":"Treatment 3","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"0","seriousAtRisk":"3","otherAffected":"1","otherAtRisk":"3"},{"id":"EG004","title":"Treatment 4","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"0","seriousAtRisk":"3","otherAffected":"1","otherAtRisk":"3"}]},"refs":[]},"NCT02471144":{"title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","ae":{"timeFrame":"Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Any AIN457 Low Dose","deathsAffected":"0","deathsAtRisk":"56","seriousAffected":"7","seriousAtRisk":"56","otherAffected":"48","otherAtRisk":"56"},{"id":"EG001","title":"Any AIN457 High Dose","deathsAffected":"0","deathsAtRisk":"58","seriousAffected":"8","seriousAtRisk":"58","otherAffected":"50","otherAtRisk":"58"},{"id":"EG002","title":"Any AIN457 Dose","deathsAffected":"0","deathsAtRisk":"114","seriousAffected":"15","seriousAtRisk":"114","otherAffected":"98","otherAtRisk":"114"},{"id":"EG003","title":"Placebo","deathsAffected":"0","deathsAtRisk":"41","seriousAffected":"0","seriousAtRisk":"41","otherAffected":"19","otherAtRisk":"41"},{"id":"EG004","title":"Etanercept","deathsAffected":"0","deathsAtRisk":"41","seriousAffected":"6","seriousAtRisk":"41","otherAffected":"30","otherAtRisk":"41"}]},"refs":[]},"NCT02748863":{"title":"Study of Secukinumab With 2 mL Pre-filled Syringes","ae":{"timeFrame":"AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks","frequencyThreshold":"2","groups":[{"id":"EG000","title":"Secukinumab 300 mg (2mL PFS)","deathsAffected":"0","deathsAtRisk":"72","seriousAffected":"0","seriousAtRisk":"72","otherAffected":"33","otherAtRisk":"72"},{"id":"EG001","title":"AIN457 300 mg (2x1mL PFS)","deathsAffected":"0","deathsAtRisk":"71","seriousAffected":"1","seriousAtRisk":"71","otherAffected":"39","otherAtRisk":"71"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"71","seriousAffected":"2","seriousAtRisk":"71","otherAffected":"29","otherAtRisk":"71"},{"id":"EG003","title":"Any AIN457 300 mg (2mL PFS)","deathsAffected":"0","deathsAtRisk":"106","seriousAffected":"8","seriousAtRisk":"106","otherAffected":"60","otherAtRisk":"106"},{"id":"EG004","title":"Any Secukuinumab 300 mg (2x1mL PFS)","deathsAffected":"0","deathsAtRisk":"105","seriousAffected":"5","seriousAtRisk":"105","otherAffected":"68","otherAtRisk":"105"},{"id":"EG005","title":"Any Secukinumab 300 mg","deathsAffected":"0","deathsAtRisk":"211","seriousAffected":"13","seriousAtRisk":"211","otherAffected":"128","otherAtRisk":"211"}]},"refs":[]},"NCT02826603":{"title":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","ae":{"timeFrame":"AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 months. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks","frequencyThreshold":"2","groups":[{"id":"EG000","title":"AIN457 300 mg","deathsAffected":"2","deathsAtRisk":"550","seriousAffected":"29","seriousAtRisk":"550","otherAffected":"216","otherAtRisk":"550"},{"id":"EG001","title":"UST 45/90 mg","deathsAffected":"0","deathsAtRisk":"552","seriousAffected":"21","seriousAtRisk":"552","otherAffected":"229","otherAtRisk":"552"},{"id":"EG002","title":"All Patients","deathsAffected":"2","deathsAtRisk":"1102","seriousAffected":"50","seriousAtRisk":"1102","otherAffected":"445","otherAtRisk":"1102"}]},"refs":[]},"NCT03055494":{"title":"Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients","ae":{"timeFrame":"Up to 52 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Secukinumab 300 mg","deathsAffected":"0","deathsAtRisk":"54","seriousAffected":"1","seriousAtRisk":"54","otherAffected":"39","otherAtRisk":"54"},{"id":"EG001","title":"Placebo/Secukinumab 300 mg","deathsAffected":"0","deathsAtRisk":"28","seriousAffected":"1","seriousAtRisk":"28","otherAffected":"25","otherAtRisk":"28"}]},"refs":[]},"NCT03066609":{"title":"Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis","ae":{"timeFrame":"12 months","frequencyThreshold":"3","groups":[{"id":"EG000","title":"AIN457 150 mg","deathsAffected":"0","deathsAtRisk":"136","seriousAffected":"5","seriousAtRisk":"136","otherAffected":"115","otherAtRisk":"136"},{"id":"EG001","title":"AIN457 300 mg","deathsAffected":"0","deathsAtRisk":"272","seriousAffected":"9","seriousAtRisk":"272","otherAffected":"221","otherAtRisk":"272"},{"id":"EG002","title":"Any AIN457 300 mg","deathsAffected":"0","deathsAtRisk":"401","seriousAffected":"14","seriousAtRisk":"401","otherAffected":"312","otherAtRisk":"401"},{"id":"EG003","title":"Any AIN457 Dose","deathsAffected":"0","deathsAtRisk":"537","seriousAffected":"19","seriousAtRisk":"537","otherAffected":"427","otherAtRisk":"537"},{"id":"EG004","title":"Placebo","deathsAffected":"0","deathsAtRisk":"135","seriousAffected":"2","seriousAtRisk":"135","otherAffected":"71","otherAtRisk":"135"}]},"refs":[]},"NCT03589885":{"title":"Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"Adverse events were collected from first dose of study treatment until end of study treatment (Week 48) plus 4 weeks post treatment.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Secukinumab 300 mg (2 mL Auto-Injector)","deathsAffected":"0","deathsAtRisk":"41","seriousAffected":"1","seriousAtRisk":"41","otherAffected":"19","otherAtRisk":"41"},{"id":"EG001","title":"Secukinumab 300 mg (2 x 1 mL PFS)","deathsAffected":"0","deathsAtRisk":"41","seriousAffected":"3","seriousAtRisk":"41","otherAffected":"16","otherAtRisk":"41"},{"id":"EG002","title":"Any Secukinumab 300 mg (2 mL AI)","deathsAffected":"0","deathsAtRisk":"57","seriousAffected":"1","seriousAtRisk":"57","otherAffected":"24","otherAtRisk":"57"},{"id":"EG003","title":"Any Secukinumab 300 mg (2 x 1 mL PFS)","deathsAffected":"0","deathsAtRisk":"58","seriousAffected":"4","seriousAtRisk":"58","otherAffected":"21","otherAtRisk":"58"},{"id":"EG004","title":"Placebo","deathsAffected":"0","deathsAtRisk":"40","seriousAffected":"0","seriousAtRisk":"40","otherAffected":"5","otherAtRisk":"40"},{"id":"EG005","title":"Any Secukinumab 300 mg","deathsAffected":"0","deathsAtRisk":"115","seriousAffected":"5","seriousAtRisk":"115","otherAffected":"45","otherAtRisk":"115"}]},"refs":[]},"NCT00332332":{"title":"Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis","ae":{"timeFrame":"Up to 13 months","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Etanercept","deathsAffected":"","deathsAtRisk":"","seriousAffected":"12","seriousAtRisk":"230","otherAffected":"59","otherAtRisk":"230"}]},"refs":[]},"NCT00585650":{"title":"Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet","ae":{"timeFrame":"Adverse event data were collected over a 28 week period.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"8","otherAffected":"3","otherAtRisk":"8"},{"id":"EG001","title":"Subjects Receiving Placebo for 12 Weeks","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"12","otherAffected":"4","otherAtRisk":"12"}]},"refs":[]},"NCT01543204":{"title":"Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab","ae":{"timeFrame":"From first dose of study drug until 30 days after the last dose (up to 28 weeks).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Etanercept 50mg BIW/50mg QW","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"64","otherAffected":"16","otherAtRisk":"64"}]},"refs":[]},"NCT02134210":{"title":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Enbrel (Etanercept)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"10","seriousAtRisk":"260","otherAffected":"156","otherAtRisk":"260"},{"id":"EG001","title":"CHS-0214","deathsAffected":"","deathsAtRisk":"","seriousAffected":"7","seriousAtRisk":"261","otherAffected":"106","otherAtRisk":"261"}]},"refs":[]},"NCT02749370":{"title":"Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast","ae":{"timeFrame":"From first dose of etanercept to 30 days after last dose, up to 28 weeks.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Etanercept","deathsAffected":"0","deathsAtRisk":"80","seriousAffected":"2","seriousAtRisk":"80","otherAffected":"18","otherAtRisk":"80"}]},"refs":[]},"NCT01265823":{"title":"Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"Adverse events were collected from start of study through 70 days after the last treatment. Treatment duration was 15 weeks.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Adalimumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"150","otherAffected":"86","otherAtRisk":"150"}]},"refs":[]},"NCT01644396":{"title":"An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation","ae":{"timeFrame":"From the first dose of study drug until 70 days after the last dose (up to 33 weeks).","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Adalimumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"50","otherAffected":"14","otherAtRisk":"50"}]},"refs":[]},"NCT01646073":{"title":"Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","ae":{"timeFrame":"Baseline up to 70 days after last dose (week 24).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Double-blind Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"3","seriousAtRisk":"87","otherAffected":"14","otherAtRisk":"87"},{"id":"EG001","title":"Double-blind Adalimumab Eow","deathsAffected":"","deathsAtRisk":"","seriousAffected":"4","seriousAtRisk":"338","otherAffected":"64","otherAtRisk":"338"},{"id":"EG002","title":"Any Adalimumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"15","seriousAtRisk":"423","otherAffected":"137","otherAtRisk":"423"}]},"refs":[]},"NCT00747344":{"title":"A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","ae":{"timeFrame":"","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo (CP)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"60","otherAffected":"30","otherAtRisk":"60"},{"id":"EG001","title":"Ustekinumab 45 mg (CP)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"61","otherAffected":"25","otherAtRisk":"61"},{"id":"EG002","title":"Placebo -> Ustekinumab 45 mg (After CP)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"5","seriousAtRisk":"55","otherAffected":"18","otherAtRisk":"55"},{"id":"EG003","title":"Ustekinumab 45 mg (After CP)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"59","otherAffected":"28","otherAtRisk":"59"}]},"refs":[]},"NCT01708603":{"title":"P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"210 mg Brodalumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"6","seriousAtRisk":"612","otherAffected":"354","otherAtRisk":"612"},{"id":"EG001","title":"140 mg Brodalumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"13","seriousAtRisk":"610","otherAffected":"365","otherAtRisk":"610"},{"id":"EG002","title":"Ustekinumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"4","seriousAtRisk":"300","otherAffected":"177","otherAtRisk":"300"},{"id":"EG003","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"8","seriousAtRisk":"309","otherAffected":"165","otherAtRisk":"309"}]},"refs":[]},"NCT03000309":{"title":"Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy","ae":{"timeFrame":"20 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Apremilast","deathsAffected":"0","deathsAtRisk":"20","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"17","otherAtRisk":"20"}]},"refs":[]},"NCT03022617":{"title":"A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis","ae":{"timeFrame":"Adverse event data was collected over the entirety of the study, 52 weeks for each participant","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Study Group","deathsAffected":"0","deathsAtRisk":"12","seriousAffected":"1","seriousAtRisk":"12","otherAffected":"10","otherAtRisk":"12"}]},"refs":[]},"NCT03587194":{"title":"Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis","ae":{"timeFrame":"16 weeks","frequencyThreshold":"3","groups":[{"id":"EG000","title":"Otezla Enstilar","deathsAffected":"0","deathsAtRisk":"31","seriousAffected":"1","seriousAtRisk":"31","otherAffected":"7","otherAtRisk":"31"}]},"refs":[]},"NCT03774875":{"title":"A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life","ae":{"timeFrame":"Placebo-controlled period: From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period. Apremilast extension period: From first dose of apremilast in the extension period to 28 days after last dose, up to 40 weeks.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo-controlled Period: Placebo","deathsAffected":"0","deathsAtRisk":"92","seriousAffected":"0","seriousAtRisk":"92","otherAffected":"38","otherAtRisk":"92"},{"id":"EG001","title":"Placebo-controlled Period: Apremilast 30 mg","deathsAffected":"0","deathsAtRisk":"185","seriousAffected":"8","seriousAtRisk":"185","otherAffected":"113","otherAtRisk":"185"},{"id":"EG002","title":"Apremilast Extension Period: Apremilast 30 mg","deathsAffected":"0","deathsAtRisk":"221","seriousAffected":"12","seriousAtRisk":"221","otherAffected":"93","otherAtRisk":"221"}]},"refs":[]},"NCT04102007":{"title":"A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","ae":{"timeFrame":"From Baseline Day 1 up to Week 52","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Risankizumab","deathsAffected":"0","deathsAtRisk":"244","seriousAffected":"17","seriousAtRisk":"244","otherAffected":"31","otherAtRisk":"244"}]},"refs":[]},"NCT03364309":{"title":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","ae":{"timeFrame":"Up to 72 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"PBO-Induction Dosing Period","deathsAffected":"0","deathsAtRisk":"88","seriousAffected":"3","seriousAtRisk":"88","otherAffected":"25","otherAtRisk":"88"},{"id":"EG001","title":"IXE80Q4W-Induction Dosing Period","deathsAffected":"0","deathsAtRisk":"174","seriousAffected":"2","seriousAtRisk":"174","otherAffected":"89","otherAtRisk":"174"},{"id":"EG002","title":"IXE80Q2W-Induction Dosing Period","deathsAffected":"0","deathsAtRisk":"176","seriousAffected":"1","seriousAtRisk":"176","otherAffected":"97","otherAtRisk":"176"},{"id":"EG003","title":"IXE80Q4W(Res)/PBO-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"47","seriousAffected":"1","seriousAtRisk":"47","otherAffected":"24","otherAtRisk":"47"},{"id":"EG004","title":"IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"92","seriousAffected":"5","seriousAtRisk":"92","otherAffected":"68","otherAtRisk":"92"},{"id":"EG005","title":"IXE80Q2W(Res)/PBO-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"50","seriousAffected":"1","seriousAtRisk":"50","otherAffected":"22","otherAtRisk":"50"},{"id":"EG006","title":"IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"100","seriousAffected":"2","seriousAtRisk":"100","otherAffected":"66","otherAtRisk":"100"},{"id":"EG007","title":"PBO(Res)/PBO-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"1","seriousAtRisk":"3","otherAffected":"1","otherAtRisk":"3"},{"id":"EG008","title":"PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period","deathsAffected":"1","deathsAtRisk":"79","seriousAffected":"5","seriousAtRisk":"79","otherAffected":"58","otherAtRisk":"79"},{"id":"EG009","title":"IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"31","seriousAffected":"0","seriousAtRisk":"31","otherAffected":"22","otherAtRisk":"31"},{"id":"EG010","title":"IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period","deathsAffected":"0","deathsAtRisk":"23","seriousAffected":"1","seriousAtRisk":"23","otherAffected":"14","otherAtRisk":"23"},{"id":"EG011","title":"PBO(Resp)/PBO-Re-treatment (Maintenance) Period","deathsAffected":"0","deathsAtRisk":"2","seriousAffected":"0","seriousAtRisk":"2","otherAffected":"1","otherAtRisk":"2"},{"id":"EG012","title":"IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period","deathsAffected":"0","deathsAtRisk":"43","seriousAffected":"1","seriousAtRisk":"43","otherAffected":"24","otherAtRisk":"43"},{"id":"EG013","title":"IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period","deathsAffected":"0","deathsAtRisk":"7","seriousAffected":"0","seriousAtRisk":"7","otherAffected":"4","otherAtRisk":"7"},{"id":"EG014","title":"IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period","deathsAffected":"0","deathsAtRisk":"45","seriousAffected":"2","seriousAtRisk":"45","otherAffected":"27","otherAtRisk":"45"},{"id":"EG015","title":"IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period","deathsAffected":"0","deathsAtRisk":"10","seriousAffected":"0","seriousAtRisk":"10","otherAffected":"5","otherAtRisk":"10"},{"id":"EG016","title":"PBO-Follow-up Period","deathsAffected":"0","deathsAtRisk":"11","seriousAffected":"0","seriousAtRisk":"11","otherAffected":"0","otherAtRisk":"11"},{"id":"EG017","title":"IXE80Q4W-Follow-up Period","deathsAffected":"0","deathsAtRisk":"375","seriousAffected":"7","seriousAtRisk":"375","otherAffected":"27","otherAtRisk":"375"},{"id":"EG018","title":"IXE80Q2W-Follow-up Period","deathsAffected":"0","deathsAtRisk":"2","seriousAffected":"0","seriousAtRisk":"2","otherAffected":"0","otherAtRisk":"2"}]},"refs":[]},"NCT01745133":{"title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Vehicle","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"19","otherAffected":"1","otherAtRisk":"19"},{"id":"EG001","title":"Calcipotriene 80%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"2","otherAtRisk":"20"},{"id":"EG002","title":"Calcipotriene + Clobetasol Propionate 79%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"19","otherAffected":"1","otherAtRisk":"19"}]},"refs":[]},"NCT03370133":{"title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","ae":{"timeFrame":"Treatment-emergent AEs were collected from Baseline to Safety Follow Up (up to Week 68)","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo Initial Period (SS)","deathsAffected":"1","deathsAtRisk":"83","seriousAffected":"2","seriousAtRisk":"83","otherAffected":"17","otherAtRisk":"83"},{"id":"EG001","title":"Bimekizumab 320 mg Q4W Initial Period (SS)","deathsAffected":"1","deathsAtRisk":"321","seriousAffected":"5","seriousAtRisk":"321","otherAffected":"87","otherAtRisk":"321"},{"id":"EG002","title":"Ustekinumab Initial Period (SS)","deathsAffected":"1","deathsAtRisk":"163","seriousAffected":"5","seriousAtRisk":"163","otherAffected":"37","otherAtRisk":"163"},{"id":"EG003","title":"Any Bimekizumab 320 mg Q4W (AMS)","deathsAffected":"2","deathsAtRisk":"395","seriousAffected":"24","seriousAtRisk":"395","otherAffected":"192","otherAtRisk":"395"},{"id":"EG004","title":"Any Ustekinumab (AMS)","deathsAffected":"1","deathsAtRisk":"163","seriousAffected":"13","seriousAtRisk":"163","otherAffected":"73","otherAtRisk":"163"}]},"refs":[{"pmid":"36648594","short":"Asahina A et al."},{"pmid":"35544084","short":"Gordon KB et al."},{"pmid":"37950894","short":"Gordon KB et al."},{"pmid":"41060492","short":"Strober B et al."}]},"NCT05020249":{"title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"From Baseline to End of Safety Follow-Up (up to Week 32)","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo","deathsAffected":"0","deathsAtRisk":"15","seriousAffected":"1","seriousAtRisk":"15","otherAffected":"6","otherAtRisk":"15"},{"id":"EG001","title":"Bimekizumab 320 mg Q4W","deathsAffected":"0","deathsAtRisk":"32","seriousAffected":"0","seriousAtRisk":"32","otherAffected":"11","otherAtRisk":"32"}]},"refs":[{"pmid":"39328126","short":"Youn SW et al."}]},"NCT01710046":{"title":"Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis","ae":{"timeFrame":"Adverse events (AEs) were reported from the time of informed consent through and including 28 calendar days after the last administration of the investigational product.","frequencyThreshold":"2","groups":[{"id":"EG000","title":"Tofacitinib 10 mg BID","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"9","otherAffected":"2","otherAtRisk":"9"},{"id":"EG001","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"3","otherAffected":"1","otherAtRisk":"3"}]},"refs":[]},"NCT05478499":{"title":"Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis","ae":{"timeFrame":"Participants were assessed for all-cause mortality from their first dose to their primary data cut-off (Up to 24 months). SAEs and Other AEs were assessed from first dose up to 30 days post last dose (Up to 13 months).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo Controlled - Deucravacitinib","deathsAffected":"0","deathsAtRisk":"103","seriousAffected":"1","seriousAtRisk":"103","otherAffected":"47","otherAtRisk":"103"},{"id":"EG001","title":"Placebo Controlled - Placebo","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"1","seriousAtRisk":"51","otherAffected":"14","otherAtRisk":"51"},{"id":"EG002","title":"Active Treatment - Deucravacitinib - Deucravacitinib","deathsAffected":"1","deathsAtRisk":"94","seriousAffected":"4","seriousAtRisk":"94","otherAffected":"42","otherAtRisk":"94"},{"id":"EG003","title":"Active Treatment - Placebo - Deucravacitinib","deathsAffected":"0","deathsAtRisk":"45","seriousAffected":"0","seriousAtRisk":"45","otherAffected":"16","otherAtRisk":"45"}]},"refs":[]},"NCT05701995":{"title":"A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting","ae":{"timeFrame":"Participants were assessed for All-cause mortality, Serious adverse events and Other adverse events for up to approximately 28 months.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo Controlled - Deucravacitinib","deathsAffected":"1","deathsAtRisk":"119","seriousAffected":"3","seriousAtRisk":"119","otherAffected":"32","otherAtRisk":"119"},{"id":"EG001","title":"Placebo Controlled - Placebo","deathsAffected":"0","deathsAtRisk":"59","seriousAffected":"1","seriousAtRisk":"59","otherAffected":"13","otherAtRisk":"59"},{"id":"EG002","title":"Active Treatment - Deucravacitinib - Deucravacitinib","deathsAffected":"1","deathsAtRisk":"103","seriousAffected":"5","seriousAtRisk":"103","otherAffected":"26","otherAtRisk":"103"},{"id":"EG003","title":"Active Treatment - Placebo - Deucravacitinib","deathsAffected":"0","deathsAtRisk":"49","seriousAffected":"3","seriousAtRisk":"49","otherAffected":"10","otherAtRisk":"49"}]},"refs":[]},"NCT00245765":{"title":"Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy","ae":{"timeFrame":"Adverse Events were collected from Baseline (Week 0) over the 12-weeks Treatment Period until the end of the Follow-up Period (up to 36 weeks).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo (SS)","deathsAffected":"0","deathsAtRisk":"58","seriousAffected":"1","seriousAtRisk":"58","otherAffected":"34","otherAtRisk":"58"},{"id":"EG001","title":"Certolizumab Pegol 200 mg (SS)","deathsAffected":"0","deathsAtRisk":"60","seriousAffected":"2","seriousAtRisk":"60","otherAffected":"32","otherAtRisk":"60"},{"id":"EG002","title":"Certolizumab Pegol 400 mg (SS)","deathsAffected":"0","deathsAtRisk":"57","seriousAffected":"5","seriousAtRisk":"57","otherAffected":"27","otherAtRisk":"57"}]},"refs":[{"pmid":"22413944","short":"Reich K et al."}]},"NCT00329303":{"title":"Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis","ae":{"timeFrame":"Over the 12 week duration of the study.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Certolizumab Pegol (CZP) 200 mg","deathsAffected":"0","deathsAtRisk":"34","seriousAffected":"0","seriousAtRisk":"34","otherAffected":"9","otherAtRisk":"34"},{"id":"EG001","title":"Certolizumab Pegol (CZP) 400 mg","deathsAffected":"0","deathsAtRisk":"37","seriousAffected":"0","seriousAtRisk":"37","otherAffected":"11","otherAtRisk":"37"}]},"refs":[{"pmid":"22413944","short":"Reich K et al."}]},"NCT03051217":{"title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","ae":{"timeFrame":"Adverse Events (AEs) were collected from Baseline (Week 0) until the Safety Follow-up Visit (Week 60).","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Placebo (SS)","deathsAffected":"0","deathsAtRisk":"26","seriousAffected":"1","seriousAtRisk":"26","otherAffected":"17","otherAtRisk":"26"},{"id":"EG001","title":"CZP 200mg Q2W (SS)","deathsAffected":"0","deathsAtRisk":"72","seriousAffected":"2","seriousAtRisk":"72","otherAffected":"41","otherAtRisk":"72"},{"id":"EG002","title":"CZP 400mg Q4W (SS)","deathsAffected":"0","deathsAtRisk":"20","seriousAffected":"0","seriousAtRisk":"20","otherAffected":"15","otherAtRisk":"20"},{"id":"EG003","title":"CZP 200 mg Q2W + CZP 400 mg Q4W (SS)","deathsAffected":"0","deathsAtRisk":"72","seriousAffected":"2","seriousAtRisk":"72","otherAffected":"48","otherAtRisk":"72"},{"id":"EG004","title":"CZP 400 mg Q2W (SS)","deathsAffected":"0","deathsAtRisk":"64","seriousAffected":"6","seriousAtRisk":"64","otherAffected":"45","otherAtRisk":"64"},{"id":"EG005","title":"All CZP (SS)","deathsAffected":"0","deathsAtRisk":"122","seriousAffected":"8","seriousAtRisk":"122","otherAffected":"91","otherAtRisk":"122"}]},"refs":[{"pmid":"34826124","short":"Imafuku S et al."}]},"NCT03897075":{"title":"Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis","ae":{"timeFrame":"72 Weeks","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Tildrakizumab 100mg","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"3","seriousAtRisk":"51","otherAffected":"28","otherAtRisk":"51"},{"id":"EG001","title":"Placebo","deathsAffected":"0","deathsAtRisk":"48","seriousAffected":"2","seriousAtRisk":"48","otherAffected":"19","otherAtRisk":"48"}]},"refs":[]},"NCT03956355":{"title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)","ae":{"timeFrame":"Subject duration: 12 weeks of treatment and 4 week follow-up for subjects not enrolled in the long-term extension study (DMVT-505-3003)","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Tapinarof (DMVT-505)","deathsAffected":"0","deathsAtRisk":"340","seriousAffected":"9","seriousAtRisk":"340","otherAffected":"131","otherAtRisk":"340"},{"id":"EG001","title":"Vehicle Cream","deathsAffected":"0","deathsAtRisk":"170","seriousAffected":"0","seriousAtRisk":"170","otherAffected":"27","otherAtRisk":"170"}]},"refs":[{"pmid":"34879448","short":"Lebwohl MG et al."}]},"NCT03983980":{"title":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)","ae":{"timeFrame":"Subject duration: 12 weeks of treatment and 4 week follow-up for subjects not enrolled in the long-term extension study (DMVT-505-3003)","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Tapinarof (DMVT-505) Cream Group","deathsAffected":"0","deathsAtRisk":"343","seriousAffected":"7","seriousAtRisk":"343","otherAffected":"123","otherAtRisk":"343"},{"id":"EG001","title":"Vehicle Cream Group","deathsAffected":"0","deathsAtRisk":"172","seriousAffected":"0","seriousAtRisk":"172","otherAffected":"28","otherAtRisk":"172"}]},"refs":[]},"NCT05680740":{"title":"A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis","ae":{"timeFrame":"13 Weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"VTAMA® (Tapinarof) Cream 1%","deathsAffected":"0","deathsAtRisk":"34","seriousAffected":"2","seriousAtRisk":"34","otherAffected":"13","otherAtRisk":"34"}]},"refs":[]},"NCT05789576":{"title":"A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region","ae":{"timeFrame":"13 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"VTAMA (Tapinarof) Cream, 1%","deathsAffected":"0","deathsAtRisk":"31","seriousAffected":"1","seriousAtRisk":"31","otherAffected":"18","otherAtRisk":"31"}]},"refs":[]},"NCT01206387":{"title":"Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"3 months","frequencyThreshold":"2","groups":[{"id":"EG000","title":"Desoximetasone Spray 0.25%","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"60","otherAffected":"17","otherAtRisk":"60"},{"id":"EG001","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"60","otherAffected":"21","otherAtRisk":"60"}]},"refs":[]},"NCT01708629":{"title":"Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"210 mg Brodalumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"9","seriousAtRisk":"624","otherAffected":"353","otherAtRisk":"624"},{"id":"EG001","title":"140 mg Brodalumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"10","seriousAtRisk":"629","otherAffected":"329","otherAtRisk":"629"},{"id":"EG002","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"3","seriousAtRisk":"315","otherAffected":"152","otherAtRisk":"315"},{"id":"EG003","title":"Ustekinumab","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"313","otherAffected":"168","otherAtRisk":"313"}]},"refs":[]},"NCT04211363":{"title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","ae":{"timeFrame":"Up to 121 days","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Rofumilast Cream 0.3%","deathsAffected":"0","deathsAtRisk":"286","seriousAffected":"2","seriousAtRisk":"286","otherAffected":"0","otherAtRisk":"286"},{"id":"EG001","title":"Vehicle Cream","deathsAffected":"0","deathsAtRisk":"153","seriousAffected":"1","seriousAtRisk":"153","otherAffected":"0","otherAtRisk":"153"}]},"refs":[]},"NCT00658606":{"title":"Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects","ae":{"timeFrame":"From the time of Informed Consent through the last study visit.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Alefacept Alone","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"49","otherAffected":"10","otherAtRisk":"49"},{"id":"EG001","title":"Alefacept + nbUVB","deathsAffected":"","deathsAtRisk":"","seriousAffected":"2","seriousAtRisk":"49","otherAffected":"40","otherAtRisk":"49"}]},"refs":[]},"NCT02886702":{"title":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","ae":{"timeFrame":"Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 85 days","frequencyThreshold":"1","groups":[{"id":"EG000","title":"Test","deathsAffected":"0","deathsAtRisk":"284","seriousAffected":"0","seriousAtRisk":"284","otherAffected":"31","otherAtRisk":"284"},{"id":"EG001","title":"Reference","deathsAffected":"0","deathsAtRisk":"286","seriousAffected":"0","seriousAtRisk":"286","otherAffected":"24","otherAtRisk":"286"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"285","seriousAffected":"3","seriousAtRisk":"285","otherAffected":"21","otherAtRisk":"285"}]},"refs":[]},"NCT02899988":{"title":"A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis","ae":{"timeFrame":"Up To 120 Weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Induction: Placebo","deathsAffected":"0","deathsAtRisk":"52","seriousAffected":"1","seriousAtRisk":"52","otherAffected":"19","otherAtRisk":"52"},{"id":"EG001","title":"Induction: 30 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"1","seriousAtRisk":"51","otherAffected":"24","otherAtRisk":"51"},{"id":"EG002","title":"Induction:100 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"0","seriousAtRisk":"51","otherAffected":"19","otherAtRisk":"51"},{"id":"EG003","title":"Induction: 300 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"1","seriousAtRisk":"51","otherAffected":"19","otherAtRisk":"51"},{"id":"EG004","title":"Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN","deathsAffected":"0","deathsAtRisk":"15","seriousAffected":"1","seriousAtRisk":"15","otherAffected":"13","otherAtRisk":"15"},{"id":"EG005","title":"Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"2","seriousAtRisk":"30","otherAffected":"20","otherAtRisk":"30"},{"id":"EG006","title":"Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN","deathsAffected":"0","deathsAtRisk":"34","seriousAffected":"1","seriousAtRisk":"34","otherAffected":"23","otherAtRisk":"34"},{"id":"EG007","title":"Maintenance: Placebo to 300 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"50","seriousAffected":"2","seriousAtRisk":"50","otherAffected":"38","otherAtRisk":"50"},{"id":"EG008","title":"Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"34","seriousAffected":"2","seriousAtRisk":"34","otherAffected":"28","otherAtRisk":"34"},{"id":"EG009","title":"Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W","deathsAffected":"0","deathsAtRisk":"21","seriousAffected":"2","seriousAtRisk":"21","otherAffected":"18","otherAtRisk":"21"},{"id":"EG010","title":"Maintenance: 300 mg Mirikizumab Q8W","deathsAffected":"0","deathsAtRisk":"15","seriousAffected":"3","seriousAtRisk":"15","otherAffected":"13","otherAtRisk":"15"},{"id":"EG011","title":"300 mg Mirikizumab Q8W-Rescue","deathsAffected":"0","deathsAtRisk":"10","seriousAffected":"1","seriousAtRisk":"10","otherAffected":"9","otherAtRisk":"10"},{"id":"EG012","title":"30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up","deathsAffected":"0","deathsAtRisk":"2","seriousAffected":"0","seriousAtRisk":"2","otherAffected":"0","otherAtRisk":"2"},{"id":"EG013","title":"100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up","deathsAffected":"0","deathsAtRisk":"4","seriousAffected":"0","seriousAtRisk":"4","otherAffected":"1","otherAtRisk":"4"},{"id":"EG014","title":"300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"0","seriousAtRisk":"3","otherAffected":"0","otherAtRisk":"3"},{"id":"EG015","title":"Placebo to 300 mg Mirikizumab Q8W-Follow-up","deathsAffected":"0","deathsAtRisk":"3","seriousAffected":"0","seriousAtRisk":"3","otherAffected":"0","otherAtRisk":"3"},{"id":"EG016","title":"30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up","deathsAffected":"0","deathsAtRisk":"6","seriousAffected":"0","seriousAtRisk":"6","otherAffected":"2","otherAtRisk":"6"},{"id":"EG017","title":"100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up","deathsAffected":"0","deathsAtRisk":"2","seriousAffected":"0","seriousAtRisk":"2","otherAffected":"1","otherAtRisk":"2"}]},"refs":[]},"NCT00778700":{"title":"A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis","ae":{"timeFrame":"From first dose up to 28 days after last dose of study drug (Up to 16 weeks)","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Vehicle Cream","deathsAffected":"0","deathsAtRisk":"50","seriousAffected":"1","seriousAtRisk":"50","otherAffected":"11","otherAtRisk":"50"},{"id":"EG001","title":"Ruxolitinib Phosphate 0.5% Cream","deathsAffected":"0","deathsAtRisk":"51","seriousAffected":"2","seriousAtRisk":"51","otherAffected":"11","otherAtRisk":"51"},{"id":"EG002","title":"Ruxolitinib Phosphate 1.0% Cream","deathsAffected":"0","deathsAtRisk":"49","seriousAffected":"0","seriousAtRisk":"49","otherAffected":"16","otherAtRisk":"49"},{"id":"EG003","title":"Ruxolitinib Phosphate 1.5% Cream","deathsAffected":"0","deathsAtRisk":"49","seriousAffected":"3","seriousAtRisk":"49","otherAffected":"18","otherAtRisk":"49"},{"id":"EG004","title":"Total","deathsAffected":"0","deathsAtRisk":"199","seriousAffected":"6","seriousAtRisk":"199","otherAffected":"56","otherAtRisk":"199"}]},"refs":[]},"NCT00428974":{"title":"Safety and Efficacy Study of CF101 to Treat Psoriasis","ae":{"timeFrame":"14 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"CF101 1 mg Twice Daily (BID)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"24","otherAffected":"2","otherAtRisk":"24"},{"id":"EG001","title":"CF101 2 mg BID","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"17","otherAffected":"1","otherAtRisk":"17"},{"id":"EG002","title":"CF101 4 mg BID","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"15","otherAffected":"1","otherAtRisk":"15"},{"id":"EG003","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"1","seriousAtRisk":"19","otherAffected":"1","otherAtRisk":"19"}]},"refs":[{"pmid":"21504485","short":"David M et al."}]},"NCT01265667":{"title":"Trial of CF101 to Treat Patients With Psoriasis","ae":{"timeFrame":"16 weeks","frequencyThreshold":"1","groups":[{"id":"EG000","title":"CF101 2 mg","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"145","otherAffected":"24","otherAtRisk":"145"},{"id":"EG001","title":"Placebo","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"148","otherAffected":"15","otherAtRisk":"148"}]},"refs":[]},"NCT04316585":{"title":"A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants","ae":{"timeFrame":"All-Cause Mortality, SAEs and non-serious AEs were collected from the start of study treatment including the Follow-up visit up to Day 120.","frequencyThreshold":"1","groups":[{"id":"EG000","title":"GSK2982772 960 mg","deathsAffected":"0","deathsAtRisk":"19","seriousAffected":"1","seriousAtRisk":"19","otherAffected":"11","otherAtRisk":"19"},{"id":"EG001","title":"Placebo","deathsAffected":"0","deathsAtRisk":"10","seriousAffected":"0","seriousAtRisk":"10","otherAffected":"6","otherAtRisk":"10"}]},"refs":[]},"NCT02969018":{"title":"Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis","ae":{"timeFrame":"From first dose of study treatment up to 20 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD","deathsAffected":"1","deathsAtRisk":"25","seriousAffected":"2","seriousAtRisk":"25","otherAffected":"11","otherAtRisk":"25"},{"id":"EG001","title":"PF-06700841 60 mg QD Followed by 10 mg QD","deathsAffected":"0","deathsAtRisk":"29","seriousAffected":"1","seriousAtRisk":"29","otherAffected":"14","otherAtRisk":"29"},{"id":"EG002","title":"PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)","deathsAffected":"0","deathsAtRisk":"26","seriousAffected":"1","seriousAtRisk":"26","otherAffected":"13","otherAtRisk":"26"},{"id":"EG003","title":"PF-06700841 60 mg QD Followed by Placebo","deathsAffected":"0","deathsAtRisk":"25","seriousAffected":"1","seriousAtRisk":"25","otherAffected":"13","otherAtRisk":"25"},{"id":"EG004","title":"PF-06700841 30 mg QD","deathsAffected":"0","deathsAtRisk":"29","seriousAffected":"0","seriousAtRisk":"29","otherAffected":"13","otherAtRisk":"29"},{"id":"EG005","title":"PF-06700841 30 mg QD Followed by 10 mg QD","deathsAffected":"0","deathsAtRisk":"25","seriousAffected":"0","seriousAtRisk":"25","otherAffected":"12","otherAtRisk":"25"},{"id":"EG006","title":"PF-06700841 30 mg QD Followed by 100 mg QW","deathsAffected":"0","deathsAtRisk":"30","seriousAffected":"0","seriousAtRisk":"30","otherAffected":"16","otherAtRisk":"30"},{"id":"EG007","title":"Placebo","deathsAffected":"0","deathsAtRisk":"23","seriousAffected":"0","seriousAtRisk":"23","otherAffected":"9","otherAtRisk":"23"}]},"refs":[]},"NCT00617903":{"title":"Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea","ae":{"timeFrame":"","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Azelaic Acid Foam, 15% (BAY39-6251)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"41","otherAffected":"14","otherAtRisk":"41"},{"id":"EG001","title":"Vehicle Foam","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"42","otherAffected":"10","otherAtRisk":"42"}]},"refs":[]},"NCT02120924":{"title":"A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea","ae":{"timeFrame":"Adverse events were monitored and collected over a period of at least 12 weeks, through to study completion.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Azelaic Acid, 15% Topical Gel","deathsAffected":"1","deathsAtRisk":"390","seriousAffected":"1","seriousAtRisk":"390","otherAffected":"109","otherAtRisk":"390"},{"id":"EG001","title":"Finacea® (Azelaic Acid) Gel, 15%","deathsAffected":"0","deathsAtRisk":"386","seriousAffected":"0","seriousAtRisk":"386","otherAffected":"98","otherAtRisk":"386"},{"id":"EG002","title":"Gel Vehicle","deathsAffected":"0","deathsAtRisk":"190","seriousAffected":"0","seriousAtRisk":"190","otherAffected":"47","otherAtRisk":"190"}]},"refs":[]},"NCT00892281":{"title":"ORCA - Oracea® for Rosacea: A Community-based Assessment","ae":{"timeFrame":"12 weeks","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Oracea® as Monotherapy","deathsAffected":"","deathsAtRisk":"","seriousAffected":"5","seriousAtRisk":"1196","otherAffected":"0","otherAtRisk":"1196"},{"id":"EG001","title":"Oracea® as add-on Therapy","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"224","otherAffected":"0","otherAtRisk":"224"}]},"refs":[]},"NCT03340961":{"title":"A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules","ae":{"timeFrame":"AEs were collected from subjects from the time of signing of the ICF up to Week 16/End of Study Visit.","frequencyThreshold":"5","groups":[{"id":"EG000","title":"DFD-29 Extended Release Capsules (40 mg)","deathsAffected":"0","deathsAtRisk":"52","seriousAffected":"1","seriousAtRisk":"52","otherAffected":"37","otherAtRisk":"52"},{"id":"EG001","title":"DFD-29 Extended Release Capsules (20 mg)","deathsAffected":"0","deathsAtRisk":"48","seriousAffected":"2","seriousAtRisk":"48","otherAffected":"33","otherAtRisk":"48"},{"id":"EG002","title":"Oraycea® (Doxycycline) Capsules","deathsAffected":"0","deathsAtRisk":"48","seriousAffected":"2","seriousAtRisk":"48","otherAffected":"27","otherAtRisk":"48"},{"id":"EG003","title":"Placebo Capsules","deathsAffected":"0","deathsAtRisk":"53","seriousAffected":"0","seriousAtRisk":"53","otherAffected":"35","otherAtRisk":"53"}]},"refs":[]},"NCT05296629":{"title":"A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.","ae":{"timeFrame":"From the signing of informed consent up to 16 weeks of study treatment.","frequencyThreshold":"1","groups":[{"id":"EG000","title":"DFD-29","deathsAffected":"0","deathsAtRisk":"121","seriousAffected":"0","seriousAtRisk":"121","otherAffected":"17","otherAtRisk":"121"},{"id":"EG001","title":"Doxycycline 40 mg","deathsAffected":"0","deathsAtRisk":"116","seriousAffected":"0","seriousAtRisk":"116","otherAffected":"19","otherAtRisk":"116"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"76","seriousAffected":"0","seriousAtRisk":"76","otherAffected":"18","otherAtRisk":"76"}]},"refs":[]},"NCT05343455":{"title":"A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)","ae":{"timeFrame":"From the signing of informed consent up to 16 weeks of study treatment.","frequencyThreshold":"1","groups":[{"id":"EG000","title":"DFD-29","deathsAffected":"0","deathsAtRisk":"122","seriousAffected":"2","seriousAtRisk":"122","otherAffected":"48","otherAtRisk":"122"},{"id":"EG001","title":"Doxycycline 40 mg","deathsAffected":"0","deathsAtRisk":"121","seriousAffected":"0","seriousAtRisk":"121","otherAffected":"37","otherAtRisk":"121"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"82","seriousAffected":"1","seriousAtRisk":"82","otherAffected":"27","otherAtRisk":"82"}]},"refs":[]},"NCT02795117":{"title":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea","ae":{"timeFrame":"Day 1 to day 84","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Test Product","deathsAffected":"0","deathsAtRisk":"193","seriousAffected":"0","seriousAtRisk":"193","otherAffected":"0","otherAtRisk":"193"},{"id":"EG001","title":"Reference Product","deathsAffected":"0","deathsAtRisk":"193","seriousAffected":"0","seriousAtRisk":"193","otherAffected":"0","otherAtRisk":"193"},{"id":"EG002","title":"Placebo","deathsAffected":"0","deathsAtRisk":"100","seriousAffected":"0","seriousAtRisk":"100","otherAffected":"0","otherAtRisk":"100"}]},"refs":[]},"NCT03352323":{"title":"An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea","ae":{"timeFrame":"15 days","frequencyThreshold":"5","groups":[{"id":"EG000","title":"Oxymetazoline Cream","deathsAffected":"0","deathsAtRisk":"50","seriousAffected":"0","seriousAtRisk":"50","otherAffected":"3","otherAtRisk":"50"}]},"refs":[]},"NCT02547441":{"title":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","ae":{"timeFrame":"12-week in Double-Blind Period and maximum 1 year in Open-Label Period","frequencyThreshold":"2","groups":[{"id":"EG000","title":"CLS001 (Omiganan) Gel (Double-Blind Period)","deathsAffected":"0","deathsAtRisk":"235","seriousAffected":"4","seriousAtRisk":"235","otherAffected":"83","otherAtRisk":"235"},{"id":"EG001","title":"Vehicle Gel (Double-Blind Period)","deathsAffected":"0","deathsAtRisk":"228","seriousAffected":"4","seriousAtRisk":"228","otherAffected":"83","otherAtRisk":"228"},{"id":"EG002","title":"CLS001 (Omiganan) Gel (Open-Label Period)","deathsAffected":"0","deathsAtRisk":"363","seriousAffected":"8","seriousAtRisk":"363","otherAffected":"116","otherAtRisk":"363"}]},"refs":[]},"NCT02576860":{"title":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","ae":{"timeFrame":"115 Days","frequencyThreshold":"2","groups":[{"id":"EG000","title":"Treatment","deathsAffected":"0","deathsAtRisk":"136","seriousAffected":"1","seriousAtRisk":"136","otherAffected":"47","otherAtRisk":"136"},{"id":"EG001","title":"Vehicle Gel","deathsAffected":"0","deathsAtRisk":"127","seriousAffected":"0","seriousAtRisk":"127","otherAffected":"36","otherAtRisk":"127"}]},"refs":[]},"NCT01045551":{"title":"Open Label Pilot Study of Apremilast in Treatment of Rosacea","ae":{"timeFrame":"Adverse event data was collected for approximately 4 years.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Apremilast 20 mg (Twice Per Day)","deathsAffected":"","deathsAtRisk":"","seriousAffected":"0","seriousAtRisk":"10","otherAffected":"6","otherAtRisk":"10"}]},"refs":[]},"NCT04555525":{"title":"A Pilot Study on the Use of Seysara for Rosacea","ae":{"timeFrame":"12 weeks average, from signing of Informed Consent until end of study participation.","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Sarecycline","deathsAffected":"0","deathsAtRisk":"72","seriousAffected":"0","seriousAtRisk":"72","otherAffected":"16","otherAtRisk":"72"},{"id":"EG001","title":"Centrum Adult Multivitamin","deathsAffected":"0","deathsAtRisk":"25","seriousAffected":"0","seriousAtRisk":"25","otherAffected":"0","otherAtRisk":"25"}]},"refs":[]},"NCT03079531":{"title":"Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea","ae":{"timeFrame":"16 weeks","frequencyThreshold":"0","groups":[{"id":"EG000","title":"Secukinumab Arm","deathsAffected":"0","deathsAtRisk":"24","seriousAffected":"0","seriousAtRisk":"24","otherAffected":"11","otherAtRisk":"24"}]},"refs":[]}},"conditions":{"acne":{"terms":{"D000068816":{"name":"Adapalene","counts":{"studiesWithResults":28,"favouredTreatment":1,"favouredComparator":2,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1,"active-comparator":2},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Success Rate on the Investigator's Global Assessment","timeFrame":"at week 12","treatmentName":"Adapalene","treatment":{"groupId":"OG001","groupLabel":"Adapalene Gel","value":21.8,"displayValue":"21.8%","denominator":418},"comparator":{"groupId":"OG003","groupLabel":"Gel Vehicle","value":17.9,"displayValue":"17.9%","denominator":418},"difference":3.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At week 12, 21.8% of people in the Adapalene Gel group had the submitted improvement result (Success Rate on the Investigator's Global Assessment), compared with 17.9% in the Gel Vehicle group—3.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00421993","sourceUrl":"https://clinicaltrials.gov/study/NCT00421993","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1670,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire","timeFrame":"Baseline (Week 0) and Week 2","treatmentName":"Adapalene","treatment":{"groupId":"OG001","groupLabel":"Differin Gel","value":-1.1,"displayValue":"-1.1 scores on a scale","denominator":84},"comparator":{"groupId":"OG000","groupLabel":"Duac Gel","value":-4.9,"displayValue":"-4.9 scores on a scale","denominator":83},"difference":-3.8,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At Baseline (Week 0) and Week 2, Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire changed by -1.1 scores on a scale in the Differin Gel group and -4.9 scores on a scale in the Duac Gel group—a difference 3.8 scores on a scale numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT00807014","sourceUrl":"https://clinicaltrials.gov/study/NCT00807014","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":169,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12","timeFrame":"Baseline, Week 12","treatmentName":"Adapalene","treatment":{"groupId":"OG001","groupLabel":"Adapalene Gel 0.3%","value":-60,"displayValue":"-60%","denominator":73},"comparator":{"groupId":"OG000","groupLabel":"Tazarotene Cream 0.1%","value":-68.1,"displayValue":"-68.1%","denominator":62},"difference":-8.1,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Baseline, Week 12, Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12 changed by -60% in the Adapalene Gel 0.3% group and -68.1% in the Tazarotene Cream 0.1% group—a difference 8.1 percentage points numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00829049","sourceUrl":"https://clinicaltrials.gov/study/NCT00829049","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":165,"comparatorClass":"active-comparator"}],"timeToEffect":{"weeks":12,"nctId":"NCT00421993"}},"D001585":{"name":"Benzoyl Peroxide","counts":{"studiesWithResults":28,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Success Rate on the Investigator's Global Assessment","timeFrame":"at week 12","treatmentName":"Benzoyl Peroxide","treatment":{"groupId":"OG002","groupLabel":"Benzoyl Peroxide Gel","value":26.7,"displayValue":"26.7%","denominator":415},"comparator":{"groupId":"OG003","groupLabel":"Gel Vehicle","value":17.9,"displayValue":"17.9%","denominator":418},"difference":8.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At week 12, 26.7% of people in the Benzoyl Peroxide Gel group had the submitted improvement result (Success Rate on the Investigator's Global Assessment), compared with 17.9% in the Gel Vehicle group—8.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00421993","sourceUrl":"https://clinicaltrials.gov/study/NCT00421993","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1670,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT00421993"}},"D002981":{"name":"Clindamycin","counts":{"studiesWithResults":17,"favouredTreatment":6,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":6},"comparative":6,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12","timeFrame":"Baseline (Day 1) and Week 12","treatmentName":"Clindamycin","treatment":{"groupId":"OG001","groupLabel":"Clindamycin Gel","value":25,"displayValue":"25%","denominator":328},"comparator":{"groupId":"OG003","groupLabel":"Vehicle Gel","value":17.8,"displayValue":"17.8%","denominator":332},"difference":7.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1) and Week 12, 25% of people in the Clindamycin Gel group had the submitted improvement result (Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12), compared with 17.8% in the Vehicle Gel group—7.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00776919","sourceUrl":"https://clinicaltrials.gov/study/NCT00776919","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1315,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts","timeFrame":"Baseline (Day 1) and Week 12","treatmentName":"Clindamycin","treatment":{"groupId":"OG001","groupLabel":"Clindamycin Gel","value":-15.6,"displayValue":"-15.6 lesion counts","denominator":318},"comparator":{"groupId":"OG003","groupLabel":"Vehicle Gel","value":-13.1,"displayValue":"-13.1 lesion counts","denominator":329},"difference":2.5,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1) and Week 12, Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts changed by -15.6 lesion counts in the Clindamycin Gel group and -13.1 lesion counts in the Vehicle Gel group—a difference 2.5 lesion counts numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00776919","sourceUrl":"https://clinicaltrials.gov/study/NCT00776919","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1315,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts","timeFrame":"Baseline (Day 1) and Week 12","treatmentName":"Clindamycin","treatment":{"groupId":"OG001","groupLabel":"Clindamycin Gel","value":-19.8,"displayValue":"-19.8 lesion counts","denominator":318},"comparator":{"groupId":"OG003","groupLabel":"Vehicle Gel","value":-14.8,"displayValue":"-14.8 lesion counts","denominator":329},"difference":5,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1) and Week 12, Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts changed by -19.8 lesion counts in the Clindamycin Gel group and -14.8 lesion counts in the Vehicle Gel group—a difference 5 lesion counts numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00776919","sourceUrl":"https://clinicaltrials.gov/study/NCT00776919","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1315,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks","timeFrame":"Percent change from baseline to 12 weeks","treatmentName":"Clindamycin","treatment":{"groupId":"OG001","groupLabel":"Clindamycin 1% Gel (Greenstone LLC)","value":-72,"displayValue":"-72%","denominator":431},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-16,"displayValue":"-16%","denominator":214},"difference":56,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Percent change from baseline to 12 weeks, Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks changed by -72% in the Clindamycin 1% Gel (Greenstone LLC) group and -16% in the Placebo group—a difference 56 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03522441","sourceUrl":"https://clinicaltrials.gov/study/NCT03522441","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1125,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks","timeFrame":"Percent change from baseline to 12 weeks","treatmentName":"Clindamycin","treatment":{"groupId":"OG000","groupLabel":"Clindamycin 1% Gel (Akorn Pharmaceuticals)","value":-66.2,"displayValue":"-66.2%","denominator":424},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-16,"displayValue":"-16%","denominator":214},"difference":50.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Percent change from baseline to 12 weeks, Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks changed by -66.2% in the Clindamycin 1% Gel (Akorn Pharmaceuticals) group and -16% in the Placebo group—a difference 50.2 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03522441","sourceUrl":"https://clinicaltrials.gov/study/NCT03522441","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1125,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts - Change in Baseline to 12 Week","timeFrame":"Percent change in baseline to 12 weeks","treatmentName":"Clindamycin","treatment":{"groupId":"OG000","groupLabel":"Clindamycin 1% Gel (Akorn Pharmaceuticals)","value":-50.4,"displayValue":"-50.4%","denominator":424},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-46.1,"displayValue":"-46.1%","denominator":214},"difference":4.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Percent change in baseline to 12 weeks, Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts - Change in Baseline to 12 Week changed by -50.4% in the Clindamycin 1% Gel (Akorn Pharmaceuticals) group and -46.1% in the Placebo group—a difference 4.3 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03522441","sourceUrl":"https://clinicaltrials.gov/study/NCT03522441","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1125,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT03522441"}},"D000068801":{"name":"Adapalene, Benzoyl Peroxide Drug Combination","counts":{"studiesWithResults":14,"favouredTreatment":5,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":4,"unclassified":1},"comparative":5,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Success Rate on the Investigator's Global Assessment","timeFrame":"at week 12","treatmentName":"Adapalene, Benzoyl Peroxide Drug Combination","treatment":{"groupId":"OG000","groupLabel":"Adapalene/Benzoyl Peroxide Gel","value":37.9,"displayValue":"37.9%","denominator":419},"comparator":{"groupId":"OG003","groupLabel":"Gel Vehicle","value":17.9,"displayValue":"17.9%","denominator":418},"difference":20,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At week 12, 37.9% of people in the Adapalene/Benzoyl Peroxide Gel group had the submitted improvement result (Success Rate on the Investigator's Global Assessment), compared with 17.9% in the Gel Vehicle group—20 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00421993","sourceUrl":"https://clinicaltrials.gov/study/NCT00421993","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1670,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)","timeFrame":"At Week 12","treatmentName":"Adapalene, Benzoyl Peroxide Drug Combination","treatment":{"groupId":"OG000","groupLabel":"Adapalene/Benzoyl Peroxide Gel","value":30.1,"displayValue":"30.1%","denominator":415},"comparator":{"groupId":"OG003","groupLabel":"Gel Vehicle","value":11.3,"displayValue":"11.3%","denominator":417},"difference":18.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 30.1% of people in the Adapalene/Benzoyl Peroxide Gel group had the submitted improvement result (Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)), compared with 11.3% in the Gel Vehicle group—18.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00422240","sourceUrl":"https://clinicaltrials.gov/study/NCT00422240","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1668,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Success Rate","timeFrame":"Baseline to Week 12 (Last Observation Carried Forward [LOCF])","treatmentName":"Adapalene, Benzoyl Peroxide Drug Combination","treatment":{"groupId":"OG000","groupLabel":"Adapalene/Benzoyl Peroxide","value":47.2,"displayValue":"47.2%","denominator":142},"comparator":{"groupId":"OG001","groupLabel":"Topical Gel Vehicle","value":15.4,"displayValue":"15.4%","denominator":143},"difference":31.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12 (Last Observation Carried Forward [LOCF]), 47.2% of people in the Adapalene/Benzoyl Peroxide group had the submitted improvement result (Success Rate), compared with 15.4% in the Topical Gel Vehicle group—31.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT01138735","sourceUrl":"https://clinicaltrials.gov/study/NCT01138735","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":285,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline in Total Lesion Counts","timeFrame":"Baseline to Week 12 (LOCF)","treatmentName":"Adapalene, Benzoyl Peroxide Drug Combination","treatment":{"groupId":"OG000","groupLabel":"Adapalene/Benzoyl Peroxide","value":-27.6,"displayValue":"-27.6 lesion count change","denominator":142},"comparator":{"groupId":"OG001","groupLabel":"Topical Gel Vehicle","value":-3.6,"displayValue":"-3.6 lesion count change","denominator":143},"difference":24,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12 (LOCF), Change From Baseline in Total Lesion Counts changed by -27.6 lesion count change in the Adapalene/Benzoyl Peroxide group and -3.6 lesion count change in the Topical Gel Vehicle group—a difference 24 lesion count change numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT01138735","sourceUrl":"https://clinicaltrials.gov/study/NCT01138735","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":285,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline (Log10 Cfu/cm²) in Count of Follicular P. Acnes","timeFrame":"Week 12","treatmentName":"Adapalene, Benzoyl Peroxide Drug Combination","treatment":{"groupId":"OG000","groupLabel":"Epiduo Gel","value":-1.9,"displayValue":"-1.9 Log10 cfu/cm²","denominator":20},"comparator":{"groupId":"OG001","groupLabel":"Benzoyl Peroxide (BPO) Gel","value":-1.6,"displayValue":"-1.6 Log10 cfu/cm²","denominator":20},"difference":0.3,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Week 12, Change From Baseline (Log10 Cfu/cm²) in Count of Follicular P. Acnes changed by -1.9 Log10 cfu/cm² in the Epiduo Gel group and -1.6 Log10 cfu/cm² in the Benzoyl Peroxide (BPO) Gel group—a difference 0.3 Log10 cfu/cm² numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01188538","sourceUrl":"https://clinicaltrials.gov/study/NCT01188538","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":40,"comparatorClass":"unclassified"}],"timeToEffect":{"weeks":12,"nctId":"NCT00421993"}},"D014212":{"name":"Tretinoin","counts":{"studiesWithResults":12,"favouredTreatment":5,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":5},"comparative":5,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Acne Lesion Percent Reduction","timeFrame":"12 week","treatmentName":"Tretinoin","treatment":{"groupId":"OG002","groupLabel":"Brand","value":-53.5,"displayValue":"-53.5%","denominator":337},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":-35,"displayValue":"-35%","denominator":110},"difference":18.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 week, Acne Lesion Percent Reduction changed by -53.5% in the Brand group and -35% in the Placebo group—a difference 18.5 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01243450","sourceUrl":"https://clinicaltrials.gov/study/NCT01243450","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":958,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Acne Lesion Percent Reduction","timeFrame":"12 week","treatmentName":"Tretinoin","treatment":{"groupId":"OG000","groupLabel":"Active Generic","value":-54.3,"displayValue":"-54.3%","denominator":318},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":-35,"displayValue":"-35%","denominator":110},"difference":19.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 week, Acne Lesion Percent Reduction changed by -54.3% in the Active Generic group and -35% in the Placebo group—a difference 19.3 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01243450","sourceUrl":"https://clinicaltrials.gov/study/NCT01243450","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":958,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in Baseline Acne Lesions at Week 12","timeFrame":"Baseline and 12 weeks","treatmentName":"Tretinoin","treatment":{"groupId":"OG001","groupLabel":"Brand Tretinoin","value":-37.3,"displayValue":"-37.3%","denominator":209},"comparator":{"groupId":"OG002","groupLabel":"Placebo Vehicle","value":-26.4,"displayValue":"-26.4%","denominator":100},"difference":10.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and 12 weeks, Percent Change in Baseline Acne Lesions at Week 12 changed by -37.3% in the Brand Tretinoin group and -26.4% in the Placebo Vehicle group—a difference 10.9 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02249767","sourceUrl":"https://clinicaltrials.gov/study/NCT02249767","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":574,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in Baseline Acne Lesions at Week 12","timeFrame":"Baseline and 12 weeks","treatmentName":"Tretinoin","treatment":{"groupId":"OG000","groupLabel":"Generic Tretinoin","value":-32.3,"displayValue":"-32.3%","denominator":200},"comparator":{"groupId":"OG002","groupLabel":"Placebo Vehicle","value":-26.4,"displayValue":"-26.4%","denominator":100},"difference":5.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and 12 weeks, Percent Change in Baseline Acne Lesions at Week 12 changed by -32.3% in the Generic Tretinoin group and -26.4% in the Placebo Vehicle group—a difference 5.9 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02249767","sourceUrl":"https://clinicaltrials.gov/study/NCT02249767","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":574,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline in Total Non-inflammatory Lesion Count","timeFrame":"Baseline to Week 12","treatmentName":"Tretinoin","treatment":{"groupId":"OG000","groupLabel":"Retin-A Micro","value":-19.9,"displayValue":"-19.9 Lesions","denominator":47},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Control","value":-9.7,"displayValue":"-9.7 Lesions","denominator":54},"difference":10.2,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, Change From Baseline in Total Non-inflammatory Lesion Count changed by -19.9 Lesions in the Retin-A Micro group and -9.7 Lesions in the Vehicle Control group—a difference 10.2 Lesions numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00907335","sourceUrl":"https://clinicaltrials.gov/study/NCT00907335","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":110,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01243450"}},"D004318":{"name":"Doxycycline","counts":{"studiesWithResults":11,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C496269":{"name":"Clascoterone","counts":{"studiesWithResults":11,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16","timeFrame":"Week 16","treatmentName":"Clascoterone","treatment":{"groupId":"OG000","groupLabel":"Winlevi (Clascoterone) 1% Cream","value":78,"displayValue":"78%","denominator":9},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At Week 16, 78% of people in the Winlevi (Clascoterone) 1% Cream group had the submitted improvement result (The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.008"},"nctId":"NCT06415305","sourceUrl":"https://clinicaltrials.gov/study/NCT06415305","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":10}],"timeToEffect":null},"D003622":{"name":"Dapsone","counts":{"studiesWithResults":11,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":3},"patientResults":[{"status":"single-arm","outcomeKind":"percent-change","outcomeType":"SECONDARY","outcomeTitle":"The Percent Change in Inflammatory Lesion Count at Week 16 Compared to Baseline","timeFrame":"16 Weeks","treatmentName":"Dapsone","treatment":{"groupId":"OG000","groupLabel":"Dapsone Gel 7.5%","value":-74,"displayValue":"-74%","denominator":15},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At 16 Weeks, The Percent Change in Inflammatory Lesion Count at Week 16 Compared to Baseline changed by -74% in the Dapsone Gel 7.5% group. There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT02944461","sourceUrl":"https://clinicaltrials.gov/study/NCT02944461","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":20},{"status":"single-arm","outcomeKind":"percent-change","outcomeType":"SECONDARY","outcomeTitle":"The Percent Change in Non-inflammatory Lesion Count at Week 16 Compared to Baseline","timeFrame":"16 Weeks","treatmentName":"Dapsone","treatment":{"groupId":"OG000","groupLabel":"Dapsone Gel 7.5%","value":-72,"displayValue":"-72%","denominator":15},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At 16 Weeks, The Percent Change in Non-inflammatory Lesion Count at Week 16 Compared to Baseline changed by -72% in the Dapsone Gel 7.5% group. There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT02944461","sourceUrl":"https://clinicaltrials.gov/study/NCT02944461","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":20}],"timeToEffect":null},"C466951":{"name":"clindamycin phosphate benzoyl peroxide combination","counts":{"studiesWithResults":10,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"active-comparator":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in Total Lesion Counts (TLs) From Baseline to Week 2","timeFrame":"Baseline (Day 1) and Week 2","treatmentName":"clindamycin phosphate benzoyl peroxide combination","treatment":{"groupId":"OG000","groupLabel":"DUAC","value":-42.2,"displayValue":"-42.2%","denominator":169},"comparator":{"groupId":"OG001","groupLabel":"ADA 0.1% +CLDM 1%","value":-35.3,"displayValue":"-35.3%","denominator":176},"difference":6.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1) and Week 2, Percent Change in Total Lesion Counts (TLs) From Baseline to Week 2 changed by -42.2% in the DUAC group and -35.3% in the ADA 0.1% +CLDM 1% group—a difference 6.9 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"difference in percent","parameterValue":"-6.83","confidenceIntervalPercent":"","confidenceIntervalLower":"-11.88","confidenceIntervalUpper":"-1.78","pValue":"0.008"},"nctId":"NCT02557399","sourceUrl":"https://clinicaltrials.gov/study/NCT02557399","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":350,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire","timeFrame":"Baseline (Week 0) and Week 2","treatmentName":"clindamycin phosphate benzoyl peroxide combination","treatment":{"groupId":"OG000","groupLabel":"Duac Gel","value":-4.9,"displayValue":"-4.9 scores on a scale","denominator":83},"comparator":{"groupId":"OG001","groupLabel":"Differin Gel","value":-1.1,"displayValue":"-1.1 scores on a scale","denominator":84},"difference":3.8,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline (Week 0) and Week 2, Mean Change From Baseline to Week 2 in the Global Score of the Participant-completed Skindex-29 Quality of Life (QoL) Questionnaire changed by -4.9 scores on a scale in the Duac Gel group and -1.1 scores on a scale in the Differin Gel group—a difference 3.8 scores on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT00807014","sourceUrl":"https://clinicaltrials.gov/study/NCT00807014","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":169,"comparatorClass":"active-comparator"}],"timeToEffect":null},"C086827":{"name":"tazarotene","counts":{"studiesWithResults":8,"favouredTreatment":6,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":6},"comparative":6,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Change in Inflammatory Lesion Counts","timeFrame":"Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG000","groupLabel":"Test","value":-58.4,"displayValue":"-58.4%","denominator":421},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-53.3,"displayValue":"-53.3%","denominator":217},"difference":5.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, Change in Inflammatory Lesion Counts changed by -58.4% in the Test group and -53.3% in the Placebo group—a difference 5.1 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-5.17","confidenceIntervalPercent":"","confidenceIntervalLower":"-9.46","confidenceIntervalUpper":"-0.87","pValue":"0.0185"},"nctId":"NCT02886715","sourceUrl":"https://clinicaltrials.gov/study/NCT02886715","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1110,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Change in Non-inflammatory Lesion Counts","timeFrame":"Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG000","groupLabel":"Test","value":-50.1,"displayValue":"-50.1%","denominator":421},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-45.7,"displayValue":"-45.7%","denominator":217},"difference":4.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, Change in Non-inflammatory Lesion Counts changed by -50.1% in the Test group and -45.7% in the Placebo group—a difference 4.4 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-4.39","confidenceIntervalPercent":"","confidenceIntervalLower":"-8.48","confidenceIntervalUpper":"-0.30","pValue":"0.0354"},"nctId":"NCT02886715","sourceUrl":"https://clinicaltrials.gov/study/NCT02886715","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1110,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Change in Inflammatory Lesion Counts","timeFrame":"Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG001","groupLabel":"Reference","value":-60.1,"displayValue":"-60.1%","denominator":418},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":-53.3,"displayValue":"-53.3%","denominator":217},"difference":6.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, Change in Inflammatory Lesion Counts changed by -60.1% in the Reference group and -53.3% in the Placebo group—a difference 6.8 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02886715","sourceUrl":"https://clinicaltrials.gov/study/NCT02886715","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1110,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts","timeFrame":"Mean percent change from baseline to Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG000","groupLabel":"Test","value":-48.2,"displayValue":"-48.2%","denominator":187},"comparator":{"groupId":"OG002","groupLabel":"Vehicle","value":-45,"displayValue":"-45%","denominator":195},"difference":3.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Mean percent change from baseline to Week 12, Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts changed by -48.2% in the Test group and -45% in the Vehicle group—a difference 3.2 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02267746","sourceUrl":"https://clinicaltrials.gov/study/NCT02267746","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":893,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts","timeFrame":"Mean percent change from baseline to Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG000","groupLabel":"Test","value":-42,"displayValue":"-42%","denominator":187},"comparator":{"groupId":"OG002","groupLabel":"Vehicle Foam","value":-37.4,"displayValue":"-37.4%","denominator":195},"difference":4.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Mean percent change from baseline to Week 12, Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts changed by -42% in the Test group and -37.4% in the Vehicle Foam group—a difference 4.6 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02267746","sourceUrl":"https://clinicaltrials.gov/study/NCT02267746","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":893,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts","timeFrame":"Mean percent change from baseline to Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG001","groupLabel":"Reference","value":-52.7,"displayValue":"-52.7%","denominator":185},"comparator":{"groupId":"OG002","groupLabel":"Vehicle","value":-45,"displayValue":"-45%","denominator":195},"difference":7.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Mean percent change from baseline to Week 12, Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts changed by -52.7% in the Reference group and -45% in the Vehicle group—a difference 7.7 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02267746","sourceUrl":"https://clinicaltrials.gov/study/NCT02267746","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":893,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT02886715"}},"D008911":{"name":"Minocycline","counts":{"studiesWithResults":7,"favouredTreatment":4,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"unclassified":2,"placebo-or-vehicle":2},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12","timeFrame":"Baseline and Week 12","treatmentName":"Minocycline","treatment":{"groupId":"OG000","groupLabel":"FMX-101, 4% Minocycline Foam","value":14.7,"displayValue":"14.7%","denominator":333},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Foam","value":7.9,"displayValue":"7.9%","denominator":162},"difference":6.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 12, 14.7% of people in the FMX-101, 4% Minocycline Foam group had the submitted improvement result (Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12), compared with 7.9% in the Vehicle Foam group—6.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk ratio","parameterValue":"1.88","confidenceIntervalPercent":"","confidenceIntervalLower":"1.02","confidenceIntervalUpper":"3.46","pValue":"0.0424"},"nctId":"NCT02815280","sourceUrl":"https://clinicaltrials.gov/study/NCT02815280","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":495,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12","timeFrame":"Baseline and Week 12","treatmentName":"Minocycline","treatment":{"groupId":"OG000","groupLabel":"FMX-101, 4% Minocycline Foam","value":8.1,"displayValue":"8.1%","denominator":307},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Foam","value":4.8,"displayValue":"4.8%","denominator":159},"difference":3.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 12, 8.1% of people in the FMX-101, 4% Minocycline Foam group had the submitted improvement result (Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12), compared with 4.8% in the Vehicle Foam group—3.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"3.33","confidenceIntervalPercent":"","confidenceIntervalLower":"-1.54","confidenceIntervalUpper":"8.19","pValue":"0.1805"},"nctId":"NCT02815267","sourceUrl":"https://clinicaltrials.gov/study/NCT02815267","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":466,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score","timeFrame":"Baseline, Week 8 End of Treatment (EOT)","treatmentName":"Minocycline","treatment":{"groupId":"OG001","groupLabel":"Minocycline","value":-9.2,"displayValue":"-9.2 score on scale","denominator":59},"comparator":{"groupId":"OG000","groupLabel":"Azithromycin","value":-8.7,"displayValue":"-8.7 score on scale","denominator":53},"difference":0.5,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline, Week 8 End of Treatment (EOT), Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score changed by -9.2 score on scale in the Minocycline group and -8.7 score on scale in the Azithromycin group—a difference 0.5 score on scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-0.47","confidenceIntervalPercent":"","confidenceIntervalLower":"-2.48","confidenceIntervalUpper":"1.54","pValue":""},"nctId":"NCT00392223","sourceUrl":"https://clinicaltrials.gov/study/NCT00392223","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":118,"comparatorClass":"unclassified"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline to End of Treatment (EOT) in Global Acne Grading System (GAGS) Score - Per Protocol Population","timeFrame":"Baseline, Week 8 EOT","treatmentName":"Minocycline","treatment":{"groupId":"OG001","groupLabel":"Minocycline","value":-10.2,"displayValue":"-10.2 score on scale","denominator":48},"comparator":{"groupId":"OG000","groupLabel":"Azithromycin","value":-9.3,"displayValue":"-9.3 score on scale","denominator":48},"difference":0.9,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline, Week 8 EOT, Change From Baseline to End of Treatment (EOT) in Global Acne Grading System (GAGS) Score - Per Protocol Population changed by -10.2 score on scale in the Minocycline group and -9.3 score on scale in the Azithromycin group—a difference 0.9 score on scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-0.87","confidenceIntervalPercent":"","confidenceIntervalLower":"-2.58","confidenceIntervalUpper":"0.84","pValue":""},"nctId":"NCT00392223","sourceUrl":"https://clinicaltrials.gov/study/NCT00392223","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":118,"comparatorClass":"unclassified"}],"timeToEffect":{"weeks":8,"nctId":"NCT00392223"}},"C000629420":{"name":"trifarotene","counts":{"studiesWithResults":7,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Primary Change in Inflammatory Lesion Counts","timeFrame":"Baseline and 12 Weeks","treatmentName":"trifarotene","treatment":{"groupId":"OG000","groupLabel":"Test: Trifarotene Cream, 0.005%","value":-72.9,"displayValue":"-72.9%","denominator":225},"comparator":{"groupId":"OG002","groupLabel":"Vehicle Product","value":-34.1,"displayValue":"-34.1%","denominator":213},"difference":38.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and 12 Weeks, Primary Change in Inflammatory Lesion Counts changed by -72.9% in the Test: Trifarotene Cream, 0.005% group and -34.1% in the Vehicle Product group—a difference 38.8 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05550337","sourceUrl":"https://clinicaltrials.gov/study/NCT05550337","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":807,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Primary Change in Non-Inflammatory Lesion Count","timeFrame":"Baseline and 12 Weeks","treatmentName":"trifarotene","treatment":{"groupId":"OG000","groupLabel":"Test: Trifarotene Cream, 0.005%","value":-62,"displayValue":"-62%","denominator":225},"comparator":{"groupId":"OG002","groupLabel":"Vehicle Product","value":-27.3,"displayValue":"-27.3%","denominator":213},"difference":34.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and 12 Weeks, Primary Change in Non-Inflammatory Lesion Count changed by -62% in the Test: Trifarotene Cream, 0.005% group and -27.3% in the Vehicle Product group—a difference 34.7 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05550337","sourceUrl":"https://clinicaltrials.gov/study/NCT05550337","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":807,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Primary Change in Inflammatory Lesion Counts","timeFrame":"Baseline and 12 Weeks","treatmentName":"trifarotene","treatment":{"groupId":"OG001","groupLabel":"AKLIEF®","value":-78.8,"displayValue":"-78.8%","denominator":196},"comparator":{"groupId":"OG002","groupLabel":"Vehicle Product","value":-34.1,"displayValue":"-34.1%","denominator":213},"difference":44.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and 12 Weeks, Primary Change in Inflammatory Lesion Counts changed by -78.8% in the AKLIEF® group and -34.1% in the Vehicle Product group—a difference 44.7 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05550337","sourceUrl":"https://clinicaltrials.gov/study/NCT05550337","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":807,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT05550337"}},"C007084":{"name":"clindamycin phosphate","counts":{"studiesWithResults":5,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000709171":{"name":"berdazimer sodium","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D015474":{"name":"Isotretinoin","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D020156":{"name":"Salicylic Acid","counts":{"studiesWithResults":5,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C008848":{"name":"1-phenyl-3,3-dimethyltriazene","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000629276":{"name":"sarecycline","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C534342":{"name":"drospirenone and ethinyl estradiol combination","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C117880":{"name":"clindamycin, tretinoin drug combination","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C557520":{"name":"Acanya Gel","counts":{"studiesWithResults":2,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Clinical Success on Investigator's Global Evaluation","timeFrame":"Baseline to week 12","treatmentName":"Acanya Gel","treatment":{"groupId":"OG001","groupLabel":"Reference Product","value":35.4,"displayValue":"35.4%","denominator":339},"comparator":{"groupId":"OG002","groupLabel":"Placebo Product","value":14.1,"displayValue":"14.1%","denominator":163},"difference":21.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to week 12, 35.4% of people in the Reference Product group had the submitted improvement result (Clinical Success on Investigator's Global Evaluation), compared with 14.1% in the Placebo Product group—21.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01796665","sourceUrl":"https://clinicaltrials.gov/study/NCT01796665","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1180,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01796665"}},"D000095742":{"name":"Red Light","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D004997":{"name":"Ethinyl Estradiol","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C475457":{"name":"methyl 5-aminolevulinate","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000622":{"name":"Aminolevulinic Acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C010038":{"name":"azelaic acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C035144":{"name":"drospirenone","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D015444":{"name":"Exercise","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D002331":{"name":"Carnitine","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D010789":{"name":"Phototherapy","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C471106":{"name":"1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000626399":{"name":"Acne RA-1,2","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C534526":{"name":"afamelanotide","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C055085":{"name":"calcipotriene","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D017135":{"name":"Desogestrel","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000431":{"name":"Ethanol","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C039909":{"name":"eucerin","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C030691":{"name":"gluconic acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C070840":{"name":"licochalcone A","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D008194":{"name":"Lymecycline","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C017576":{"name":"norgestimate","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D004364":{"name":"Pharmaceutical Preparations","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D014260":{"name":"Triclosan","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C505730":{"name":"apremilast","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null}},"recruiting":[{"nctId":"NCT06316297","title":"Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne","enrollmentTarget":800,"countries":["United States","Australia","Canada","Puerto Rico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06316297"},{"nctId":"NCT06403501","title":"Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris","enrollmentTarget":692,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06403501"},{"nctId":"NCT07186413","title":"A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris","enrollmentTarget":561,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07186413"},{"nctId":"NCT06447480","title":"Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients","enrollmentTarget":420,"countries":["France","French Guiana"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06447480"},{"nctId":"NCT07013747","title":"Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne","enrollmentTarget":228,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07013747"},{"nctId":"NCT07056673","title":"Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study","enrollmentTarget":220,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07056673"},{"nctId":"NCT07366229","title":"Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne","enrollmentTarget":196,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07366229"},{"nctId":"NCT06989840","title":"Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne","enrollmentTarget":128,"countries":["United States","Australia"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06989840"},{"nctId":"NCT07102186","title":"Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris","enrollmentTarget":120,"countries":["Egypt"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07102186"},{"nctId":"NCT07524946","title":"Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo","enrollmentTarget":100,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07524946"},{"nctId":"NCT06655129","title":"Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder","enrollmentTarget":85,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06655129"},{"nctId":"NCT06716398","title":"A Comparative Study of Cosmetic Product in Subjects With Facial Acne During an Associated-treatment Phase Followed by a Maintenance Phase","enrollmentTarget":60,"countries":["Brazil"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06716398"},{"nctId":"NCT07007078","title":"Efficacy of Dihydroartemisinin for Treating Acne Vulgaris","enrollmentTarget":60,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07007078"},{"nctId":"NCT07054398","title":"Assessment of Serum Catestatin Level in Acne Vulgaris Patients","enrollmentTarget":60,"countries":["Egypt"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07054398"},{"nctId":"NCT06225570","title":"Weekly Isotretinoin vs Tetracycline for Moderate Acne","enrollmentTarget":50,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06225570"},{"nctId":"NCT06311890","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne","enrollmentTarget":46,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06311890"},{"nctId":"NCT07749469","title":"Safety and Efficacy of Skincare Products for Managing Mild to Moderate Acne in Individuals With Sensitive Skin","enrollmentTarget":34,"countries":["Malaysia"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07749469"},{"nctId":"NCT03883269","title":"Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients","enrollmentTarget":30,"countries":["Netherlands"],"sourceUrl":"https://clinicaltrials.gov/study/NCT03883269"},{"nctId":"NCT07544251","title":"Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.","enrollmentTarget":30,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07544251"}],"pairs":[{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D001585","name":"Benzoyl Peroxide"},"coRegistered":15,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D002981","name":"Clindamycin"},"coRegistered":6,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D014212","name":"Tretinoin"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D004318","name":"Doxycycline"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D015474","name":"Isotretinoin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":12,"headToHeadResults":0},{"a":{"key":"D000068816","name":"Adapalene"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D002981","name":"Clindamycin"},"coRegistered":15,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D014212","name":"Tretinoin"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D004318","name":"Doxycycline"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D015474","name":"Isotretinoin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":8,"headToHeadResults":0},{"a":{"key":"D001585","name":"Benzoyl Peroxide"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D002981","name":"Clindamycin"},"b":{"key":"D014212","name":"Tretinoin"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D002981","name":"Clindamycin"},"b":{"key":"D004318","name":"Doxycycline"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D002981","name":"Clindamycin"},"b":{"key":"D015474","name":"Isotretinoin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D002981","name":"Clindamycin"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D002981","name":"Clindamycin"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D004318","name":"Doxycycline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D015474","name":"Isotretinoin"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D015474","name":"Isotretinoin"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D015474","name":"Isotretinoin"},"b":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D015474","name":"Isotretinoin"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000068801","name":"Adapalene, Benzoyl Peroxide Drug Combination"},"b":{"key":"D003622","name":"Dapsone"},"coRegistered":0,"headToHeadResults":0}]},"eczema":{"terms":{"C582203":{"name":"dupilumab","counts":{"studiesWithResults":33,"favouredTreatment":5,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":5},"comparative":5,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16","timeFrame":"At week 16","treatmentName":"dupilumab","treatment":{"groupId":"OG001","groupLabel":"Dupilumab Q2W","value":40.3,"displayValue":"40.3%","denominator":67},"comparator":{"groupId":"OG000","groupLabel":"Matching Placebo","value":16.7,"displayValue":"16.7%","denominator":66},"difference":23.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At week 16, 40.3% of people in the Dupilumab Q2W group had the submitted improvement result (Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16), compared with 16.7% in the Matching Placebo group—23.6 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"=0.0030"},"nctId":"NCT04417894","sourceUrl":"https://clinicaltrials.gov/study/NCT04417894","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":133,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)","timeFrame":"Baseline to Week 12","treatmentName":"dupilumab","treatment":{"groupId":"OG001","groupLabel":"Dupilumab 300 mg","value":-74,"displayValue":"-74%","denominator":55},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":-23.3,"displayValue":"-23.3%","denominator":54},"difference":50.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF) changed by -74% in the Dupilumab 300 mg group and -23.3% in the Placebo group—a difference 50.7 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01548404","sourceUrl":"https://clinicaltrials.gov/study/NCT01548404","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":109,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" at Week 16","timeFrame":"Week 16","treatmentName":"dupilumab","treatment":{"groupId":"OG001","groupLabel":"Dupilumab 300 mg qw","value":44.3,"displayValue":"44.3%","denominator":97},"comparator":{"groupId":"OG000","groupLabel":"Placebo qw","value":10.3,"displayValue":"10.3%","denominator":97},"difference":34,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 44.3% of people in the Dupilumab 300 mg qw group had the submitted improvement result (Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" at Week 16), compared with 10.3% in the Placebo qw group—34 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Percentage Difference","parameterValue":"34.0","confidenceIntervalPercent":"","confidenceIntervalLower":"24.29","confidenceIntervalUpper":"43.75","pValue":"<0.0001"},"nctId":"NCT02210780","sourceUrl":"https://clinicaltrials.gov/study/NCT02210780","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":194,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16","timeFrame":"Week 16","treatmentName":"dupilumab","treatment":{"groupId":"OG001","groupLabel":"Dupilumab 300 mg qw","value":72.2,"displayValue":"72.2%","denominator":97},"comparator":{"groupId":"OG000","groupLabel":"Placebo qw","value":32,"displayValue":"32%","denominator":97},"difference":40.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 72.2% of people in the Dupilumab 300 mg qw group had the submitted improvement result (Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16), compared with 32% in the Placebo qw group—40.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Percentage Difference","parameterValue":"40.2","confidenceIntervalPercent":"","confidenceIntervalLower":"29.40","confidenceIntervalUpper":"51.01","pValue":"<0.0001"},"nctId":"NCT02210780","sourceUrl":"https://clinicaltrials.gov/study/NCT02210780","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":194,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16","timeFrame":"Week 16","treatmentName":"dupilumab","treatment":{"groupId":"OG001","groupLabel":"Dupilumab 300 mg qw","value":53.6,"displayValue":"53.6%","denominator":97},"comparator":{"groupId":"OG000","groupLabel":"Placebo qw","value":19.6,"displayValue":"19.6%","denominator":97},"difference":34,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 53.6% of people in the Dupilumab 300 mg qw group had the submitted improvement result (Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16), compared with 19.6% in the Placebo qw group—34 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Percentage Difference","parameterValue":"34.0","confidenceIntervalPercent":"","confidenceIntervalLower":"23.38","confidenceIntervalUpper":"44.66","pValue":"<0.0001"},"nctId":"NCT02210780","sourceUrl":"https://clinicaltrials.gov/study/NCT02210780","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":194,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01548404"}},"C561806":{"name":"lebrikizumab","counts":{"studiesWithResults":12,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline in Eczema Area and Severity Index (EASI)","timeFrame":"Baseline, Week 16","treatmentName":"lebrikizumab","treatment":{"groupId":"OG001","groupLabel":"250 mg Lebrikizumab (Q4W)","value":-69.2,"displayValue":"-69.2%","denominator":80},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-41.1,"displayValue":"-41.1%","denominator":52},"difference":28.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline, Week 16, Percent Change From Baseline in Eczema Area and Severity Index (EASI) changed by -69.2% in the 250 mg Lebrikizumab (Q4W) group and -41.1% in the Placebo group—a difference 28.1 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.0022"},"nctId":"NCT03443024","sourceUrl":"https://clinicaltrials.gov/study/NCT03443024","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":280,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline in Eczema Area and Severity Index (EASI)","timeFrame":"Baseline, Week 16","treatmentName":"lebrikizumab","treatment":{"groupId":"OG002","groupLabel":"250 mg Lebrikizumab (Q2W)","value":-72.1,"displayValue":"-72.1%","denominator":75},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-41.1,"displayValue":"-41.1%","denominator":52},"difference":31,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline, Week 16, Percent Change From Baseline in Eczema Area and Severity Index (EASI) changed by -72.1% in the 250 mg Lebrikizumab (Q2W) group and -41.1% in the Placebo group—a difference 31 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.0005"},"nctId":"NCT03443024","sourceUrl":"https://clinicaltrials.gov/study/NCT03443024","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":280,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline in Eczema Area and Severity Index (EASI)","timeFrame":"Baseline, Week 16","treatmentName":"lebrikizumab","treatment":{"groupId":"OG000","groupLabel":"125 mg Lebrikizumab (Q4W)","value":-62.3,"displayValue":"-62.3%","denominator":73},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-41.1,"displayValue":"-41.1%","denominator":52},"difference":21.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline, Week 16, Percent Change From Baseline in Eczema Area and Severity Index (EASI) changed by -62.3% in the 125 mg Lebrikizumab (Q4W) group and -41.1% in the Placebo group—a difference 21.2 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.0165"},"nctId":"NCT03443024","sourceUrl":"https://clinicaltrials.gov/study/NCT03443024","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":280,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT03443024"}},"C574065":{"name":"tralokinumab","counts":{"studiesWithResults":10,"favouredTreatment":5,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":5},"comparative":5,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"At Week 16","treatmentName":"tralokinumab","treatment":{"groupId":"OG000","groupLabel":"Tralokinumab 300 mg Q2W","value":15.8,"displayValue":"15.8%","denominator":601},"comparator":{"groupId":"OG001","groupLabel":"Placebo Q2W","value":7.1,"displayValue":"7.1%","denominator":197},"difference":8.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 15.8% of people in the Tralokinumab 300 mg Q2W group had the submitted improvement result (Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16), compared with 7.1% in the Placebo Q2W group—8.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"8.6","confidenceIntervalPercent":"","confidenceIntervalLower":"4.1","confidenceIntervalUpper":"13.1","pValue":"0.002"},"nctId":"NCT03131648","sourceUrl":"https://clinicaltrials.gov/study/NCT03131648","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":802,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16","timeFrame":"At Week 16","treatmentName":"tralokinumab","treatment":{"groupId":"OG000","groupLabel":"Tralokinumab 300 mg Q2W","value":25,"displayValue":"25%","denominator":601},"comparator":{"groupId":"OG001","groupLabel":"Placebo Q2W","value":12.7,"displayValue":"12.7%","denominator":197},"difference":12.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 25% of people in the Tralokinumab 300 mg Q2W group had the submitted improvement result (Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16), compared with 12.7% in the Placebo Q2W group—12.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"12.1","confidenceIntervalPercent":"","confidenceIntervalLower":"6.5","confidenceIntervalUpper":"17.7","pValue":"<0.001"},"nctId":"NCT03131648","sourceUrl":"https://clinicaltrials.gov/study/NCT03131648","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":802,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.","timeFrame":"At Week 16","treatmentName":"tralokinumab","treatment":{"groupId":"OG000","groupLabel":"Tralokinumab 300 mg Q2W","value":22.2,"displayValue":"22.2%","denominator":591},"comparator":{"groupId":"OG001","groupLabel":"Placebo Q2W","value":10.9,"displayValue":"10.9%","denominator":201},"difference":11.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 22.2% of people in the Tralokinumab 300 mg Q2W group had the submitted improvement result (Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16), compared with 10.9% in the Placebo Q2W group—11.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"11.1","confidenceIntervalPercent":"","confidenceIntervalLower":"5.8","confidenceIntervalUpper":"16.4","pValue":"<0.001"},"nctId":"NCT03160885","sourceUrl":"https://clinicaltrials.gov/study/NCT03160885","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":794,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI].","timeFrame":"At Week 16","treatmentName":"tralokinumab","treatment":{"groupId":"OG000","groupLabel":"Tralokinumab 300 mg Q2W","value":33.2,"displayValue":"33.2%","denominator":591},"comparator":{"groupId":"OG001","groupLabel":"Placebo Q2W","value":11.4,"displayValue":"11.4%","denominator":201},"difference":21.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 33.2% of people in the Tralokinumab 300 mg Q2W group had the submitted improvement result (Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI]), compared with 11.4% in the Placebo Q2W group—21.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"21.6","confidenceIntervalPercent":"","confidenceIntervalLower":"15.8","confidenceIntervalUpper":"27.3","pValue":"<0.001"},"nctId":"NCT03160885","sourceUrl":"https://clinicaltrials.gov/study/NCT03160885","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":794,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear)","timeFrame":"At Week 16","treatmentName":"tralokinumab","treatment":{"groupId":"OG000","groupLabel":"Tralokinumab","value":40,"displayValue":"40%","denominator":156},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":10.6,"displayValue":"10.6%","denominator":79},"difference":29.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 40% of people in the Tralokinumab group had the submitted improvement result (Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear)), compared with 10.6% in the Placebo group—29.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"treatment difference in percentage","parameterValue":"29.7","confidenceIntervalPercent":"","confidenceIntervalLower":"19.0","confidenceIntervalUpper":"40.4","pValue":"<.001"},"nctId":"NCT05958407","sourceUrl":"https://clinicaltrials.gov/study/NCT05958407","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":235,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT03131648"}},"D000305":{"name":"Adrenal Cortex Hormones","counts":{"studiesWithResults":11,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000634427":{"name":"abrocitinib","counts":{"studiesWithResults":9,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000596027":{"name":"baricitinib","counts":{"studiesWithResults":9,"favouredTreatment":2,"favouredComparator":2,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":4},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)","timeFrame":"Week 16","treatmentName":"baricitinib","treatment":{"groupId":"OG003","groupLabel":"Baricitinib 2-mg Open-Label Addendum","value":50,"displayValue":"50%","denominator":30},"comparator":{"groupId":"OG000","groupLabel":"Placebo/Baricitinib 2-mg","value":59,"displayValue":"59%","denominator":117},"difference":-9,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Week 16, 50% of people in the Baricitinib 2-mg Open-Label Addendum group had the submitted improvement result (Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)), compared with 59% in the Placebo/Baricitinib 2-mg group—9 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03559270","sourceUrl":"https://clinicaltrials.gov/study/NCT03559270","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":374,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 (Participants Not Entered Into Substudy)","timeFrame":"Week 104","treatmentName":"baricitinib","treatment":{"groupId":"OG000","groupLabel":"4 mg Bari to 4 mg Bari Non-substudy","value":41.3,"displayValue":"41.3%","denominator":264},"comparator":{"groupId":"OG003","groupLabel":"Placebo to Placebo Non-substudy","value":51.4,"displayValue":"51.4%","denominator":70},"difference":-10.1,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Week 104, 41.3% of people in the 4 mg Bari to 4 mg Bari Non-substudy group had the submitted improvement result (Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 (Participants Not Entered Into Substudy)), compared with 51.4% in the Placebo to Placebo Non-substudy group—10.1 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03334435","sourceUrl":"https://clinicaltrials.gov/study/NCT03334435","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1645,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS","timeFrame":"Week 16","treatmentName":"baricitinib","treatment":{"groupId":"OG002","groupLabel":"RPR Bari 4 mg","value":46.4,"displayValue":"46.4%","denominator":56},"comparator":{"groupId":"OG000","groupLabel":"RPR Placebo","value":37.5,"displayValue":"37.5%","denominator":32},"difference":8.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 46.4% of people in the RPR Bari 4 mg group had the submitted improvement result (RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS), compared with 37.5% in the RPR Placebo group—8.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03334435","sourceUrl":"https://clinicaltrials.gov/study/NCT03334435","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1645,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS","timeFrame":"Week 16","treatmentName":"baricitinib","treatment":{"groupId":"OG001","groupLabel":"RPR Bari 2 mg","value":45.8,"displayValue":"45.8%","denominator":48},"comparator":{"groupId":"OG000","groupLabel":"RPR Placebo","value":37.5,"displayValue":"37.5%","denominator":32},"difference":8.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 45.8% of people in the RPR Bari 2 mg group had the submitted improvement result (RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS), compared with 37.5% in the RPR Placebo group—8.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03334435","sourceUrl":"https://clinicaltrials.gov/study/NCT03334435","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1645,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT03334435"}},"C000711049":{"name":"difamilast","counts":{"studiesWithResults":7,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000613732":{"name":"upadacitinib","counts":{"studiesWithResults":8,"favouredTreatment":6,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":6},"comparative":6,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG002","groupLabel":"Upadacitinib 30 mg QD","value":79.7,"displayValue":"79.7%","denominator":285},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":16.3,"displayValue":"16.3%","denominator":281},"difference":63.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 79.7% of people in the Upadacitinib 30 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16), compared with 16.3% in the Placebo group—63.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"63.4","confidenceIntervalPercent":"","confidenceIntervalLower":"57.1","confidenceIntervalUpper":"69.8","pValue":"<0.001"},"nctId":"NCT03569293","sourceUrl":"https://clinicaltrials.gov/study/NCT03569293","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG001","groupLabel":"Upadacitinib 15 mg QD","value":69.6,"displayValue":"69.6%","denominator":281},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":16.3,"displayValue":"16.3%","denominator":281},"difference":53.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 69.6% of people in the Upadacitinib 15 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16), compared with 16.3% in the Placebo group—53.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"53.3","confidenceIntervalPercent":"","confidenceIntervalLower":"46.4","confidenceIntervalUpper":"60.2","pValue":"<0.001"},"nctId":"NCT03569293","sourceUrl":"https://clinicaltrials.gov/study/NCT03569293","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG001","groupLabel":"Upadacitinib 15 mg QD","value":48.1,"displayValue":"48.1%","denominator":281},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":8.4,"displayValue":"8.4%","denominator":281},"difference":39.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 48.1% of people in the Upadacitinib 15 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16), compared with 8.4% in the Placebo group—39.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"39.8","confidenceIntervalPercent":"","confidenceIntervalLower":"33.2","confidenceIntervalUpper":"46.4","pValue":"<0.001"},"nctId":"NCT03569293","sourceUrl":"https://clinicaltrials.gov/study/NCT03569293","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG002","groupLabel":"Upadacitinib 30 mg QD","value":72.9,"displayValue":"72.9%","denominator":282},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":13.3,"displayValue":"13.3%","denominator":278},"difference":59.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 72.9% of people in the Upadacitinib 30 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16), compared with 13.3% in the Placebo group—59.6 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"59.6","confidenceIntervalPercent":"","confidenceIntervalLower":"53.1","confidenceIntervalUpper":"66.2","pValue":"<0.001"},"nctId":"NCT03607422","sourceUrl":"https://clinicaltrials.gov/study/NCT03607422","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG001","groupLabel":"Upadacitinib 15 mg QD","value":60.1,"displayValue":"60.1%","denominator":276},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":13.3,"displayValue":"13.3%","denominator":278},"difference":46.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 60.1% of people in the Upadacitinib 15 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16), compared with 13.3% in the Placebo group—46.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"46.9","confidenceIntervalPercent":"","confidenceIntervalLower":"39.9","confidenceIntervalUpper":"53.9","pValue":"<0.001"},"nctId":"NCT03607422","sourceUrl":"https://clinicaltrials.gov/study/NCT03607422","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"upadacitinib","treatment":{"groupId":"OG001","groupLabel":"Upadacitinib 15 mg QD","value":38.8,"displayValue":"38.8%","denominator":276},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":4.7,"displayValue":"4.7%","denominator":278},"difference":34.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 38.8% of people in the Upadacitinib 15 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16), compared with 4.7% in the Placebo group—34.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Response Rate Difference","parameterValue":"34.0","confidenceIntervalPercent":"","confidenceIntervalLower":"27.8","confidenceIntervalUpper":"40.2","pValue":"<0.001"},"nctId":"NCT03607422","sourceUrl":"https://clinicaltrials.gov/study/NCT03607422","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":912,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT03569293"}},"C000612881":{"name":"nemolizumab","counts":{"studiesWithResults":8,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C117268":{"name":"pimecrolimus","counts":{"studiesWithResults":8,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])","timeFrame":"Day 15","treatmentName":"pimecrolimus","treatment":{"groupId":"OG000","groupLabel":"Test","value":50.9,"displayValue":"50.9%","denominator":212},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":45.6,"displayValue":"45.6%","denominator":215},"difference":5.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Day 15, 50.9% of people in the Test group had the submitted improvement result (Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])), compared with 45.6% in the Placebo group—5.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.2874"},"nctId":"NCT03107611","sourceUrl":"https://clinicaltrials.gov/study/NCT03107611","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":654,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])","timeFrame":"Day 15","treatmentName":"pimecrolimus","treatment":{"groupId":"OG001","groupLabel":"Reference Standard","value":54.2,"displayValue":"54.2%","denominator":212},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":45.6,"displayValue":"45.6%","denominator":215},"difference":8.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Day 15, 54.2% of people in the Reference Standard group had the submitted improvement result (Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])), compared with 45.6% in the Placebo group—8.6 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.0817"},"nctId":"NCT03107611","sourceUrl":"https://clinicaltrials.gov/study/NCT03107611","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":654,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Per Protocol Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])","timeFrame":"Day 15","treatmentName":"pimecrolimus","treatment":{"groupId":"OG000","groupLabel":"Test","value":52.2,"displayValue":"52.2%","denominator":201},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":46.8,"displayValue":"46.8%","denominator":203},"difference":5.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Day 15, 52.2% of people in the Test group had the submitted improvement result (Proportion of Per Protocol Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])), compared with 46.8% in the Placebo group—5.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03107611","sourceUrl":"https://clinicaltrials.gov/study/NCT03107611","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":654,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":2,"nctId":"NCT03107611"}},"C505730":{"name":"apremilast","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Patients Who Achieve an Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.","timeFrame":"week 16","treatmentName":"apremilast","treatment":{"groupId":"OG000","groupLabel":"Apremilast","value":20,"displayValue":"20%","denominator":10},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At week 16, 20% of people in the Apremilast group had the submitted improvement result (Proportion of Patients Who Achieve an Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT04306965","sourceUrl":"https://clinicaltrials.gov/study/NCT04306965","phase":"Phase 2","sponsorClass":"Other organization","enrollmentCount":10}],"timeToEffect":null},"C540383":{"name":"ruxolitinib","counts":{"studiesWithResults":4,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8","timeFrame":"Baseline to Week 8","treatmentName":"ruxolitinib","treatment":{"groupId":"OG001","groupLabel":"VC Period: Ruxolitinib 0.75% Cream BID","value":36.6,"displayValue":"36.6%","denominator":134},"comparator":{"groupId":"OG000","groupLabel":"VC Period: Vehicle Cream BID","value":10.8,"displayValue":"10.8%","denominator":65},"difference":25.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 8, 36.6% of people in the VC Period: Ruxolitinib 0.75% Cream BID group had the submitted improvement result (VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8), compared with 10.8% in the VC Period: Vehicle Cream BID group—25.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"4.74","confidenceIntervalPercent":"","confidenceIntervalLower":"1.951","confidenceIntervalUpper":"13.315","pValue":"0.0001"},"nctId":"NCT04921969","sourceUrl":"https://clinicaltrials.gov/study/NCT04921969","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":330,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8","timeFrame":"Baseline to Week 8","treatmentName":"ruxolitinib","treatment":{"groupId":"OG002","groupLabel":"VC Period: Ruxolitinib 1.5% Cream BID","value":56.5,"displayValue":"56.5%","denominator":131},"comparator":{"groupId":"OG000","groupLabel":"VC Period: Vehicle Cream BID","value":10.8,"displayValue":"10.8%","denominator":65},"difference":45.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 8, 56.5% of people in the VC Period: Ruxolitinib 1.5% Cream BID group had the submitted improvement result (VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8), compared with 10.8% in the VC Period: Vehicle Cream BID group—45.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"10.72","confidenceIntervalPercent":"","confidenceIntervalLower":"4.429","confidenceIntervalUpper":"30.042","pValue":"<0.0001"},"nctId":"NCT04921969","sourceUrl":"https://clinicaltrials.gov/study/NCT04921969","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":330,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID","timeFrame":"Baseline and Week 4","treatmentName":"ruxolitinib","treatment":{"groupId":"OG001","groupLabel":"DB: Ruxolitinib 1.5% BID","value":-71.6,"displayValue":"-71.6%","denominator":49},"comparator":{"groupId":"OG000","groupLabel":"DB: Vehicle BID","value":-11.9,"displayValue":"-11.9%","denominator":44},"difference":59.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 4, Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID changed by -71.6% in the DB: Ruxolitinib 1.5% BID group and -11.9% in the DB: Vehicle BID group—a difference 59.7 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Difference in Least Square (LS) Mean","parameterValue":"-59.66","confidenceIntervalPercent":"","confidenceIntervalLower":"-77.85","confidenceIntervalUpper":"-41.47","pValue":"< 0.0001"},"nctId":"NCT03011892","sourceUrl":"https://clinicaltrials.gov/study/NCT03011892","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":307,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":4,"nctId":"NCT03011892"}},"C543085":{"name":"crisaborole","counts":{"studiesWithResults":6,"favouredTreatment":0,"favouredComparator":2,"noObservedDifference":0,"byComparatorClass":{"unclassified":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in Children's PROMIS Pediatric Itch Short-Form","timeFrame":"baseline to 12 weeks","treatmentName":"crisaborole","treatment":{"groupId":"OG000","groupLabel":"Crisaborole","value":-0.3,"displayValue":"-0.3 score on a scale","denominator":16},"comparator":{"groupId":"OG001","groupLabel":"Tacrolimus 0.03%","value":-0.4,"displayValue":"-0.4 score on a scale","denominator":20},"difference":-0.1,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At baseline to 12 weeks, Mean Change in Children's PROMIS Pediatric Itch Short-Form changed by -0.3 score on a scale in the Crisaborole group and -0.4 score on a scale in the Tacrolimus 0.03% group—a difference 0.1 score on a scale numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.433"},"nctId":"NCT03645057","sourceUrl":"https://clinicaltrials.gov/study/NCT03645057","phase":"Phase 3","sponsorClass":"Other organization","enrollmentCount":92,"comparatorClass":"unclassified"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in PROMIS Pain Interference-Children (Adaptive Test)","timeFrame":"baseline to 12 weeks","treatmentName":"crisaborole","treatment":{"groupId":"OG000","groupLabel":"Crisaborole","value":-6.4,"displayValue":"-6.4 T-score","denominator":16},"comparator":{"groupId":"OG001","groupLabel":"Tacrolimus 0.03%","value":-6.8,"displayValue":"-6.8 T-score","denominator":20},"difference":-0.4,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At baseline to 12 weeks, Mean Change in PROMIS Pain Interference-Children (Adaptive Test) changed by -6.4 T-score in the Crisaborole group and -6.8 T-score in the Tacrolimus 0.03% group—a difference 0.4 T-score numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.836"},"nctId":"NCT03645057","sourceUrl":"https://clinicaltrials.gov/study/NCT03645057","phase":"Phase 3","sponsorClass":"Other organization","enrollmentCount":92,"comparatorClass":"unclassified"}],"timeToEffect":null},"D015444":{"name":"Exercise","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D004643":{"name":"Emollients","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D005447":{"name":"Fluocinonide","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000069444":{"name":"Omalizumab","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C093875":{"name":"montelukast","counts":{"studiesWithResults":2,"favouredTreatment":1,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in Investigator Global Assessment (IGA)","timeFrame":"Baseline and 9 weeks","treatmentName":"montelukast","treatment":{"groupId":"OG000","groupLabel":"Treatment Arm","value":-0.1,"displayValue":"-0.1 units on a scale","denominator":9},"comparator":{"groupId":"OG001","groupLabel":"Placebo Arm","value":-0.7,"displayValue":"-0.7 units on a scale","denominator":11},"difference":-0.6,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At Baseline and 9 weeks, Mean Change in Investigator Global Assessment (IGA) changed by -0.1 units on a scale in the Treatment Arm group and -0.7 units on a scale in the Placebo Arm group—a difference 0.6 units on a scale numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00557284","sourceUrl":"https://clinicaltrials.gov/study/NCT00557284","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":20,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in PADC (Caregivers Perception of Disease Control)","timeFrame":"Baseline and 9 weeks","treatmentName":"montelukast","treatment":{"groupId":"OG000","groupLabel":"Treatment Arm","value":-0.8,"displayValue":"-0.8 units on a scale","denominator":9},"comparator":{"groupId":"OG001","groupLabel":"Placebo Arm","value":-0.1,"displayValue":"-0.1 units on a scale","denominator":11},"difference":0.7,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline and 9 weeks, Mean Change in PADC (Caregivers Perception of Disease Control) changed by -0.8 units on a scale in the Treatment Arm group and -0.1 units on a scale in the Placebo Arm group—a difference 0.7 units on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00557284","sourceUrl":"https://clinicaltrials.gov/study/NCT00557284","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":20,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":9,"nctId":"NCT00557284"}},"D000068298":{"name":"Fluticasone","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D014221":{"name":"Triamcinolone","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D010577":{"name":"Petrolatum","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000622721":{"name":"tezepelumab","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C472067":{"name":"levocetirizine","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000069549":{"name":"Ustekinumab","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D016559":{"name":"Tacrolimus","counts":{"studiesWithResults":1,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"active-comparator":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in Children's PROMIS Pediatric Itch Short-Form","timeFrame":"baseline to 12 weeks","treatmentName":"Tacrolimus","treatment":{"groupId":"OG001","groupLabel":"Tacrolimus 0.03%","value":-0.4,"displayValue":"-0.4 score on a scale","denominator":20},"comparator":{"groupId":"OG000","groupLabel":"Crisaborole","value":-0.3,"displayValue":"-0.3 score on a scale","denominator":16},"difference":0.1,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At baseline to 12 weeks, Mean Change in Children's PROMIS Pediatric Itch Short-Form changed by -0.4 score on a scale in the Tacrolimus 0.03% group and -0.3 score on a scale in the Crisaborole group—a difference 0.1 score on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.433"},"nctId":"NCT03645057","sourceUrl":"https://clinicaltrials.gov/study/NCT03645057","phase":"Phase 3","sponsorClass":"Other organization","enrollmentCount":92,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Mean Change in PROMIS Pain Interference-Children (Adaptive Test)","timeFrame":"baseline to 12 weeks","treatmentName":"Tacrolimus","treatment":{"groupId":"OG001","groupLabel":"Tacrolimus 0.03%","value":-6.8,"displayValue":"-6.8 T-score","denominator":20},"comparator":{"groupId":"OG000","groupLabel":"Crisaborole","value":-6.4,"displayValue":"-6.4 T-score","denominator":16},"difference":0.4,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At baseline to 12 weeks, Mean Change in PROMIS Pain Interference-Children (Adaptive Test) changed by -6.8 T-score in the Tacrolimus 0.03% group and -6.4 T-score in the Crisaborole group—a difference 0.4 T-score numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.836"},"nctId":"NCT03645057","sourceUrl":"https://clinicaltrials.gov/study/NCT03645057","phase":"Phase 3","sponsorClass":"Other organization","enrollmentCount":92,"comparatorClass":"active-comparator"}],"timeToEffect":{"weeks":12,"nctId":"NCT03645057"}},"D016572":{"name":"Cyclosporine","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C479163":{"name":"tofacitinib","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D002762":{"name":"Cholecalciferol","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D006854":{"name":"Hydrocortisone","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D012973":{"name":"Sodium Hypochlorite","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C571829":{"name":"tapinarof","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D003898":{"name":"Desonide","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D014222":{"name":"Triamcinolone Acetonide","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000608195":{"name":"GSK1070806","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000707471":{"name":"gusacitinib","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000627613":{"name":"KHK4083","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D001494":{"name":"Baths","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C539259":{"name":"EpiCeram","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C007975":{"name":"hydrocortisone-17-butyrate","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C555450":{"name":"secukinumab","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D007279":{"name":"Injections, Subcutaneous","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000615713":{"name":"ivarmacitinib","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D014867":{"name":"Water","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000592443":{"name":"2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D015126":{"name":"8,11,14-Eicosatrienoic Acid","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C571386":{"name":"benralizumab","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline","timeFrame":"Baseline (Week 0) and at Week 16","treatmentName":"benralizumab","treatment":{"groupId":"OG000","groupLabel":"Benralizumab","value":9.4,"displayValue":"9.4%","denominator":96},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":17.3,"displayValue":"17.3%","denominator":98},"difference":-7.9,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Baseline (Week 0) and at Week 16, 9.4% of people in the Benralizumab group had the submitted improvement result (Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline), compared with 17.3% in the Placebo group—7.9 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Difference in response rate","parameterValue":"-8.62","confidenceIntervalPercent":"","confidenceIntervalLower":"-17.94","confidenceIntervalUpper":"0.71","pValue":"0.080"},"nctId":"NCT04605094","sourceUrl":"https://clinicaltrials.gov/study/NCT04605094","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":194,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"C000656249":{"name":"etrasimod","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16","timeFrame":"DB Period: Week 16","treatmentName":"etrasimod","treatment":{"groupId":"OG000","groupLabel":"DB Period: Etrasimod 2 mg","value":3.3,"displayValue":"3.3%","denominator":30},"comparator":{"groupId":"OG001","groupLabel":"DB Period: Placebo","value":7.1,"displayValue":"7.1%","denominator":28},"difference":-3.8,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At DB Period: Week 16, 3.3% of people in the DB Period: Etrasimod 2 mg group had the submitted improvement result (Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16), compared with 7.1% in the DB Period: Placebo group—3.8 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Difference in percentage","parameterValue":"-3.76","confidenceIntervalPercent":"","confidenceIntervalLower":"-16.36","confidenceIntervalUpper":"8.83","pValue":"=0.5580"},"nctId":"NCT05732454","sourceUrl":"https://clinicaltrials.gov/study/NCT05732454","phase":"Phase 2 / Phase 3","sponsorClass":"Industry","enrollmentCount":58,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"C508887":{"name":"retapamulin","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C424423":{"name":"Roflumilast","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C551592":{"name":"serlopitant","counts":{"studiesWithResults":2,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"WI-NRS 4-point Responder Rate at Week 6","timeFrame":"Week 6 compared to Baseline","treatmentName":"serlopitant","treatment":{"groupId":"OG001","groupLabel":"Serlopitant 1 mg","value":22.4,"displayValue":"22.4%","denominator":161},"comparator":{"groupId":"OG002","groupLabel":"Placebo Oral Tablet","value":16.5,"displayValue":"16.5%","denominator":158},"difference":5.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 6 compared to Baseline, 22.4% of people in the Serlopitant 1 mg group had the submitted improvement result (WI-NRS 4-point Responder Rate at Week 6), compared with 16.5% in the Placebo Oral Tablet group—5.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02975206","sourceUrl":"https://clinicaltrials.gov/study/NCT02975206","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":484,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"WI-NRS 4-point Responder Rate at Week 6","timeFrame":"Week 6 compared to Baseline","treatmentName":"serlopitant","treatment":{"groupId":"OG000","groupLabel":"Serlopitant 5 mg","value":20.6,"displayValue":"20.6%","denominator":160},"comparator":{"groupId":"OG002","groupLabel":"Placebo Oral Tablet","value":16.5,"displayValue":"16.5%","denominator":158},"difference":4.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 6 compared to Baseline, 20.6% of people in the Serlopitant 5 mg group had the submitted improvement result (WI-NRS 4-point Responder Rate at Week 6), compared with 16.5% in the Placebo Oral Tablet group—4.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02975206","sourceUrl":"https://clinicaltrials.gov/study/NCT02975206","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":484,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":6,"nctId":"NCT02975206"}},"C000712973":{"name":"spesolimab","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":3},"patientResults":[{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Patients With a 50% Improvement From Baseline in EASI (EASI50) at Week 48","timeFrame":"At baseline and at Week 48.","treatmentName":"spesolimab","treatment":{"groupId":"OG000","groupLabel":"Spesolimab 600 mg","value":33.3,"displayValue":"33.3%","denominator":9},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At baseline and at Week 48, 33.3% of people in the Spesolimab 600 mg group had the submitted improvement result (Percentage of Patients With a 50% Improvement From Baseline in EASI (EASI50) at Week 48). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT04086121","sourceUrl":"https://clinicaltrials.gov/study/NCT04086121","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":14},{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Patients With a 75% Improvement From Baseline in EASI (EASI75) at Week 48","timeFrame":"At baseline and at Week 48.","treatmentName":"spesolimab","treatment":{"groupId":"OG000","groupLabel":"Spesolimab 600 mg","value":22.2,"displayValue":"22.2%","denominator":9},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At baseline and at Week 48, 22.2% of people in the Spesolimab 600 mg group had the submitted improvement result (Percentage of Patients With a 75% Improvement From Baseline in EASI (EASI75) at Week 48). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT04086121","sourceUrl":"https://clinicaltrials.gov/study/NCT04086121","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":14}],"timeToEffect":null},"C571151":{"name":"(5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C582990":{"name":"4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C538783":{"name":"6-(5-chloro-2-methoxybenzyl)-4-alarkylaminocarbonyl-1,4-diazepane-2,5-dione","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000077944":{"name":"Alefacept","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D001205":{"name":"Ascorbic Acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000711667":{"name":"astegolimab","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C494814":{"name":"BID protein, human","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000706608":{"name":"BMS-986166","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":3,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16","timeFrame":"From baseline and 16 weeks","treatmentName":"BMS-986166","treatment":{"groupId":"OG002","groupLabel":"Treatment 2","value":0,"displayValue":"0%","denominator":4},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":4},"difference":0,"differenceUnit":"percentage-points","direction":"no-observed-difference","plainLanguage":"At From baseline and 16 weeks, 0% of people in the Treatment 2 group had the submitted improvement result (Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16), compared with 0% in the Placebo group—0 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05014438","sourceUrl":"https://clinicaltrials.gov/study/NCT05014438","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":17,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16","timeFrame":"From baseline and 16 weeks","treatmentName":"BMS-986166","treatment":{"groupId":"OG001","groupLabel":"Treatment 1","value":0,"displayValue":"0%","denominator":3},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":4},"difference":0,"differenceUnit":"percentage-points","direction":"no-observed-difference","plainLanguage":"At From baseline and 16 weeks, 0% of people in the Treatment 1 group had the submitted improvement result (Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16), compared with 0% in the Placebo group—0 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05014438","sourceUrl":"https://clinicaltrials.gov/study/NCT05014438","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":17,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16","timeFrame":"From baseline and 16 weeks","treatmentName":"BMS-986166","treatment":{"groupId":"OG003","groupLabel":"Treatment 3","value":0,"displayValue":"0%","denominator":3},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":4},"difference":0,"differenceUnit":"percentage-points","direction":"no-observed-difference","plainLanguage":"At From baseline and 16 weeks, 0% of people in the Treatment 3 group had the submitted improvement result (Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16), compared with 0% in the Placebo group—0 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05014438","sourceUrl":"https://clinicaltrials.gov/study/NCT05014438","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":17,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"C000710709":{"name":"branebrutinib","counts":{"studiesWithResults":1,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Mean Percentage Change From Baseline in EASI Score at Week 16","timeFrame":"From baseline and 16 weeks","treatmentName":"branebrutinib","treatment":{"groupId":"OG004","groupLabel":"Treatment 4","value":-92.3,"displayValue":"-92.3%","denominator":1},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":-83.1,"displayValue":"-83.1%","denominator":1},"difference":9.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At From baseline and 16 weeks, Mean Percentage Change From Baseline in EASI Score at Week 16 changed by -92.3% in the Treatment 4 group and -83.1% in the Placebo group—a difference 9.2 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05014438","sourceUrl":"https://clinicaltrials.gov/study/NCT05014438","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":17,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT05014438"}}},"recruiting":[{"nctId":"NCT04334031","title":"Deployment o the Multidisciplinary Prospective Cohort Imminent","enrollmentTarget":2200,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT04334031"},{"nctId":"NCT07347743","title":"Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.","enrollmentTarget":768,"countries":["Belgium"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07347743"},{"nctId":"NCT06461897","title":"A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis","enrollmentTarget":675,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06461897"},{"nctId":"NCT06241118","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","enrollmentTarget":636,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06241118"},{"nctId":"NCT06775860","title":"ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis","enrollmentTarget":552,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06775860"},{"nctId":"NCT07358156","title":"A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.","enrollmentTarget":519,"countries":["Germany","United Kingdom"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07358156"},{"nctId":"NCT07690371","title":"A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":510,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07690371"},{"nctId":"NCT07711418","title":"A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":510,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07711418"},{"nctId":"NCT06807281","title":"A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema","enrollmentTarget":500,"countries":["United States","China","Germany","Hungary","Japan","Mexico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06807281"},{"nctId":"NCT07316465","title":"Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","enrollmentTarget":500,"countries":["Belgium"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07316465"},{"nctId":"NCT06723080","title":"Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","enrollmentTarget":480,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06723080"},{"nctId":"NCT06587685","title":"A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis","enrollmentTarget":472,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06587685"},{"nctId":"NCT07037901","title":"A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":405,"countries":["United States","Australia","Canada","New Zealand"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07037901"},{"nctId":"NCT07330934","title":"A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis","enrollmentTarget":403,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07330934"},{"nctId":"NCT06943469","title":"Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function","enrollmentTarget":400,"countries":["Belgium","France","Germany","Poland","Spain"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06943469"},{"nctId":"NCT06880276","title":"Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","enrollmentTarget":360,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06880276"},{"nctId":"NCT07592585","title":"Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","enrollmentTarget":360,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07592585"},{"nctId":"NCT07003425","title":"A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis","enrollmentTarget":350,"countries":["United States","Canada","Czechia","Germany","Hungary","Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07003425"},{"nctId":"NCT05995964","title":"A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis","enrollmentTarget":340,"countries":["United States","Australia","Canada","China","Germany","Japan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05995964"},{"nctId":"NCT06390878","title":"Nationwide Research on the Rewilding of Kindergarten Yards","enrollmentTarget":320,"countries":["Finland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06390878"},{"nctId":"NCT03928431","title":"Restoration of Microbiota in Neonates","enrollmentTarget":300,"countries":["Sweden"],"sourceUrl":"https://clinicaltrials.gov/study/NCT03928431"},{"nctId":"NCT07411755","title":"A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection","enrollmentTarget":294,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07411755"},{"nctId":"NCT07599813","title":"A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":280,"countries":["United States","Bulgaria","Canada","Czechia","Germany","Hungary"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07599813"},{"nctId":"NCT06239311","title":"Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.","enrollmentTarget":277,"countries":["Czechia","France","Italy","Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06239311"},{"nctId":"NCT07230483","title":"A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","enrollmentTarget":246,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07230483"},{"nctId":"NCT06808477","title":"A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)","enrollmentTarget":237,"countries":["United States","Australia","New Zealand","Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06808477"},{"nctId":"NCT06362629","title":"AI App for Management of Atopic Dermatitis","enrollmentTarget":232,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06362629"},{"nctId":"NCT06947993","title":"Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis","enrollmentTarget":224,"countries":["United States","Argentina","Canada","China","Czechia","France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06947993"},{"nctId":"NCT06004986","title":"DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","enrollmentTarget":216,"countries":["Netherlands"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06004986"},{"nctId":"NCT07309055","title":"A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis","enrollmentTarget":201,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07309055"},{"nctId":"NCT06300697","title":"Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project","enrollmentTarget":200,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06300697"},{"nctId":"NCT06389136","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","enrollmentTarget":200,"countries":["United States","Canada","Colombia","Italy","Japan","Puerto Rico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06389136"},{"nctId":"NCT06947980","title":"Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":200,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06947980"},{"nctId":"NCT07441395","title":"Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","enrollmentTarget":200,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07441395"},{"nctId":"NCT07445919","title":"A Clinical Study to Evaluate SM17 for Atopic Dermatitis","enrollmentTarget":200,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07445919"},{"nctId":"NCT07643766","title":"A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":200,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07643766"},{"nctId":"NCT06311682","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","enrollmentTarget":195,"countries":["United States","Belgium","Canada","Croatia","Germany","Ireland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06311682"},{"nctId":"NCT07042126","title":"Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis","enrollmentTarget":180,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07042126"},{"nctId":"NCT07216027","title":"A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema","enrollmentTarget":165,"countries":["United States","Canada","China","Japan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07216027"},{"nctId":"NCT07277660","title":"A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis","enrollmentTarget":160,"countries":["United States","Bulgaria","Canada","Czechia","Germany","Hungary"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07277660"},{"nctId":"NCT07629778","title":"HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis","enrollmentTarget":156,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07629778"},{"nctId":"NCT07558668","title":"A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis","enrollmentTarget":149,"countries":["United States","Bulgaria","Denmark","Germany","Ireland","United Kingdom"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07558668"},{"nctId":"NCT07527923","title":"First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis","enrollmentTarget":144,"countries":["Belgium"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07527923"},{"nctId":"NCT07444008","title":"Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete","enrollmentTarget":140,"countries":["Russia"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07444008"},{"nctId":"NCT01631617","title":"Effects of Treatments on Atopic Dermatitis","enrollmentTarget":130,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT01631617"},{"nctId":"NCT06082323","title":"A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers","enrollmentTarget":127,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06082323"},{"nctId":"NCT07453602","title":"Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234","enrollmentTarget":125,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07453602"},{"nctId":"NCT06096857","title":"Cardamom and Topical Roseomonas in Atopic Dermatitis","enrollmentTarget":120,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06096857"},{"nctId":"NCT06636240","title":"Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis","enrollmentTarget":120,"countries":["Taiwan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06636240"},{"nctId":"NCT07223697","title":"A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis","enrollmentTarget":120,"countries":["United States","Brazil","Canada","Germany","Italy","Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07223697"},{"nctId":"NCT07399067","title":"A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis","enrollmentTarget":120,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07399067"},{"nctId":"NCT07598383","title":"A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis","enrollmentTarget":120,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07598383"},{"nctId":"NCT06564389","title":"FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients","enrollmentTarget":119,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06564389"},{"nctId":"NCT06934252","title":"Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis","enrollmentTarget":115,"countries":["Australia","New Zealand"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06934252"},{"nctId":"NCT06397911","title":"Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis","enrollmentTarget":114,"countries":["United States","Taiwan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06397911"},{"nctId":"NCT07193589","title":"A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis","enrollmentTarget":111,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07193589"},{"nctId":"NCT06547372","title":"Dietary Intervention on Atopy","enrollmentTarget":110,"countries":["Singapore"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06547372"},{"nctId":"NCT07355075","title":"A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)","enrollmentTarget":110,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07355075"},{"nctId":"NCT07014007","title":"Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks","enrollmentTarget":105,"countries":["Mauritius"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07014007"},{"nctId":"NCT06946641","title":"A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients","enrollmentTarget":102,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06946641"}],"pairs":[{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"C117268","name":"pimecrolimus"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"D000305","name":"Adrenal Cortex Hormones"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"C561806","name":"lebrikizumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"D016559","name":"Tacrolimus"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"C000613732","name":"upadacitinib"},"coRegistered":6,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"C582203","name":"dupilumab"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"D000305","name":"Adrenal Cortex Hormones"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"C561806","name":"lebrikizumab"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"D016559","name":"Tacrolimus"},"coRegistered":5,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"C000613732","name":"upadacitinib"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C117268","name":"pimecrolimus"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000305","name":"Adrenal Cortex Hormones"},"b":{"key":"C561806","name":"lebrikizumab"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"D000305","name":"Adrenal Cortex Hormones"},"b":{"key":"D016559","name":"Tacrolimus"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000305","name":"Adrenal Cortex Hormones"},"b":{"key":"C000613732","name":"upadacitinib"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000305","name":"Adrenal Cortex Hormones"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000305","name":"Adrenal Cortex Hormones"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C561806","name":"lebrikizumab"},"b":{"key":"D016559","name":"Tacrolimus"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C561806","name":"lebrikizumab"},"b":{"key":"C000613732","name":"upadacitinib"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C561806","name":"lebrikizumab"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C561806","name":"lebrikizumab"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D016559","name":"Tacrolimus"},"b":{"key":"C000613732","name":"upadacitinib"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D016559","name":"Tacrolimus"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D016559","name":"Tacrolimus"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C000613732","name":"upadacitinib"},"b":{"key":"C574065","name":"tralokinumab"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"C000613732","name":"upadacitinib"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"C574065","name":"tralokinumab"},"b":{"key":"C000634427","name":"abrocitinib"},"coRegistered":2,"headToHeadResults":0}]},"psoriasis":{"terms":{"C555450":{"name":"secukinumab","counts":{"studiesWithResults":51,"favouredTreatment":14,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":12,"active-comparator":2},"comparative":14,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12","timeFrame":"Week 12","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 300mg (2 x 150 mg)","value":66.5,"displayValue":"66.5%","denominator":550},"comparator":{"groupId":"OG001","groupLabel":"Ustekinumab 2 x 45mg or 90mg","value":48,"displayValue":"48%","denominator":552},"difference":18.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 66.5% of people in the Secukinumab 300mg (2 x 150 mg) group had the submitted improvement result (Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12), compared with 48% in the Ustekinumab 2 x 45mg or 90mg group—18.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"2.21","confidenceIntervalPercent":"","confidenceIntervalLower":"1.72","confidenceIntervalUpper":"2.84","pValue":"<0.0001"},"nctId":"NCT02826603","sourceUrl":"https://clinicaltrials.gov/study/NCT02826603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1114,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants With IGA Mod 2011 0 or 1 at Week 12","timeFrame":"Week 12","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 300mg (2 x 150 mg)","value":72.2,"displayValue":"72.2%","denominator":550},"comparator":{"groupId":"OG001","groupLabel":"Ustekinumab 2 x 45mg or 90mg","value":55.4,"displayValue":"55.4%","denominator":552},"difference":16.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 72.2% of people in the Secukinumab 300mg (2 x 150 mg) group had the submitted improvement result (Participants With IGA Mod 2011 0 or 1 at Week 12), compared with 55.4% in the Ustekinumab 2 x 45mg or 90mg group—16.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"2.10","confidenceIntervalPercent":"","confidenceIntervalLower":"1.63","confidenceIntervalUpper":"2.72","pValue":"<0.0001"},"nctId":"NCT02826603","sourceUrl":"https://clinicaltrials.gov/study/NCT02826603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1114,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)","timeFrame":"Week 12","treatmentName":"secukinumab","treatment":{"groupId":"OG001","groupLabel":"Secukinumab 300mg","value":93.4,"displayValue":"93.4%","denominator":272},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":4.4,"displayValue":"4.4%","denominator":135},"difference":89,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 93.4% of people in the Secukinumab 300mg group had the submitted improvement result (Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)), compared with 4.4% in the Placebo group—89 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"557.98","confidenceIntervalPercent":"","confidenceIntervalLower":"187.2","confidenceIntervalUpper":"1663.4","pValue":"<0.0001"},"nctId":"NCT03066609","sourceUrl":"https://clinicaltrials.gov/study/NCT03066609","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":543,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)","timeFrame":"Week 12","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 150mg","value":82.4,"displayValue":"82.4%","denominator":136},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":4.4,"displayValue":"4.4%","denominator":135},"difference":78,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 82.4% of people in the Secukinumab 150mg group had the submitted improvement result (Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)), compared with 4.4% in the Placebo group—78 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"153.94","confidenceIntervalPercent":"","confidenceIntervalLower":"54.02","confidenceIntervalUpper":"438.67","pValue":"<0.0001"},"nctId":"NCT03066609","sourceUrl":"https://clinicaltrials.gov/study/NCT03066609","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":543,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)","timeFrame":"Week 12","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 150mg","value":67.6,"displayValue":"67.6%","denominator":136},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":3,"displayValue":"3%","denominator":135},"difference":64.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 67.6% of people in the Secukinumab 150mg group had the submitted improvement result (Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)), compared with 3% in the Placebo group—64.6 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"75.82","confidenceIntervalPercent":"","confidenceIntervalLower":"25.81","confidenceIntervalUpper":"222.72","pValue":"<0.0001"},"nctId":"NCT03066609","sourceUrl":"https://clinicaltrials.gov/study/NCT03066609","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":543,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 2 mL PFS","value":88.9,"displayValue":"88.9%","denominator":72},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":1.4,"displayValue":"1.4%","denominator":71},"difference":87.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 88.9% of people in the Secukinumab 2 mL PFS group had the submitted improvement result (Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment), compared with 1.4% in the Placebo group—87.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"717.42","confidenceIntervalPercent":"","confidenceIntervalLower":"68.00","confidenceIntervalUpper":"7569.56","pValue":"< 0.0001"},"nctId":"NCT02748863","sourceUrl":"https://clinicaltrials.gov/study/NCT02748863","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":214,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 2 mL PFS","value":76.4,"displayValue":"76.4%","denominator":72},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":1.4,"displayValue":"1.4%","denominator":71},"difference":75,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 76.4% of people in the Secukinumab 2 mL PFS group had the submitted improvement result (Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment), compared with 1.4% in the Placebo group—75 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"400.58","confidenceIntervalPercent":"","confidenceIntervalLower":"47.48","confidenceIntervalUpper":"3379.99","pValue":"< 0.0001"},"nctId":"NCT02748863","sourceUrl":"https://clinicaltrials.gov/study/NCT02748863","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":214,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 300 mg","value":79.6,"displayValue":"79.6%","denominator":54},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":3.6,"displayValue":"3.6%","denominator":28},"difference":76,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 79.6% of people in the Secukinumab 300 mg group had the submitted improvement result (Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12), compared with 3.6% in the Placebo group—76 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"difference in percentages","parameterValue":"76.1","confidenceIntervalPercent":"","confidenceIntervalLower":"63.3","confidenceIntervalUpper":"88.8","pValue":""},"nctId":"NCT03055494","sourceUrl":"https://clinicaltrials.gov/study/NCT03055494","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":102,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 300 mg","value":53.7,"displayValue":"53.7%","denominator":54},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":28},"difference":53.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 53.7% of people in the Secukinumab 300 mg group had the submitted improvement result (Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12), compared with 0% in the Placebo group—53.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"difference in percentages","parameterValue":"55.8","confidenceIntervalPercent":"","confidenceIntervalLower":"42.3","confidenceIntervalUpper":"69.3","pValue":""},"nctId":"NCT03055494","sourceUrl":"https://clinicaltrials.gov/study/NCT03055494","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":102,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"AIN457 Low Dose","value":80,"displayValue":"80%","denominator":40},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":14.6,"displayValue":"14.6%","denominator":41},"difference":65.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 80% of people in the AIN457 Low Dose group had the submitted improvement result (Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12), compared with 14.6% in the Placebo group—65.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02471144","sourceUrl":"https://clinicaltrials.gov/study/NCT02471144","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":162,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG001","groupLabel":"AIN457 High Dose","value":77.5,"displayValue":"77.5%","denominator":40},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":14.6,"displayValue":"14.6%","denominator":41},"difference":62.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 77.5% of people in the AIN457 High Dose group had the submitted improvement result (Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12), compared with 14.6% in the Placebo group—62.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02471144","sourceUrl":"https://clinicaltrials.gov/study/NCT02471144","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":162,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"PASI 75 Response After 12 Weeks of Treatment","timeFrame":"12 weeks","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab 2 mL Auto-injector","value":95.1,"displayValue":"95.1%","denominator":41},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":10,"displayValue":"10%","denominator":40},"difference":85.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 95.1% of people in the Secukinumab 2 mL Auto-injector group had the submitted improvement result (PASI 75 Response After 12 Weeks of Treatment), compared with 10% in the Placebo group—85.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"1014.07","confidenceIntervalPercent":"","confidenceIntervalLower":"68.83","confidenceIntervalUpper":"14940.62","pValue":"<0.0001"},"nctId":"NCT03589885","sourceUrl":"https://clinicaltrials.gov/study/NCT03589885","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":122,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT02826603"}},"D000068800":{"name":"Etanercept","counts":{"studiesWithResults":37,"favouredTreatment":0,"favouredComparator":2,"noObservedDifference":1,"byComparatorClass":{"placebo-or-vehicle":1,"active-comparator":2},"comparative":3,"singleArm":5},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12","timeFrame":"12-weeks","treatmentName":"Etanercept","treatment":{"groupId":"OG000","groupLabel":"Enbrel (Etanercept)","value":62.3,"displayValue":"62.3%","denominator":228},"comparator":{"groupId":"OG001","groupLabel":"CHS-0214","value":64.5,"displayValue":"64.5%","denominator":228},"difference":-2.2,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At 12-weeks, 62.3% of people in the Enbrel (Etanercept) group had the submitted improvement result (Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12), compared with 64.5% in the CHS-0214 group—2.2 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02134210","sourceUrl":"https://clinicaltrials.gov/study/NCT02134210","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":521,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks","timeFrame":"12 Weeks","treatmentName":"Etanercept","treatment":{"groupId":"OG000","groupLabel":"Enbrel (Etanercept)","value":-73.4,"displayValue":"-73.4%","denominator":226},"comparator":{"groupId":"OG001","groupLabel":"CHS-0214","value":-76.7,"displayValue":"-76.7%","denominator":228},"difference":-3.3,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At 12 Weeks, Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks changed by -73.4% in the Enbrel (Etanercept) group and -76.7% in the CHS-0214 group—a difference 3.3 percentage points numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02134210","sourceUrl":"https://clinicaltrials.gov/study/NCT02134210","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":521,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks.","timeFrame":"Week 12","treatmentName":"Etanercept","treatment":{"groupId":"OG000","groupLabel":"Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks","value":100,"displayValue":"100%","denominator":8},"comparator":{"groupId":"OG001","groupLabel":"Subjects Receiving Placebo for the First 12 Weeks","value":100,"displayValue":"100%","denominator":12},"difference":0,"differenceUnit":"percentage-points","direction":"no-observed-difference","plainLanguage":"At Week 12, 100% of people in the Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks group had the submitted improvement result (The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks), compared with 100% in the Subjects Receiving Placebo for the First 12 Weeks group—0 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00585650","sourceUrl":"https://clinicaltrials.gov/study/NCT00585650","phase":"Phase 1 / Phase 2","sponsorClass":"Other organization","enrollmentCount":20,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"D000068879":{"name":"Adalimumab","counts":{"studiesWithResults":32,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":3},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12","timeFrame":"Week 12","treatmentName":"Adalimumab","treatment":{"groupId":"OG001","groupLabel":"Adalimumab Eow","value":77.8,"displayValue":"77.8%","denominator":338},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":11.5,"displayValue":"11.5%","denominator":87},"difference":66.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 77.8% of people in the Adalimumab Eow group had the submitted improvement result (Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12), compared with 11.5% in the Placebo group—66.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01646073","sourceUrl":"https://clinicaltrials.gov/study/NCT01646073","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":425,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01646073"}},"D000069549":{"name":"Ustekinumab","counts":{"studiesWithResults":33,"favouredTreatment":2,"favouredComparator":2,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2,"active-comparator":2},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12","timeFrame":"Week 12","treatmentName":"Ustekinumab","treatment":{"groupId":"OG001","groupLabel":"Ustekinumab 2 x 45mg or 90mg","value":48,"displayValue":"48%","denominator":552},"comparator":{"groupId":"OG000","groupLabel":"Secukinumab 300mg (2 x 150 mg)","value":66.5,"displayValue":"66.5%","denominator":550},"difference":-18.5,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Week 12, 48% of people in the Ustekinumab 2 x 45mg or 90mg group had the submitted improvement result (Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12), compared with 66.5% in the Secukinumab 300mg (2 x 150 mg) group—18.5 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"2.21","confidenceIntervalPercent":"","confidenceIntervalLower":"1.72","confidenceIntervalUpper":"2.84","pValue":"<0.0001"},"nctId":"NCT02826603","sourceUrl":"https://clinicaltrials.gov/study/NCT02826603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1114,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Participants With IGA Mod 2011 0 or 1 at Week 12","timeFrame":"Week 12","treatmentName":"Ustekinumab","treatment":{"groupId":"OG001","groupLabel":"Ustekinumab 2 x 45mg or 90mg","value":55.4,"displayValue":"55.4%","denominator":552},"comparator":{"groupId":"OG000","groupLabel":"Secukinumab 300mg (2 x 150 mg)","value":72.2,"displayValue":"72.2%","denominator":550},"difference":-16.8,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Week 12, 55.4% of people in the Ustekinumab 2 x 45mg or 90mg group had the submitted improvement result (Participants With IGA Mod 2011 0 or 1 at Week 12), compared with 72.2% in the Secukinumab 300mg (2 x 150 mg) group—16.8 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"2.10","confidenceIntervalPercent":"","confidenceIntervalLower":"1.63","confidenceIntervalUpper":"2.72","pValue":"<0.0001"},"nctId":"NCT02826603","sourceUrl":"https://clinicaltrials.gov/study/NCT02826603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1114,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12","timeFrame":"12 Weeks","treatmentName":"Ustekinumab","treatment":{"groupId":"OG003","groupLabel":"Ustekinumab","value":21.7,"displayValue":"21.7%","denominator":300},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":0.6,"displayValue":"0.6%","denominator":309},"difference":21.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 Weeks, 21.7% of people in the Ustekinumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12), compared with 0.6% in the Placebo group—21.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708603","sourceUrl":"https://clinicaltrials.gov/study/NCT01708603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1831,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) at Week 12","timeFrame":"Week 12","treatmentName":"Ustekinumab","treatment":{"groupId":"OG001","groupLabel":"Ustekinumab 45 mg","value":67.2,"displayValue":"67.2%","denominator":61},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":5,"displayValue":"5%","denominator":60},"difference":62.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 67.2% of people in the Ustekinumab 45 mg group had the submitted improvement result (The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) at Week 12), compared with 5% in the Placebo group—62.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT00747344","sourceUrl":"https://clinicaltrials.gov/study/NCT00747344","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":121,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01708603"}},"C505730":{"name":"apremilast","counts":{"studiesWithResults":24,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":5},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16","timeFrame":"Baseline and week 16","treatmentName":"apremilast","treatment":{"groupId":"OG001","groupLabel":"Apremilast 30 mg","value":73.3,"displayValue":"73.3%","denominator":185},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":41.3,"displayValue":"41.3%","denominator":92},"difference":32,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and week 16, 73.3% of people in the Apremilast 30 mg group had the submitted improvement result (Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16), compared with 41.3% in the Placebo group—32 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Adjusted Difference in Response Rates","parameterValue":"31.9","confidenceIntervalPercent":"","confidenceIntervalLower":"18.6","confidenceIntervalUpper":"45.2","pValue":"<0.0001"},"nctId":"NCT03774875","sourceUrl":"https://clinicaltrials.gov/study/NCT03774875","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":277,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT03774875"}},"C000601773":{"name":"risankizumab","counts":{"studiesWithResults":19,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1","timeFrame":"At Week 16","treatmentName":"risankizumab","treatment":{"groupId":"OG000","groupLabel":"Risankizumab","value":57.4,"displayValue":"57.4%","denominator":244},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At Week 16, 57.4% of people in the Risankizumab group had the submitted improvement result (Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":{"parameterType":"Proportion of sPGA 0/1 @ WK 16","parameterValue":"57.4","confidenceIntervalPercent":"","confidenceIntervalLower":"51.1","confidenceIntervalUpper":"63.4","pValue":""},"nctId":"NCT04102007","sourceUrl":"https://clinicaltrials.gov/study/NCT04102007","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":244}],"timeToEffect":null},"C549079":{"name":"ixekizumab","counts":{"studiesWithResults":18,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement","timeFrame":"Week 12","treatmentName":"ixekizumab","treatment":{"groupId":"OG002","groupLabel":"Ixekizumab 80mg Q2W","value":86.4,"displayValue":"86.4%","denominator":176},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":3.4,"displayValue":"3.4%","denominator":88},"difference":83,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 86.4% of people in the Ixekizumab 80mg Q2W group had the submitted improvement result (Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement), compared with 3.4% in the Placebo group—83 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"99.99","confidenceIntervalPercent":"","confidenceIntervalLower":"52.49","confidenceIntervalUpper":"99.99","pValue":"<0.001"},"nctId":"NCT03364309","sourceUrl":"https://clinicaltrials.gov/study/NCT03364309","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":438,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement","timeFrame":"Week 12","treatmentName":"ixekizumab","treatment":{"groupId":"OG001","groupLabel":"Ixekizumab 80mg Q4W","value":79.9,"displayValue":"79.9%","denominator":174},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":3.4,"displayValue":"3.4%","denominator":88},"difference":76.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 79.9% of people in the Ixekizumab 80mg Q4W group had the submitted improvement result (Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement), compared with 3.4% in the Placebo group—76.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"99.99","confidenceIntervalPercent":"","confidenceIntervalLower":"33.57","confidenceIntervalUpper":"99.99","pValue":"<0.0001"},"nctId":"NCT03364309","sourceUrl":"https://clinicaltrials.gov/study/NCT03364309","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":438,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)","timeFrame":"Week 12","treatmentName":"ixekizumab","treatment":{"groupId":"OG001","groupLabel":"Ixekizumab 80mg Q4W","value":87.4,"displayValue":"87.4%","denominator":174},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":8,"displayValue":"8%","denominator":88},"difference":79.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 87.4% of people in the Ixekizumab 80mg Q4W group had the submitted improvement result (Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)), compared with 8% in the Placebo group—79.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"79.95","confidenceIntervalPercent":"","confidenceIntervalLower":"32.76","confidenceIntervalUpper":"99.99","pValue":"<0.001"},"nctId":"NCT03364309","sourceUrl":"https://clinicaltrials.gov/study/NCT03364309","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":438,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT03364309"}},"C055085":{"name":"calcipotriene","counts":{"studiesWithResults":17,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Physician Global Assessement","timeFrame":"10 weeks","treatmentName":"calcipotriene","treatment":{"groupId":"OG001","groupLabel":"Calcipotriene 80%","value":80,"displayValue":"80%","denominator":16},"comparator":{"groupId":"OG000","groupLabel":"Vehicle 68%","value":68,"displayValue":"68%","denominator":13},"difference":12,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 10 weeks, 80% of people in the Calcipotriene 80% group had the submitted improvement result (Physician Global Assessement), compared with 68% in the Vehicle 68% group—12 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01745133","sourceUrl":"https://clinicaltrials.gov/study/NCT01745133","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":63,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":10,"nctId":"NCT01745133"}},"C000588857":{"name":"guselkumab","counts":{"studiesWithResults":16,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000625981":{"name":"bimekizumab","counts":{"studiesWithResults":13,"favouredTreatment":4,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"active-comparator":2,"placebo-or-vehicle":2},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16","timeFrame":"Week 16","treatmentName":"bimekizumab","treatment":{"groupId":"OG001","groupLabel":"Bimekizumab 320 mg Q4W","value":81.3,"displayValue":"81.3%","denominator":32},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":15},"difference":81.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 81.3% of people in the Bimekizumab 320 mg Q4W group had the submitted improvement result (Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16), compared with 0% in the Placebo group—81.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT05020249","sourceUrl":"https://clinicaltrials.gov/study/NCT05020249","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":47,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16","timeFrame":"Week 16","treatmentName":"bimekizumab","treatment":{"groupId":"OG001","groupLabel":"Bimekizumab 320 mg Q4W","value":87.5,"displayValue":"87.5%","denominator":32},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":15},"difference":87.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 87.5% of people in the Bimekizumab 320 mg Q4W group had the submitted improvement result (Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16), compared with 0% in the Placebo group—87.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.001"},"nctId":"NCT05020249","sourceUrl":"https://clinicaltrials.gov/study/NCT05020249","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":47,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants With a PASI90 Response at Week 52","timeFrame":"Week 52","treatmentName":"bimekizumab","treatment":{"groupId":"OG000","groupLabel":"Bimekizumab 320 mg Q4W (RS)","value":81.9,"displayValue":"81.9%","denominator":321},"comparator":{"groupId":"OG001","groupLabel":"Ustekinumab (RS)","value":55.8,"displayValue":"55.8%","denominator":163},"difference":26.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 52, 81.9% of people in the Bimekizumab 320 mg Q4W (RS) group had the submitted improvement result (Percentage of Participants With a PASI90 Response at Week 52), compared with 55.8% in the Ustekinumab (RS) group—26.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"3.795","confidenceIntervalPercent":"","confidenceIntervalLower":"2.442","confidenceIntervalUpper":"5.899","pValue":"<0.001"},"nctId":"NCT03370133","sourceUrl":"https://clinicaltrials.gov/study/NCT03370133","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":567,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52","timeFrame":"Week 52","treatmentName":"bimekizumab","treatment":{"groupId":"OG000","groupLabel":"Bimekizumab 320 mg Q4W (RS)","value":78.2,"displayValue":"78.2%","denominator":321},"comparator":{"groupId":"OG001","groupLabel":"Ustekinumab (RS)","value":60.7,"displayValue":"60.7%","denominator":163},"difference":17.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 52, 78.2% of people in the Bimekizumab 320 mg Q4W (RS) group had the submitted improvement result (Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52), compared with 60.7% in the Ustekinumab (RS) group—17.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"2.412","confidenceIntervalPercent":"","confidenceIntervalLower":"1.573","confidenceIntervalUpper":"3.699","pValue":"<0.001"},"nctId":"NCT03370133","sourceUrl":"https://clinicaltrials.gov/study/NCT03370133","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":567,"comparatorClass":"active-comparator"}],"timeToEffect":{"weeks":16,"nctId":"NCT05020249"}},"C479163":{"name":"tofacitinib","counts":{"studiesWithResults":12,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12","timeFrame":"Week 12","treatmentName":"tofacitinib","treatment":{"groupId":"OG000","groupLabel":"Tofacitinib 10 mg BID","value":62.5,"displayValue":"62.5%","denominator":8},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":33.3,"displayValue":"33.3%","denominator":3},"difference":29.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 62.5% of people in the Tofacitinib 10 mg BID group had the submitted improvement result (Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12), compared with 33.3% in the Placebo group—29.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01710046","sourceUrl":"https://clinicaltrials.gov/study/NCT01710046","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":12,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of \"Clear\" or \"Almost Clear\" at Week 12","timeFrame":"Week 12","treatmentName":"tofacitinib","treatment":{"groupId":"OG000","groupLabel":"Tofacitinib 10 mg BID","value":50,"displayValue":"50%","denominator":8},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":33.3,"displayValue":"33.3%","denominator":3},"difference":16.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 50% of people in the Tofacitinib 10 mg BID group had the submitted improvement result (Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of \"Clear\" or \"Almost Clear\" at Week 12), compared with 33.3% in the Placebo group—16.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01710046","sourceUrl":"https://clinicaltrials.gov/study/NCT01710046","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":12,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01710046"}},"D000069285":{"name":"Infliximab","counts":{"studiesWithResults":12,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D008727":{"name":"Methotrexate","counts":{"studiesWithResults":10,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D015444":{"name":"Exercise","counts":{"studiesWithResults":8,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000628674":{"name":"deucravacitinib","counts":{"studiesWithResults":10,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16","timeFrame":"At Week 16","treatmentName":"deucravacitinib","treatment":{"groupId":"OG000","groupLabel":"Deucravacitinib","value":35.5,"displayValue":"35.5%","denominator":107},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":8.2,"displayValue":"8.2%","denominator":49},"difference":27.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 35.5% of people in the Deucravacitinib group had the submitted improvement result (Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16), compared with 8.2% in the Placebo group—27.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"5.9","confidenceIntervalPercent":"","confidenceIntervalLower":"2.0","confidenceIntervalUpper":"17.4","pValue":"0.0004"},"nctId":"NCT05701995","sourceUrl":"https://clinicaltrials.gov/study/NCT05701995","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":180,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16","timeFrame":"Baseline and Week 16","treatmentName":"deucravacitinib","treatment":{"groupId":"OG000","groupLabel":"Deucravacitinib","value":51,"displayValue":"51%","denominator":96},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":4.3,"displayValue":"4.3%","denominator":47},"difference":46.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 16, 51% of people in the Deucravacitinib group had the submitted improvement result (Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16), compared with 4.3% in the Placebo group—46.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"23.9","confidenceIntervalPercent":"","confidenceIntervalLower":"5.4","confidenceIntervalUpper":"105.6","pValue":"<0.0001"},"nctId":"NCT05478499","sourceUrl":"https://clinicaltrials.gov/study/NCT05478499","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":154,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT05701995"}},"D001623":{"name":"Betamethasone","counts":{"studiesWithResults":8,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D002990":{"name":"Clobetasol","counts":{"studiesWithResults":8,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000068582":{"name":"Certolizumab Pegol","counts":{"studiesWithResults":6,"favouredTreatment":4,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3,"same-treatment":1},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12","timeFrame":"Week 12","treatmentName":"Certolizumab Pegol","treatment":{"groupId":"OG002","groupLabel":"Certolizumab Pegol 400 mg (ITT)","value":72.4,"displayValue":"72.4%","denominator":58},"comparator":{"groupId":"OG000","groupLabel":"Placebo (ITT)","value":1.7,"displayValue":"1.7%","denominator":59},"difference":70.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 72.4% of people in the Certolizumab Pegol 400 mg (ITT) group had the submitted improvement result (Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12), compared with 1.7% in the Placebo (ITT) group—70.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"162.6","confidenceIntervalPercent":"","confidenceIntervalLower":"31.4","confidenceIntervalUpper":"2999.2","pValue":"<0.001"},"nctId":"NCT00245765","sourceUrl":"https://clinicaltrials.gov/study/NCT00245765","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":176,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16","timeFrame":"Week 16","treatmentName":"Certolizumab Pegol","treatment":{"groupId":"OG002","groupLabel":"CZP 400 mg Q2W (FAS)","value":87.1,"displayValue":"87.1%","denominator":53},"comparator":{"groupId":"OG000","groupLabel":"Placebo (FAS)","value":7.9,"displayValue":"7.9%","denominator":26},"difference":79.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 87.1% of people in the CZP 400 mg Q2W (FAS) group had the submitted improvement result (Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16), compared with 7.9% in the Placebo (FAS) group—79.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Estimated difference in responder rate","parameterValue":"79.1","confidenceIntervalPercent":"","confidenceIntervalLower":"65.10","confidenceIntervalUpper":"93.17","pValue":""},"nctId":"NCT03051217","sourceUrl":"https://clinicaltrials.gov/study/NCT03051217","phase":"Phase 2 / Phase 3","sponsorClass":"Industry","enrollmentCount":127,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16","timeFrame":"Week 16","treatmentName":"Certolizumab Pegol","treatment":{"groupId":"OG001","groupLabel":"CZP 200 mg Q2W (FAS)","value":73,"displayValue":"73%","denominator":48},"comparator":{"groupId":"OG000","groupLabel":"Placebo (FAS)","value":7.9,"displayValue":"7.9%","denominator":26},"difference":65.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 73% of people in the CZP 200 mg Q2W (FAS) group had the submitted improvement result (Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16), compared with 7.9% in the Placebo (FAS) group—65.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Estimated difference in responder rate","parameterValue":"65.1","confidenceIntervalPercent":"","confidenceIntervalLower":"48.22","confidenceIntervalUpper":"81.90","pValue":""},"nctId":"NCT03051217","sourceUrl":"https://clinicaltrials.gov/study/NCT03051217","phase":"Phase 2 / Phase 3","sponsorClass":"Industry","enrollmentCount":127,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Percentage of Subjects Who Achieve a Psoriasis Global Assessment (PGA) Clear or Almost Clear Response at Week 12 of Re-treatment in This Study","timeFrame":"Week 12 of re-treatment in this study","treatmentName":"Certolizumab Pegol","treatment":{"groupId":"OG001","groupLabel":"Certolizumab Pegol (CZP) 400 mg","value":56.8,"displayValue":"56.8%","denominator":37},"comparator":{"groupId":"OG000","groupLabel":"Certolizumab Pegol (CZP) 200 mg","value":52.9,"displayValue":"52.9%","denominator":34},"difference":3.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12 of re-treatment in this study, 56.8% of people in the Certolizumab Pegol (CZP) 400 mg group had the submitted improvement result (Percentage of Subjects Who Achieve a Psoriasis Global Assessment (PGA) Clear or Almost Clear Response at Week 12 of Re-treatment in This Study), compared with 52.9% in the Certolizumab Pegol (CZP) 200 mg group—3.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00329303","sourceUrl":"https://clinicaltrials.gov/study/NCT00329303","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":71,"comparatorClass":"same-treatment"}],"timeToEffect":{"weeks":12,"nctId":"NCT00245765"}},"C000712973":{"name":"spesolimab","counts":{"studiesWithResults":6,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C472181":{"name":"efalizumab","counts":{"studiesWithResults":6,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C517164":{"name":"betamethasone dipropionate, calcipotriol drug combination","counts":{"studiesWithResults":7,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000598434":{"name":"tildrakizumab","counts":{"studiesWithResults":6,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28.","timeFrame":"Week 28","treatmentName":"tildrakizumab","treatment":{"groupId":"OG001","groupLabel":"Tildrakizumab 100 mg","value":25.5,"displayValue":"25.5%","denominator":51},"comparator":{"groupId":"OG000","groupLabel":"Placebo","value":4.2,"displayValue":"4.2%","denominator":48},"difference":21.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 28, 25.5% of people in the Tildrakizumab 100 mg group had the submitted improvement result (The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28), compared with 4.2% in the Placebo group—21.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.00311"},"nctId":"NCT03897075","sourceUrl":"https://clinicaltrials.gov/study/NCT03897075","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":99,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":28,"nctId":"NCT03897075"}},"C571829":{"name":"tapinarof","counts":{"studiesWithResults":5,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":2},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation","timeFrame":"Baseline to Week 12","treatmentName":"tapinarof","treatment":{"groupId":"OG000","groupLabel":"Tapinarof (DMVT-505) Cream Group","value":40.2,"displayValue":"40.2%","denominator":343},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Cream Group","value":6.3,"displayValue":"6.3%","denominator":172},"difference":33.9,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, 40.2% of people in the Tapinarof (DMVT-505) Cream Group group had the submitted improvement result (Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation), compared with 6.3% in the Vehicle Cream Group group—33.9 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Ratio (RR)","parameterValue":"6.10","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.0001"},"nctId":"NCT03983980","sourceUrl":"https://clinicaltrials.gov/study/NCT03983980","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":515,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation","timeFrame":"Baseline to Week 12","treatmentName":"tapinarof","treatment":{"groupId":"OG000","groupLabel":"Tapinarof (DMVT-505)","value":35.4,"displayValue":"35.4%","denominator":340},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Cream","value":6,"displayValue":"6%","denominator":170},"difference":29.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, 35.4% of people in the Tapinarof (DMVT-505) group had the submitted improvement result (Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation), compared with 6% in the Vehicle Cream group—29.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Ratio (RR)","parameterValue":"5.78","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.0001"},"nctId":"NCT03956355","sourceUrl":"https://clinicaltrials.gov/study/NCT03956355","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":510,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT03983980"}},"D003899":{"name":"Desoximetasone","counts":{"studiesWithResults":5,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Clinical Success","timeFrame":"28 days","treatmentName":"Desoximetasone","treatment":{"groupId":"OG000","groupLabel":"Desoximetasone Spray 0.25%","value":30.5,"displayValue":"30.5%","denominator":59},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":5,"displayValue":"5%","denominator":60},"difference":25.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 28 days, 30.5% of people in the Desoximetasone Spray 0.25% group had the submitted improvement result (Clinical Success), compared with 5% in the Placebo group—25.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.0003"},"nctId":"NCT01206387","sourceUrl":"https://clinicaltrials.gov/study/NCT01206387","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":120,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Treatment Success","timeFrame":"28 days","treatmentName":"Desoximetasone","treatment":{"groupId":"OG000","groupLabel":"Desoximetasone Spray 0.25%","value":39,"displayValue":"39%","denominator":59},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":6.7,"displayValue":"6.7%","denominator":60},"difference":32.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 28 days, 39% of people in the Desoximetasone Spray 0.25% group had the submitted improvement result (Treatment Success), compared with 6.7% in the Placebo group—32.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"<0.0001"},"nctId":"NCT01206387","sourceUrl":"https://clinicaltrials.gov/study/NCT01206387","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":120,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":4,"nctId":"NCT01206387"}},"C571216":{"name":"brodalumab","counts":{"studiesWithResults":11,"favouredTreatment":6,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":6},"comparative":6,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG001","groupLabel":"140 mg Brodalumab","value":69.2,"displayValue":"69.2%","denominator":629},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":6,"displayValue":"6%","denominator":315},"difference":63.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 69.2% of people in the 140 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12), compared with 6% in the Placebo group—63.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708629","sourceUrl":"https://clinicaltrials.gov/study/NCT01708629","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1881,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG000","groupLabel":"210 mg Brodalumab","value":85.1,"displayValue":"85.1%","denominator":624},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":6,"displayValue":"6%","denominator":315},"difference":79.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 85.1% of people in the 210 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12), compared with 6% in the Placebo group—79.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708629","sourceUrl":"https://clinicaltrials.gov/study/NCT01708629","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1881,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Static Physician Global Assessment (sPGA) Success Score (Score of 0 or 1) at Week 12 - Comparison to Placebo","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG000","groupLabel":"210 mg Brodalumab","value":79.6,"displayValue":"79.6%","denominator":624},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":4.1,"displayValue":"4.1%","denominator":315},"difference":75.5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 79.6% of people in the 210 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Static Physician Global Assessment (sPGA) Success Score (Score of 0 or 1) at Week 12 - Comparison to Placebo), compared with 4.1% in the Placebo group—75.5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708629","sourceUrl":"https://clinicaltrials.gov/study/NCT01708629","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1881,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG000","groupLabel":"210 mg Brodalumab","value":78.6,"displayValue":"78.6%","denominator":612},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":3.9,"displayValue":"3.9%","denominator":309},"difference":74.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 78.6% of people in the 210 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12), compared with 3.9% in the Placebo group—74.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708603","sourceUrl":"https://clinicaltrials.gov/study/NCT01708603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1831,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG000","groupLabel":"210 mg Brodalumab","value":86.3,"displayValue":"86.3%","denominator":612},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":8.1,"displayValue":"8.1%","denominator":309},"difference":78.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 86.3% of people in the 210 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12), compared with 8.1% in the Placebo group—78.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708603","sourceUrl":"https://clinicaltrials.gov/study/NCT01708603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1831,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12","timeFrame":"12 weeks","treatmentName":"brodalumab","treatment":{"groupId":"OG001","groupLabel":"140 mg Brodalumab","value":58,"displayValue":"58%","denominator":610},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":3.9,"displayValue":"3.9%","denominator":309},"difference":54.1,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 58% of people in the 140 mg Brodalumab group had the submitted improvement result (Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12), compared with 3.9% in the Placebo group—54.1 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01708603","sourceUrl":"https://clinicaltrials.gov/study/NCT01708603","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1831,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01708629"}},"C064466":{"name":"halobetasol","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C424423":{"name":"Roflumilast","counts":{"studiesWithResults":4,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8","timeFrame":"Baseline (Day 1) and Week 8","treatmentName":"Roflumilast","treatment":{"groupId":"OG000","groupLabel":"Rofumilast Cream 0.3%","value":42.4,"displayValue":"42.4%","denominator":255},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Cream","value":6.1,"displayValue":"6.1%","denominator":132},"difference":36.3,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1) and Week 8, 42.4% of people in the Rofumilast Cream 0.3% group had the submitted improvement result (Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8), compared with 6.1% in the Vehicle Cream group—36.3 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Odds Ratio (OR)","parameterValue":"20.69","confidenceIntervalPercent":"","confidenceIntervalLower":"7.58","confidenceIntervalUpper":"56.48","pValue":"<0.0001"},"nctId":"NCT04211363","sourceUrl":"https://clinicaltrials.gov/study/NCT04211363","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":439,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"D002117":{"name":"Calcitriol","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D005650":{"name":"Fumarates","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000077944":{"name":"Alefacept","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"same-treatment":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Subjects Who Achieve Psoriasis Area and Severity Index (PASI) 75 at Week 16","timeFrame":"Week 16","treatmentName":"Alefacept","treatment":{"groupId":"OG000","groupLabel":"Alefacept Alone","value":22.4,"displayValue":"22.4%","denominator":49},"comparator":{"groupId":"OG001","groupLabel":"Alefacept + nbUVB","value":44.9,"displayValue":"44.9%","denominator":49},"difference":-22.5,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Week 16, 22.4% of people in the Alefacept Alone group had the submitted improvement result (Percentage of Subjects Who Achieve Psoriasis Area and Severity Index (PASI) 75 at Week 16), compared with 44.9% in the Alefacept + nbUVB group—22.5 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.032"},"nctId":"NCT00658606","sourceUrl":"https://clinicaltrials.gov/study/NCT00658606","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":98,"comparatorClass":"same-treatment"}],"timeToEffect":null},"C011175":{"name":"betamethasone-17,21-dipropionate","counts":{"studiesWithResults":5,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C086827":{"name":"tazarotene","counts":{"studiesWithResults":4,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Treatment Success Assessed by IGA","timeFrame":"Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG001","groupLabel":"Reference","value":63.2,"displayValue":"63.2%","denominator":266},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":56,"displayValue":"56%","denominator":275},"difference":7.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 63.2% of people in the Reference group had the submitted improvement result (Treatment Success Assessed by IGA), compared with 56% in the Placebo group—7.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02886702","sourceUrl":"https://clinicaltrials.gov/study/NCT02886702","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":855,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Treatment Success Assessed by IGA","timeFrame":"Week 12","treatmentName":"tazarotene","treatment":{"groupId":"OG000","groupLabel":"Test","value":60.8,"displayValue":"60.8%","denominator":263},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":56,"displayValue":"56%","denominator":275},"difference":4.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 12, 60.8% of people in the Test group had the submitted improvement result (Treatment Success Assessed by IGA), compared with 56% in the Placebo group—4.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.3520"},"nctId":"NCT02886702","sourceUrl":"https://clinicaltrials.gov/study/NCT02886702","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":855,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT02886702"}},"D010789":{"name":"Phototherapy","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C543085":{"name":"crisaborole","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000708407":{"name":"mirikizumab","counts":{"studiesWithResults":6,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)","timeFrame":"Week 16","treatmentName":"mirikizumab","treatment":{"groupId":"OG001","groupLabel":"Induction: 30 mg Mirikizumab","value":29.4,"displayValue":"29.4%","denominator":51},"comparator":{"groupId":"OG000","groupLabel":"Induction: Placebo","value":0,"displayValue":"0%","denominator":52},"difference":29.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 29.4% of people in the Induction: 30 mg Mirikizumab group had the submitted improvement result (Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)), compared with 0% in the Induction: Placebo group—29.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"29.4","confidenceIntervalPercent":"","confidenceIntervalLower":"16.9","confidenceIntervalUpper":"41.9","pValue":"0.009"},"nctId":"NCT02899988","sourceUrl":"https://clinicaltrials.gov/study/NCT02899988","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":205,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)","timeFrame":"Week 16","treatmentName":"mirikizumab","treatment":{"groupId":"OG002","groupLabel":"Induction: 100 mg Mirikizumab","value":58.8,"displayValue":"58.8%","denominator":51},"comparator":{"groupId":"OG000","groupLabel":"Induction: Placebo","value":0,"displayValue":"0%","denominator":52},"difference":58.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 58.8% of people in the Induction: 100 mg Mirikizumab group had the submitted improvement result (Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)), compared with 0% in the Induction: Placebo group—58.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"58.8","confidenceIntervalPercent":"","confidenceIntervalLower":"45.3","confidenceIntervalUpper":"72.3","pValue":"<0.001"},"nctId":"NCT02899988","sourceUrl":"https://clinicaltrials.gov/study/NCT02899988","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":205,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)","timeFrame":"Week 16","treatmentName":"mirikizumab","treatment":{"groupId":"OG003","groupLabel":"Induction: 300 mg Mirikizumab","value":66.7,"displayValue":"66.7%","denominator":51},"comparator":{"groupId":"OG000","groupLabel":"Induction: Placebo","value":0,"displayValue":"0%","denominator":52},"difference":66.7,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Week 16, 66.7% of people in the Induction: 300 mg Mirikizumab group had the submitted improvement result (Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)), compared with 0% in the Induction: Placebo group—66.7 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Risk Difference (RD)","parameterValue":"66.7","confidenceIntervalPercent":"","confidenceIntervalLower":"53.7","confidenceIntervalUpper":"79.6","pValue":"<0.001"},"nctId":"NCT02899988","sourceUrl":"https://clinicaltrials.gov/study/NCT02899988","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":205,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":16,"nctId":"NCT02899988"}},"C000718240":{"name":"belumosudil","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D006854":{"name":"Hydrocortisone","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000619755":{"name":"KD025","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C540383":{"name":"ruxolitinib","counts":{"studiesWithResults":3,"favouredTreatment":3,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84","timeFrame":"From Baseline (Day 1) to Day 84","treatmentName":"ruxolitinib","treatment":{"groupId":"OG001","groupLabel":"Ruxolitinib Phosphate 0.5% Cream","value":-2.2,"displayValue":"-2.2 score on a scale","denominator":49},"comparator":{"groupId":"OG000","groupLabel":"Vehicle Cream","value":-1.1,"displayValue":"-1.1 score on a scale","denominator":47},"difference":1.1,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At From Baseline (Day 1) to Day 84, Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 changed by -2.2 score on a scale in the Ruxolitinib Phosphate 0.5% Cream group and -1.1 score on a scale in the Vehicle Cream group—a difference 1.1 score on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Least Squares (LS) Mean Difference","parameterValue":"-1.18","confidenceIntervalPercent":"","confidenceIntervalLower":"-1.85","confidenceIntervalUpper":"-0.51","pValue":"0.0041"},"nctId":"NCT00778700","sourceUrl":"https://clinicaltrials.gov/study/NCT00778700","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":199,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84","timeFrame":"From Baseline (Day 1) to Day 84","treatmentName":"ruxolitinib","treatment":{"groupId":"OG002","groupLabel":"Ruxolitinib Phosphate 1.0% Cream","value":-2.5,"displayValue":"-2.5 score on a scale","denominator":49},"comparator":{"groupId":"OG000","groupLabel":"Vehicle Cream","value":-1.1,"displayValue":"-1.1 score on a scale","denominator":47},"difference":1.4,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At From Baseline (Day 1) to Day 84, Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 changed by -2.5 score on a scale in the Ruxolitinib Phosphate 1.0% Cream group and -1.1 score on a scale in the Vehicle Cream group—a difference 1.4 score on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"LS Mean Difference","parameterValue":"-1.40","confidenceIntervalPercent":"","confidenceIntervalLower":"-2.08","confidenceIntervalUpper":"-0.73","pValue":"0.0007"},"nctId":"NCT00778700","sourceUrl":"https://clinicaltrials.gov/study/NCT00778700","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":199,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84","timeFrame":"From Baseline (Day 1) to Day 84","treatmentName":"ruxolitinib","treatment":{"groupId":"OG003","groupLabel":"Ruxolitinib Phosphate 1.5% Cream","value":-2.3,"displayValue":"-2.3 score on a scale","denominator":48},"comparator":{"groupId":"OG000","groupLabel":"Vehicle Cream","value":-1.1,"displayValue":"-1.1 score on a scale","denominator":47},"difference":1.2,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At From Baseline (Day 1) to Day 84, Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 changed by -2.3 score on a scale in the Ruxolitinib Phosphate 1.5% Cream group and -1.1 score on a scale in the Vehicle Cream group—a difference 1.2 score on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"LS Mean Difference","parameterValue":"-1.21","confidenceIntervalPercent":"","confidenceIntervalLower":"-1.88","confidenceIntervalUpper":"-0.53","pValue":"0.0035"},"nctId":"NCT00778700","sourceUrl":"https://clinicaltrials.gov/study/NCT00778700","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":199,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"D017255":{"name":"Acitretin","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000069462":{"name":"Dimethyl Fumarate","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C494814":{"name":"BID protein, human","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C478920":{"name":"CF101","counts":{"studiesWithResults":2,"favouredTreatment":3,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":4},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks","timeFrame":"12 weeks","treatmentName":"CF101","treatment":{"groupId":"OG000","groupLabel":"CF101 2 mg","value":8.5,"displayValue":"8.5%","denominator":141},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":6.9,"displayValue":"6.9%","denominator":144},"difference":1.6,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 8.5% of people in the CF101 2 mg group had the submitted improvement result (Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks), compared with 6.9% in the Placebo group—1.6 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT01265667","sourceUrl":"https://clinicaltrials.gov/study/NCT01265667","phase":"Phase 2 / Phase 3","sponsorClass":"Industry","enrollmentCount":293,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score","timeFrame":"12 weeks minus baseline","treatmentName":"CF101","treatment":{"groupId":"OG000","groupLabel":"CF101 1 mg Twice Daily (BID)","value":-0.7,"displayValue":"-0.7 Scores on a scale","denominator":24},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-2.7,"displayValue":"-2.7 Scores on a scale","denominator":19},"difference":-2,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At 12 weeks minus baseline, Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score changed by -0.7 Scores on a scale in the CF101 1 mg Twice Daily (BID) group and -2.7 Scores on a scale in the Placebo group—a difference 2 Scores on a scale numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00428974","sourceUrl":"https://clinicaltrials.gov/study/NCT00428974","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":76,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score","timeFrame":"12 weeks minus baseline","treatmentName":"CF101","treatment":{"groupId":"OG001","groupLabel":"CF101 2 mg BID","value":-8.8,"displayValue":"-8.8 Scores on a scale","denominator":17},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-2.7,"displayValue":"-2.7 Scores on a scale","denominator":19},"difference":6.1,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At 12 weeks minus baseline, Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score changed by -8.8 Scores on a scale in the CF101 2 mg BID group and -2.7 Scores on a scale in the Placebo group—a difference 6.1 Scores on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.031"},"nctId":"NCT00428974","sourceUrl":"https://clinicaltrials.gov/study/NCT00428974","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":76,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score","timeFrame":"12 weeks minus baseline","treatmentName":"CF101","treatment":{"groupId":"OG002","groupLabel":"CF101 4 mg BID","value":-4.1,"displayValue":"-4.1 Scores on a scale","denominator":15},"comparator":{"groupId":"OG003","groupLabel":"Placebo","value":-2.7,"displayValue":"-2.7 Scores on a scale","denominator":19},"difference":1.4,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At 12 weeks minus baseline, Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score changed by -4.1 Scores on a scale in the CF101 4 mg BID group and -2.7 Scores on a scale in the Placebo group—a difference 1.4 Scores on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00428974","sourceUrl":"https://clinicaltrials.gov/study/NCT00428974","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":76,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT01265667"}},"C084956":{"name":"N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D054018":{"name":"Lasers, Excimer","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D013812":{"name":"Therapeutics","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000305":{"name":"Adrenal Cortex Hormones","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000630676":{"name":"ABP 501","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000632724":{"name":"BI 695501","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000708951":{"name":"GSK2982772","counts":{"studiesWithResults":2,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12","timeFrame":"Baseline and Week 12","treatmentName":"GSK2982772","treatment":{"groupId":"OG000","groupLabel":"GSK2982772 960 mg","value":5,"displayValue":"5%","denominator":19},"comparator":{"groupId":"OG001","groupLabel":"Placebo","value":0,"displayValue":"0%","denominator":10},"difference":5,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline and Week 12, 5% of people in the GSK2982772 960 mg group had the submitted improvement result (Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12), compared with 0% in the Placebo group—5 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-2.28","confidenceIntervalPercent":"","confidenceIntervalLower":"-9.19","confidenceIntervalUpper":"8.28","pValue":""},"nctId":"NCT04316585","sourceUrl":"https://clinicaltrials.gov/study/NCT04316585","phase":"Phase 1","sponsorClass":"Industry","enrollmentCount":29,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT04316585"}},"D009821":{"name":"Oils","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000630838":{"name":"PF-06700841","counts":{"studiesWithResults":3,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"SECONDARY","outcomeTitle":"Change From Baseline in PASI Scores at Week 4 by Induction Dose","timeFrame":"Baseline (Day 1 pre-dose), Week 4","treatmentName":"PF-06700841","treatment":{"groupId":"OG000","groupLabel":"PF-06700841 60 mg QD as the Induction Dose","value":-13.2,"displayValue":"-13.2 units on a scale","denominator":100},"comparator":{"groupId":"OG002","groupLabel":"Placebo as the Induction Dose","value":-4.2,"displayValue":"-4.2 units on a scale","denominator":21},"difference":9,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1 pre-dose), Week 4, Change From Baseline in PASI Scores at Week 4 by Induction Dose changed by -13.2 units on a scale in the PF-06700841 60 mg QD as the Induction Dose group and -4.2 units on a scale in the Placebo as the Induction Dose group—a difference 9 units on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Least Squares Mean Difference","parameterValue":"-9.00","confidenceIntervalPercent":"","confidenceIntervalLower":"-11.43","confidenceIntervalUpper":"-6.57","pValue":"<0.0001"},"nctId":"NCT02969018","sourceUrl":"https://clinicaltrials.gov/study/NCT02969018","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":212,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"SECONDARY","outcomeTitle":"Change From Baseline in PASI Scores at Week 4 by Induction Dose","timeFrame":"Baseline (Day 1 pre-dose), Week 4","treatmentName":"PF-06700841","treatment":{"groupId":"OG001","groupLabel":"PF-06700841 30 mg QD as the Induction Dose","value":-12.2,"displayValue":"-12.2 units on a scale","denominator":81},"comparator":{"groupId":"OG002","groupLabel":"Placebo as the Induction Dose","value":-4.2,"displayValue":"-4.2 units on a scale","denominator":21},"difference":8,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline (Day 1 pre-dose), Week 4, Change From Baseline in PASI Scores at Week 4 by Induction Dose changed by -12.2 units on a scale in the PF-06700841 30 mg QD as the Induction Dose group and -4.2 units on a scale in the Placebo as the Induction Dose group—a difference 8 units on a scale numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"Least Squares Mean Difference","parameterValue":"-7.99","confidenceIntervalPercent":"","confidenceIntervalLower":"-10.48","confidenceIntervalUpper":"-5.51","pValue":"<0.0001"},"nctId":"NCT02969018","sourceUrl":"https://clinicaltrials.gov/study/NCT02969018","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":212,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"C000720458":{"name":"ropsacitinib","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C511308":{"name":"sodium luminolate","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D013535":{"name":"Suspensions","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D016572":{"name":"Cyclosporine","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D008874":{"name":"Midazolam","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D007267":{"name":"Injections","counts":{"studiesWithResults":2,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000069594":{"name":"Abatacept","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D001624":{"name":"Betamethasone Valerate","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null}},"recruiting":[{"nctId":"NCT07116967","title":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","enrollmentTarget":3040,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07116967"},{"nctId":"NCT06702293","title":"Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients","enrollmentTarget":690,"countries":["Singapore"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06702293"},{"nctId":"NCT06382051","title":"Modifying PEST for Psoriatic Arthritis Screening","enrollmentTarget":502,"countries":["Canada"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06382051"},{"nctId":"NCT07326813","title":"A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis","enrollmentTarget":477,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07326813"},{"nctId":"NCT07532486","title":"A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis","enrollmentTarget":400,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07532486"},{"nctId":"NCT07130604","title":"Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis","enrollmentTarget":390,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07130604"},{"nctId":"NCT06842199","title":"Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis","enrollmentTarget":383,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06842199"},{"nctId":"NCT07672561","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","enrollmentTarget":375,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07672561"},{"nctId":"NCT06979453","title":"A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":366,"countries":["United States","Argentina","Belgium","Brazil","Canada","China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06979453"},{"nctId":"NCT07511647","title":"A Phase 3 Clinical Study of QL2106 Injection","enrollmentTarget":318,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07511647"},{"nctId":"NCT03816345","title":"Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","enrollmentTarget":300,"countries":["United States","Canada"],"sourceUrl":"https://clinicaltrials.gov/study/NCT03816345"},{"nctId":"NCT07362017","title":"Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","enrollmentTarget":300,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07362017"},{"nctId":"NCT07426120","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","enrollmentTarget":300,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07426120"},{"nctId":"NCT07449702","title":"An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis","enrollmentTarget":240,"countries":["United States","Canada"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07449702"},{"nctId":"NCT07129382","title":"A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":220,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07129382"},{"nctId":"NCT07258745","title":"Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants","enrollmentTarget":213,"countries":["Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07258745"},{"nctId":"NCT06398106","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","enrollmentTarget":210,"countries":["Belgium"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06398106"},{"nctId":"NCT06592274","title":"A Phase 2 Study of HB0017 in Psoriasis Patients","enrollmentTarget":200,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06592274"},{"nctId":"NCT06857942","title":"A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","enrollmentTarget":200,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06857942"},{"nctId":"NCT07194200","title":"Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial","enrollmentTarget":184,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07194200"},{"nctId":"NCT06058546","title":"Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis","enrollmentTarget":180,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06058546"},{"nctId":"NCT05004727","title":"Multi-Center PAMPA Study","enrollmentTarget":176,"countries":["United States","Canada"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05004727"},{"nctId":"NCT07251998","title":"Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":172,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07251998"},{"nctId":"NCT06726213","title":"Walk and Talk: Connecting People With Psoriasis","enrollmentTarget":170,"countries":["United Kingdom"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06726213"},{"nctId":"NCT07474792","title":"Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis","enrollmentTarget":160,"countries":["United States","Canada"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07474792"},{"nctId":"NCT04772079","title":"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":153,"countries":["Argentina","Australia","Brazil","Canada","France","Germany"],"sourceUrl":"https://clinicaltrials.gov/study/NCT04772079"},{"nctId":"NCT07033234","title":"Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118","enrollmentTarget":142,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07033234"},{"nctId":"NCT07234591","title":"A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis","enrollmentTarget":140,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07234591"},{"nctId":"NCT06846710","title":"Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118","enrollmentTarget":132,"countries":["United States","New Zealand"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06846710"},{"nctId":"NCT07615257","title":"Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control","enrollmentTarget":128,"countries":["Pakistan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07615257"},{"nctId":"NCT07038720","title":"A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis","enrollmentTarget":124,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07038720"},{"nctId":"NCT07390487","title":"The Effects of Audio-Based Therapy on Anxiety in Psoriasis","enrollmentTarget":120,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07390487"},{"nctId":"NCT07250802","title":"A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis","enrollmentTarget":110,"countries":["United States","China","Germany","Italy","Japan","Poland"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07250802"},{"nctId":"NCT07337434","title":"To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital","enrollmentTarget":106,"countries":["Pakistan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07337434"},{"nctId":"NCT07265284","title":"A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":104,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07265284"},{"nctId":"NCT04080635","title":"Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)","enrollmentTarget":100,"countries":["Belgium"],"sourceUrl":"https://clinicaltrials.gov/study/NCT04080635"},{"nctId":"NCT05399433","title":"Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis","enrollmentTarget":100,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05399433"},{"nctId":"NCT05503875","title":"Immunoclassification of Psoriasis: a Strategy for Precision Medicine","enrollmentTarget":100,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05503875"},{"nctId":"NCT07204639","title":"Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects","enrollmentTarget":100,"countries":["Mexico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07204639"},{"nctId":"NCT07471048","title":"A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis","enrollmentTarget":100,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07471048"},{"nctId":"NCT07024602","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis","enrollmentTarget":94,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07024602"},{"nctId":"NCT05642182","title":"Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques","enrollmentTarget":90,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05642182"},{"nctId":"NCT05644782","title":"Dietary Approach to Mild-to-moderate Psoriasis","enrollmentTarget":82,"countries":["Italy"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05644782"},{"nctId":"NCT07261306","title":"Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","enrollmentTarget":75,"countries":["Pakistan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07261306"},{"nctId":"NCT07489885","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","enrollmentTarget":75,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07489885"},{"nctId":"NCT05500794","title":"Meditation in Inflammatory Dermatosis","enrollmentTarget":72,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05500794"},{"nctId":"NCT07029516","title":"Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis","enrollmentTarget":72,"countries":["Italy"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07029516"},{"nctId":"NCT06735911","title":"Assessment of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psoriasis","enrollmentTarget":70,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06735911"},{"nctId":"NCT07401992","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","enrollmentTarget":62,"countries":["Mexico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07401992"},{"nctId":"NCT07719530","title":"Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis","enrollmentTarget":60,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07719530"},{"nctId":"NCT07736651","title":"Anti Inflammatory Diet With Physical Therapy on Psoriasis","enrollmentTarget":60,"countries":["Egypt"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07736651"},{"nctId":"NCT05815797","title":"Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis","enrollmentTarget":58,"countries":["Hong Kong"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05815797"},{"nctId":"NCT05270733","title":"Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","enrollmentTarget":56,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05270733"},{"nctId":"NCT05725876","title":"Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.","enrollmentTarget":56,"countries":["Netherlands"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05725876"},{"nctId":"NCT07086924","title":"Genetic Variation in TRAF3IP2 (rs13190932)","enrollmentTarget":50,"countries":["Egypt"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07086924"},{"nctId":"NCT07149792","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","enrollmentTarget":50,"countries":["Taiwan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07149792"},{"nctId":"NCT07250997","title":"PALLAS Laser for Skin Diseases","enrollmentTarget":50,"countries":["Hungary"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07250997"},{"nctId":"NCT06982352","title":"Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis","enrollmentTarget":48,"countries":["United States","Jordan"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06982352"},{"nctId":"NCT03987763","title":"A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis","enrollmentTarget":45,"countries":["United States","Dominican Republic","Panama"],"sourceUrl":"https://clinicaltrials.gov/study/NCT03987763"},{"nctId":"NCT04537689","title":"Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","enrollmentTarget":40,"countries":["Singapore"],"sourceUrl":"https://clinicaltrials.gov/study/NCT04537689"}],"pairs":[{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"D000068800","name":"Etanercept"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"C055085","name":"calcipotriene"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"D000068879","name":"Adalimumab"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"D000069549","name":"Ustekinumab"},"coRegistered":4,"headToHeadResults":1},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"C505730","name":"apremilast"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"C555450","name":"secukinumab"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"C055085","name":"calcipotriene"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"D000068879","name":"Adalimumab"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"D000069549","name":"Ustekinumab"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"C505730","name":"apremilast"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D000068800","name":"Etanercept"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C055085","name":"calcipotriene"},"b":{"key":"D000068879","name":"Adalimumab"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"C055085","name":"calcipotriene"},"b":{"key":"D000069549","name":"Ustekinumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C055085","name":"calcipotriene"},"b":{"key":"C505730","name":"apremilast"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C055085","name":"calcipotriene"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C055085","name":"calcipotriene"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000068879","name":"Adalimumab"},"b":{"key":"D000069549","name":"Ustekinumab"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000068879","name":"Adalimumab"},"b":{"key":"C505730","name":"apremilast"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000068879","name":"Adalimumab"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":6,"headToHeadResults":0},{"a":{"key":"D000068879","name":"Adalimumab"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000069549","name":"Ustekinumab"},"b":{"key":"C505730","name":"apremilast"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000069549","name":"Ustekinumab"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D000069549","name":"Ustekinumab"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":6,"headToHeadResults":0},{"a":{"key":"C505730","name":"apremilast"},"b":{"key":"D008727","name":"Methotrexate"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"C505730","name":"apremilast"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D008727","name":"Methotrexate"},"b":{"key":"C000601773","name":"risankizumab"},"coRegistered":2,"headToHeadResults":0}]},"rosacea":{"terms":{"C010038":{"name":"azelaic acid","counts":{"studiesWithResults":9,"favouredTreatment":3,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":4},"comparative":4,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.","timeFrame":"Baseline to Week 12","treatmentName":"azelaic acid","treatment":{"groupId":"OG000","groupLabel":"Azelaic Acid, 15% Topical Gel","value":-67,"displayValue":"-67%","denominator":293},"comparator":{"groupId":"OG002","groupLabel":"Gel Vehicle","value":-38.6,"displayValue":"-38.6%","denominator":127},"difference":28.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts changed by -67% in the Azelaic Acid, 15% Topical Gel group and -38.6% in the Gel Vehicle group—a difference 28.4 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02120924","sourceUrl":"https://clinicaltrials.gov/study/NCT02120924","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1009,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"percent-change","outcomeType":"PRIMARY","outcomeTitle":"Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.","timeFrame":"Baseline to Week 12","treatmentName":"azelaic acid","treatment":{"groupId":"OG001","groupLabel":"Finacea® (Azelaic Acid) Gel, 15%","value":-68.6,"displayValue":"-68.6%","denominator":274},"comparator":{"groupId":"OG002","groupLabel":"Gel Vehicle","value":-38.6,"displayValue":"-38.6%","denominator":127},"difference":30,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts changed by -68.6% in the Finacea® (Azelaic Acid) Gel, 15% group and -38.6% in the Gel Vehicle group—a difference 30 percentage points numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02120924","sourceUrl":"https://clinicaltrials.gov/study/NCT02120924","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":1009,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)","timeFrame":"Baseline and End of Study (Week 12)","treatmentName":"azelaic acid","treatment":{"groupId":"OG000","groupLabel":"Azelaic Acid Foam, 15% (BAY39-6251)","value":-11.7,"displayValue":"-11.7 Inflammatory lesions","denominator":41},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Foam","value":-10.8,"displayValue":"-10.8 Inflammatory lesions","denominator":42},"difference":0.9,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At Baseline and End of Study (Week 12), Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward) changed by -11.7 Inflammatory lesions in the Azelaic Acid Foam, 15% (BAY39-6251) group and -10.8 Inflammatory lesions in the Vehicle Foam group—a difference 0.9 Inflammatory lesions numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00617903","sourceUrl":"https://clinicaltrials.gov/study/NCT00617903","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":83,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Study (LOCF)","timeFrame":"At End of Study (Week 12)","treatmentName":"azelaic acid","treatment":{"groupId":"OG000","groupLabel":"Azelaic Acid Foam, 15% (BAY39-6251)","value":46.3,"displayValue":"46.3%","denominator":41},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Foam","value":47.6,"displayValue":"47.6%","denominator":42},"difference":-1.3,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At End of Study (Week 12), 46.3% of people in the Azelaic Acid Foam, 15% (BAY39-6251) group had the submitted improvement result (Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Study (LOCF)), compared with 47.6% in the Vehicle Foam group—1.3 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00617903","sourceUrl":"https://clinicaltrials.gov/study/NCT00617903","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":83,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT02120924"}},"D004318":{"name":"Doxycycline","counts":{"studiesWithResults":9,"favouredTreatment":3,"favouredComparator":4,"noObservedDifference":0,"byComparatorClass":{"unclassified":1,"placebo-or-vehicle":2,"active-comparator":4},"comparative":7,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe","timeFrame":"16 weeks","treatmentName":"Doxycycline","treatment":{"groupId":"OG002","groupLabel":"Oraycea® (Doxycycline) Capsules","value":33.3,"displayValue":"33.3%","denominator":48},"comparator":{"groupId":"OG003","groupLabel":"Placebo Capsules","value":11.5,"displayValue":"11.5%","denominator":52},"difference":21.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 16 weeks, 33.3% of people in the Oraycea® (Doxycycline) Capsules group had the submitted improvement result (Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe), compared with 11.5% in the Placebo Capsules group—21.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03340961","sourceUrl":"https://clinicaltrials.gov/study/NCT03340961","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":205,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Total Inflammatory Lesion Count Reduction","timeFrame":"16 Weeks","treatmentName":"Doxycycline","treatment":{"groupId":"OG002","groupLabel":"Oraycea® (Doxycycline) Capsules","value":-10.5,"displayValue":"-10.5 Count of lesions","denominator":48},"comparator":{"groupId":"OG003","groupLabel":"Placebo Capsules","value":-7.3,"displayValue":"-7.3 Count of lesions","denominator":52},"difference":3.2,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At 16 Weeks, Total Inflammatory Lesion Count Reduction changed by -10.5 Count of lesions in the Oraycea® (Doxycycline) Capsules group and -7.3 Count of lesions in the Placebo Capsules group—a difference 3.2 Count of lesions numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT03340961","sourceUrl":"https://clinicaltrials.gov/study/NCT03340961","phase":"Phase 2","sponsorClass":"Industry","enrollmentCount":205,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)","timeFrame":"Baseline to Week 12","treatmentName":"Doxycycline","treatment":{"groupId":"OG000","groupLabel":"Oracea® as Monotherapy","value":51.5,"displayValue":"51.5%","denominator":1197},"comparator":{"groupId":"OG001","groupLabel":"Oracea® as add-on Therapy","value":47.3,"displayValue":"47.3%","denominator":224},"difference":4.2,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Baseline to Week 12, 51.5% of people in the Oracea® as Monotherapy group had the submitted improvement result (Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)), compared with 47.3% in the Oracea® as add-on Therapy group—4.2 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT00892281","sourceUrl":"https://clinicaltrials.gov/study/NCT00892281","phase":"Phase 4","sponsorClass":"Industry","enrollmentCount":1421,"comparatorClass":"unclassified"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"IGA Treatment Success Compared to Doxycycline.","timeFrame":"Baseline to Week 16.","treatmentName":"Doxycycline","treatment":{"groupId":"OG001","groupLabel":"Doxycycline 40 mg","value":31.2,"displayValue":"31.2%","denominator":125},"comparator":{"groupId":"OG000","groupLabel":"DFD-29","value":60.2,"displayValue":"60.2%","denominator":123},"difference":-29,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Baseline to Week 16, 31.2% of people in the Doxycycline 40 mg group had the submitted improvement result (IGA Treatment Success Compared to Doxycycline), compared with 60.2% in the DFD-29 group—29 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05343455","sourceUrl":"https://clinicaltrials.gov/study/NCT05343455","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":330,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"SECONDARY","outcomeTitle":"Change in Total Inflammatory Lesion Count Compared to Doxycycline.","timeFrame":"Baseline to Week 16.","treatmentName":"Doxycycline","treatment":{"groupId":"OG001","groupLabel":"Doxycycline 40 mg","value":-14.6,"displayValue":"-14.6 lesions","denominator":125},"comparator":{"groupId":"OG000","groupLabel":"DFD-29","value":-18.1,"displayValue":"-18.1 lesions","denominator":123},"difference":-3.5,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At Baseline to Week 16, Change in Total Inflammatory Lesion Count Compared to Doxycycline changed by -14.6 lesions in the Doxycycline 40 mg group and -18.1 lesions in the DFD-29 group—a difference 3.5 lesions numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05343455","sourceUrl":"https://clinicaltrials.gov/study/NCT05343455","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":330,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"IGA Treatment Success Compared to Doxycycline.","timeFrame":"Baseline to Week 16.","treatmentName":"Doxycycline","treatment":{"groupId":"OG001","groupLabel":"Doxycycline 40 mg","value":46.3,"displayValue":"46.3%","denominator":121},"comparator":{"groupId":"OG000","groupLabel":"DFD-29","value":64.8,"displayValue":"64.8%","denominator":122},"difference":-18.5,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At Baseline to Week 16, 46.3% of people in the Doxycycline 40 mg group had the submitted improvement result (IGA Treatment Success Compared to Doxycycline), compared with 64.8% in the DFD-29 group—18.5 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05296629","sourceUrl":"https://clinicaltrials.gov/study/NCT05296629","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":323,"comparatorClass":"active-comparator"},{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"SECONDARY","outcomeTitle":"Change in Total Inflammatory Lesion Count Compared to Doxycycline.","timeFrame":"Baseline to Week 16.","treatmentName":"Doxycycline","treatment":{"groupId":"OG001","groupLabel":"Doxycycline 40 mg","value":-15.6,"displayValue":"-15.6 lesions","denominator":121},"comparator":{"groupId":"OG000","groupLabel":"DFD-29","value":-20.6,"displayValue":"-20.6 lesions","denominator":122},"difference":-5,"differenceUnit":"outcome-units","direction":"favoured-comparator","plainLanguage":"At Baseline to Week 16, Change in Total Inflammatory Lesion Count Compared to Doxycycline changed by -15.6 lesions in the Doxycycline 40 mg group and -20.6 lesions in the DFD-29 group—a difference 5 lesions numerically smaller in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT05296629","sourceUrl":"https://clinicaltrials.gov/study/NCT05296629","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":323,"comparatorClass":"active-comparator"}],"timeToEffect":{"weeks":12,"nctId":"NCT00892281"}},"D007559":{"name":"Ivermectin","counts":{"studiesWithResults":6,"favouredTreatment":2,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":2},"comparative":2,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Subjects With Clinical Success on the Investigator Global Assessment","timeFrame":"Day 1 to Day 84","treatmentName":"Ivermectin","treatment":{"groupId":"OG000","groupLabel":"Test Product","value":45.5,"displayValue":"45.5%","denominator":156},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":34.7,"displayValue":"34.7%","denominator":75},"difference":10.8,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Day 1 to Day 84, 45.5% of people in the Test Product group had the submitted improvement result (Subjects With Clinical Success on the Investigator Global Assessment), compared with 34.7% in the Placebo group—10.8 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02795117","sourceUrl":"https://clinicaltrials.gov/study/NCT02795117","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":486,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"SECONDARY","outcomeTitle":"Subjects With Clinical Success on the Investigator Global Assessment","timeFrame":"Day 1 to Day 84","treatmentName":"Ivermectin","treatment":{"groupId":"OG001","groupLabel":"Reference Product","value":53.7,"displayValue":"53.7%","denominator":147},"comparator":{"groupId":"OG002","groupLabel":"Placebo","value":34.7,"displayValue":"34.7%","denominator":75},"difference":19,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At Day 1 to Day 84, 53.7% of people in the Reference Product group had the submitted improvement result (Subjects With Clinical Success on the Investigator Global Assessment), compared with 34.7% in the Placebo group—19 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT02795117","sourceUrl":"https://clinicaltrials.gov/study/NCT02795117","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":486,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":null},"D000068438":{"name":"Brimonidine Tartrate","counts":{"studiesWithResults":5,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D010109":{"name":"Oxymetazoline","counts":{"studiesWithResults":4,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Responder","timeFrame":"Day 15","treatmentName":"Oxymetazoline","treatment":{"groupId":"OG000","groupLabel":"Oxymetazoline Cream","value":16.7,"displayValue":"16.7%","denominator":48},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At Day 15, 16.7% of people in the Oxymetazoline Cream group had the submitted improvement result (Responder). There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":null,"nctId":"NCT03352323","sourceUrl":"https://clinicaltrials.gov/study/NCT03352323","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":50}],"timeToEffect":null},"D008795":{"name":"Metronidazole","counts":{"studiesWithResults":3,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000625752":{"name":"Omiganan","counts":{"studiesWithResults":3,"favouredTreatment":2,"favouredComparator":1,"noObservedDifference":0,"byComparatorClass":{"placebo-or-vehicle":3},"comparative":3,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change in Inflammatory Lesion Count From Baseline to Week 12","timeFrame":"12 weeks","treatmentName":"Omiganan","treatment":{"groupId":"OG000","groupLabel":"Treatment","value":-18.1,"displayValue":"-18.1 Lesions","denominator":235},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Gel","value":-13.5,"displayValue":"-13.5 Lesions","denominator":228},"difference":4.6,"differenceUnit":"outcome-units","direction":"favoured-treatment","plainLanguage":"At 12 weeks, Change in Inflammatory Lesion Count From Baseline to Week 12 changed by -18.1 Lesions in the Treatment group and -13.5 Lesions in the Vehicle Gel group—a difference 4.6 Lesions numerically larger in the selected group.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.043"},"nctId":"NCT02547441","sourceUrl":"https://clinicaltrials.gov/study/NCT02547441","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":463,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Percentage of Participants Who Achieved 2 Grade IGA Reduction.","timeFrame":"12 weeks","treatmentName":"Omiganan","treatment":{"groupId":"OG000","groupLabel":"Treatment","value":26.3,"displayValue":"26.3%","denominator":235},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Gel","value":16.9,"displayValue":"16.9%","denominator":228},"difference":9.4,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 26.3% of people in the Treatment group had the submitted improvement result (Percentage of Participants Who Achieved 2 Grade IGA Reduction), compared with 16.9% in the Vehicle Gel group—9.4 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.019"},"nctId":"NCT02547441","sourceUrl":"https://clinicaltrials.gov/study/NCT02547441","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":463,"comparatorClass":"placebo-or-vehicle"},{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"Efficacy IGA: 2 Grade Reduction","timeFrame":"12 weeks","treatmentName":"Omiganan","treatment":{"groupId":"OG000","groupLabel":"Treatment","value":24.6,"displayValue":"24.6%","denominator":136},"comparator":{"groupId":"OG001","groupLabel":"Vehicle Gel","value":25.6,"displayValue":"25.6%","denominator":127},"difference":-1,"differenceUnit":"percentage-points","direction":"favoured-comparator","plainLanguage":"At 12 weeks, 24.6% of people in the Treatment group had the submitted improvement result (Efficacy IGA: 2 Grade Reduction), compared with 25.6% in the Vehicle Gel group—1 fewer people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.858"},"nctId":"NCT02576860","sourceUrl":"https://clinicaltrials.gov/study/NCT02576860","phase":"Phase 3","sponsorClass":"Industry","enrollmentCount":263,"comparatorClass":"placebo-or-vehicle"}],"timeToEffect":{"weeks":12,"nctId":"NCT02547441"}},"D012965":{"name":"Sodium Chloride","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000078262":{"name":"Rifaximin","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000622":{"name":"Aminolevulinic Acid","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C505730":{"name":"apremilast","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline in the Total Number of Papulopustular Lesions at Week 12","timeFrame":"Baseline to Week 12","treatmentName":"apremilast","treatment":{"groupId":"OG000","groupLabel":"Open Label Apremilast 20 mg (Twice Per Day)","value":-0.2,"displayValue":"-0.2 papule count","denominator":10},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At Baseline to Week 12, Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 changed by -0.2 papule count in the Open Label Apremilast 20 mg (Twice Per Day) group. There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":{"parameterType":"Mean Difference (Final Values)","parameterValue":"-0.2","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.98"},"nctId":"NCT01045551","sourceUrl":"https://clinicaltrials.gov/study/NCT01045551","phase":"Phase 2","sponsorClass":"Other organization","enrollmentCount":10}],"timeToEffect":null},"C007084":{"name":"clindamycin phosphate","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C117880":{"name":"clindamycin, tretinoin drug combination","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D004205":{"name":"Cromolyn Sodium","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D016568":{"name":"Drugs, Generic","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000588857":{"name":"guselkumab","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C545476":{"name":"incobotulinumtoxinA","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D000069416":{"name":"Intravital Microscopy","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C529130":{"name":"pyratine 6","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C000629276":{"name":"sarecycline","counts":{"studiesWithResults":1,"favouredTreatment":1,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{"active-comparator":1},"comparative":1,"singleArm":0},"patientResults":[{"status":"comparative","outcomeKind":"response-rate","outcomeType":"PRIMARY","outcomeTitle":"IGA (Investigator Global Assessment)","timeFrame":"12 weeks","treatmentName":"sarecycline","treatment":{"groupId":"OG000","groupLabel":"Sarecycline","value":75,"displayValue":"75%","denominator":72},"comparator":{"groupId":"OG001","groupLabel":"Centrum Adult Multivitamin","value":16,"displayValue":"16%","denominator":25},"difference":59,"differenceUnit":"percentage-points","direction":"favoured-treatment","plainLanguage":"At 12 weeks, 75% of people in the Sarecycline group had the submitted improvement result (IGA (Investigator Global Assessment)), compared with 16% in the Centrum Adult Multivitamin group—59 more people per 100.","caution":"This is one submitted registry outcome, not a pooled treatment estimate. Skinlogie calculated the absolute difference from the submitted group values; the numerical difference does not by itself show a clear or clinically important advantage.","submittedAnalysis":null,"nctId":"NCT04555525","sourceUrl":"https://clinicaltrials.gov/study/NCT04555525","phase":"Phase 4","sponsorClass":"Other organization","enrollmentCount":100,"comparatorClass":"active-comparator"}],"timeToEffect":{"weeks":12,"nctId":"NCT04555525"}},"C555450":{"name":"secukinumab","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":1},"patientResults":[{"status":"single-arm","outcomeKind":"change-from-baseline","outcomeType":"PRIMARY","outcomeTitle":"Change From Baseline in Papule/Pustule Count at Week 16","timeFrame":"Baseline, week 16","treatmentName":"secukinumab","treatment":{"groupId":"OG000","groupLabel":"Secukinumab Arm","value":-5,"displayValue":"-5 papules and pustules","denominator":17},"comparator":null,"difference":null,"differenceUnit":null,"direction":"within-group-only","plainLanguage":"At Baseline, week 16, Change From Baseline in Papule/Pustule Count at Week 16 changed by -5 papules and pustules in the Secukinumab Arm group. There was no usable comparison group, so this does not show how much improvement the treatment itself caused.","caution":"Without a usable comparison group, change over time cannot be attributed to the treatment.","submittedAnalysis":{"parameterType":"","parameterValue":"","confidenceIntervalPercent":"","confidenceIntervalLower":"","confidenceIntervalUpper":"","pValue":"0.01"},"nctId":"NCT03079531","sourceUrl":"https://clinicaltrials.gov/study/NCT03079531","phase":"Phase 1 / Phase 2","sponsorClass":"Other organization","enrollmentCount":24}],"timeToEffect":null},"D013473":{"name":"Sunscreening Agents","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D014212":{"name":"Tretinoin","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C557522":{"name":"Atralin Gel","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D041623":{"name":"Tomography, Optical Coherence","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D019287":{"name":"Zinc Sulfate","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null}},"recruiting":[{"nctId":"NCT06466018","title":"Research Into Diagnostic and Prognostic Molecular and Imaging Biomarkers of Ocular Disorders Associated With Neurovascular Deregulation: Biocor Cohort","enrollmentTarget":400,"countries":["France"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06466018"},{"nctId":"NCT07343635","title":"The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","enrollmentTarget":186,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07343635"},{"nctId":"NCT05942248","title":"The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","enrollmentTarget":150,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05942248"},{"nctId":"NCT07296497","title":"Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety","enrollmentTarget":104,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07296497"},{"nctId":"NCT07681271","title":"A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)","enrollmentTarget":100,"countries":["United States","Canada","South Korea"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07681271"},{"nctId":"NCT07637032","title":"Clinical Study of a Facial Cream for Rosacea","enrollmentTarget":76,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07637032"},{"nctId":"NCT07106957","title":"Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin","enrollmentTarget":72,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07106957"},{"nctId":"NCT06312813","title":"Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","enrollmentTarget":48,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06312813"},{"nctId":"NCT07341087","title":"Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial","enrollmentTarget":30,"countries":["United Kingdom"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07341087"},{"nctId":"NCT06072066","title":"Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","enrollmentTarget":24,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06072066"},{"nctId":"NCT06801717","title":"Rosacea Radiofrequency Microneedling","enrollmentTarget":20,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06801717"},{"nctId":"NCT06952517","title":"Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea","enrollmentTarget":20,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06952517"},{"nctId":"NCT07600424","title":"Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea","enrollmentTarget":10,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07600424"}],"pairs":[{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D004318","name":"Doxycycline"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D008795","name":"Metronidazole"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D007559","name":"Ivermectin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D000068438","name":"Brimonidine Tartrate"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D010109","name":"Oxymetazoline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C010038","name":"azelaic acid"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D008795","name":"Metronidazole"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D007559","name":"Ivermectin"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D000068438","name":"Brimonidine Tartrate"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D010109","name":"Oxymetazoline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D004318","name":"Doxycycline"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008795","name":"Metronidazole"},"b":{"key":"D007559","name":"Ivermectin"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D008795","name":"Metronidazole"},"b":{"key":"D000068438","name":"Brimonidine Tartrate"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008795","name":"Metronidazole"},"b":{"key":"D010109","name":"Oxymetazoline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008795","name":"Metronidazole"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008795","name":"Metronidazole"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D007559","name":"Ivermectin"},"b":{"key":"D000068438","name":"Brimonidine Tartrate"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D007559","name":"Ivermectin"},"b":{"key":"D010109","name":"Oxymetazoline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D007559","name":"Ivermectin"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D007559","name":"Ivermectin"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000068438","name":"Brimonidine Tartrate"},"b":{"key":"D010109","name":"Oxymetazoline"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000068438","name":"Brimonidine Tartrate"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000068438","name":"Brimonidine Tartrate"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D010109","name":"Oxymetazoline"},"b":{"key":"C000625752","name":"Omiganan"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D010109","name":"Oxymetazoline"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C000625752","name":"Omiganan"},"b":{"key":"D012965","name":"Sodium Chloride"},"coRegistered":0,"headToHeadResults":0}]},"melasma":{"terms":{"D014212":{"name":"Tretinoin","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D002615":{"name":"Chemexfoliation","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"C031927":{"name":"hydroquinone","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null},"D005446":{"name":"Fluocinolone Acetonide","counts":{"studiesWithResults":1,"favouredTreatment":0,"favouredComparator":0,"noObservedDifference":0,"byComparatorClass":{},"comparative":0,"singleArm":0},"patientResults":[],"timeToEffect":null}},"recruiting":[{"nctId":"NCT07679945","title":"A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants","enrollmentTarget":152,"countries":["Brazil"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07679945"},{"nctId":"NCT05942248","title":"The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","enrollmentTarget":150,"countries":["United States"],"sourceUrl":"https://clinicaltrials.gov/study/NCT05942248"},{"nctId":"NCT06454747","title":"Randomized Study Using SM-030 Gel for Adults With Melasma","enrollmentTarget":138,"countries":["El Salvador"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06454747"},{"nctId":"NCT06221787","title":"Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration","enrollmentTarget":80,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06221787"},{"nctId":"NCT07071363","title":"COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS","enrollmentTarget":40,"countries":["Mauritius"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07071363"},{"nctId":"NCT07769268","title":"Efficacy Evaluation of a Cosmetic Product for Facial Hyperpigmentation","enrollmentTarget":40,"countries":["Brazil"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07769268"},{"nctId":"NCT07202156","title":"Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma","enrollmentTarget":35,"countries":["China"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07202156"},{"nctId":"NCT06845540","title":"Oral Metformin for Treating Melasma in Latin American Women","enrollmentTarget":30,"countries":["Puerto Rico"],"sourceUrl":"https://clinicaltrials.gov/study/NCT06845540"},{"nctId":"NCT07540702","title":"Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma","enrollmentTarget":21,"countries":["Egypt"],"sourceUrl":"https://clinicaltrials.gov/study/NCT07540702"}],"pairs":[{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"C031927","name":"hydroquinone"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D014212","name":"Tretinoin"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D005446","name":"Fluocinolone Acetonide"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D008687","name":"Metformin"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":2,"headToHeadResults":0},{"a":{"key":"D014148","name":"Tranexamic Acid"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D014212","name":"Tretinoin"},"coRegistered":4,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D005446","name":"Fluocinolone Acetonide"},"coRegistered":5,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D008687","name":"Metformin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"C031927","name":"hydroquinone"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D005446","name":"Fluocinolone Acetonide"},"coRegistered":3,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D008687","name":"Metformin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D014212","name":"Tretinoin"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D005446","name":"Fluocinolone Acetonide"},"b":{"key":"D008687","name":"Metformin"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D005446","name":"Fluocinolone Acetonide"},"b":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D005446","name":"Fluocinolone Acetonide"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D005446","name":"Fluocinolone Acetonide"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008687","name":"Metformin"},"b":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008687","name":"Metformin"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D008687","name":"Metformin"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"b":{"key":"D007834","name":"Lasers"},"coRegistered":1,"headToHeadResults":0},{"a":{"key":"D000097244","name":"Percutaneous Collagen Induction"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0},{"a":{"key":"D007834","name":"Lasers"},"b":{"key":"D053844","name":"Lasers, Solid-State"},"coRegistered":0,"headToHeadResults":0}]}}}